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1 Introduction 
1.1   Background 
Nearly three decades ago, the first cases of the acquired immunodeficiency syndrome 
(AIDS) were reported in the United States.1 An anomalously high number of patients suffered 
from numerous unusual life-threatening opportunistic infections, e.g. an otherwise rarely 
occurring form of pneumonia (P. carinii) indicating that the immune response in these 
patients was suppressed. This newly occurring epidemic seemed to cause a gradual 
destruction of the patient’s immune response and was therefore termed early on “acquired 
immunodeficiency syndrome” (AIDS). Before the discovery of AIDS being caused by 
infection with the human immunodeficiency virus (HIV), most of the patients died within two 
years.2 Today, AIDS has reached pandemic proportions: The world health organization 
(WHO) estimates that about 33.2 million people live with the disease worldwide and that 
about 2.5 million people get newly infected every year. Approximately 2 million people died 
of AIDS-related conditions last year.3 In the past 20 years, chemotherapy against HIV 
infection has been tackled intensively by modern drug discovery and development. Several 
stages in the viral replication cycle (chapter 1.2) have been targeted to reduce the viral load 
thus delaying the progression to AIDS. However, an entire remedy of the infection or a 
vaccination is still an unaccomplished goal.  
1.2   The human immunodeficiency virus 
HIV is a lentivirus and belongs to the class of retroviruses. In lentiviruses the genetic 
information is encoded in the viral single-stranded positive-sense enveloped RNA and upon 
host cell entry the viral genome is transcribed into double-stranded DNA. Lentiviruses are 
characterized by a long incubation period between th  initial infection and the final outbreak 
of the disease. The HI-viron is schematically represented in Figure 1. It has a spherical shape 
and a diameter of about 100nM. The viron’s envelope consists of a lipid bilayer, originally 
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derived from an infected human cell. The HIV envelop  contains the surface and  
transmembrane glycoprotein gp160, composed of the subdomains gp120 and gp41 which are 
essential for the adsorption and penetration processes. The viral matrix protein (p17) serves as 
a structural protein, the capsid protein (p24) builds up the nucleocapsid, which contains two 
identical strands of single-stranded RNA. The (+)-ssRNA is protected by a high amount of the 
nucleocapsid protein. In addition to these proteins, HIV-1 encodes at least six regulatory 
proteins (Tat, Rev, Nef, Vif, Vpr, Vpu) and three viral enzymes, the HIV protease, the reverse 
transcriptase, and the integrase. Two variants of HIV are differentiated, the HIV-1 and HIV-2 
type. Whereas HIV-1 is widely spread in America, Europe, and Asia, the HIV-2 type is 
mainly observed in West Africa.  
Figure 1: Schematic representation of the HI-viron, selected proteins are indicated and labeled 
  
The HI-virus replicates inside human cells. The replication cycle is schematically 
represented in Figure 2. The HI virons bind with their envelope glycoprotein (gp120) to the 
human CD4 receptors present on the surface of host T-cells (1). For cell entry, HIV 
additionally requires one of two chemokine receptors, either CCR5 or CXCR4 (2).4 Via 
binding of gp120 to CD4 and a co-receptor, the insertion of the second glycoprotein gp41 
facilitates the fusion of the viral and the host cell membrane. Inside the cell, the viral RNA, 
which is still protected in the nucleocapsid, is released and uncoated (3).5 The single-stranded 
viral RNA is then transcribed into double-stranded DNA by the reverse transcriptase (4)6 and 
transported to the nucleus, where it is integrated into the host cell genome by the viral 
integrase (5).7 In this state, the viral DNA is referred to as provi us and the host cell is now 
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latently infected with HIV. By activation of the imune cell, the virus’s genetic information 
is consecutively transcribed into RNA molecules using the protein machinery of the cell (6) 
and then translated into HIV proteins (7).8 These expressed components assemble near the 
cell membrane (8) and than undergo the process of budding and release from the host cell 
(9).9 The viral protease plays a crucial role in the maturation process of the virons. In this 
process, the gag and pol polypeptide chains are cleaved into their functional units (10).  
  
Figure 2: Replication cycle of HIV, numbering corresponds to the text. Current targets of approved drugs are 
colored in green (gp160, reverse transcriptase, HIV protease, integrase and chemokine receptor 5 (CCR 5)), and 
possible additional targets are colored in orange (ch mokine receptor 4 (CXCR 4), RNase H, Tat, Rev, Nef and 
Vif). 10
Several steps of the HIV life cycle have been identifi d as promising drug targets. Today, 
inhibitors of the viral enzymes reverse transcriptase, protease, and integrase as well as 
inhibitors of the cell entry process are available.10
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1.3   HAART 
The development of the Highly Active Anti-Retroviral Therapy (HAART) for treatment of 
the HIV infection is one of the great success stories of modern medicine: In the past 25 years, 
the mortality of HIV-positive patients could be reduced dramatically and changed AIDS from 
a nearly completely fatal illness into a nowadays often manageable chronic illness.11 HAART 
not only significantly prolongs but also improves the quality of the patient’s life.12, 13 The first 
approved drug for the treatment of HIV was an inhibitor of the viral reverse transcriptase 
Zidovudine (AZT). The class of reverse-transcriptase inhibitors can be divided into nucleoside 
(NRTI) and nucleotide (NtRTI) inhibitors on the one hand and non-nucleoside inhibitors on 
the other hand.14 In this content several different lead structures had been approved, however, 
the rapid occurrence of drug resistant strains demanded the development of new drugs 
possessing a different mode of action. The HIV-protease was identified early on as promising 
target and several inhibitors of this protease have m anwhile been approved. All 
recommended HAART regimens generally include at least one non-nucleoside reverse-
transcriptase inhibitor or HIV protease inhibitor combined with two nucleoside or nucleotide 
reverse-transcriptase inhibitors. In 2003, the entry inhibitor enfuvirtide15 was approved and 
very recently raltegravir16 the first inhibitor of the viral integrase has been launched to the 
market. However, despite the success of the antiretroviral therapy, it still suffers from major 
drawbacks. Many of the applied drugs possess relativ y short half-lifes, low bioavailability, 
poor permeability and often cause severe side effects. Besides this, the development of drug-
resistant strains of HIV increasingly hampers an effective therapy (chapter 1.6) thus 
demanding the development of new drugs with improved properties. 
1.4   HIV-1 protease 
By comparing the genomic sequence of HIV-1 with that of other retroviruses, Ratner et al.
postulated that the genome encodes for a protease.17 This was confirmed by the identification 
of the Asp-Thr-Gly motif which is characteristic for retroviral aspartic proteases.18 It has been 
shown that inactivation of the viral protease by eith r mutation or chemical inhibition leads to 
immature, noninfectious virus particles.19, 20 Since that discovery, unprecedented efforts were 
made to solve the three-dimensional structure of this promising target enzyme. Hampered by 
the fact that the protease is only a minor component of HI-virons, a synthetic or recombinant 
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access to the protein material was required.21, 22 Both techniques were finally successful and 
enabled the determination of the structure by NMR and X-ray techniques.23-25
1.4.1   Structural aspects of HIV-1 protease 
Today, HIV protease is probably one of the most studied and hence best characterized 
enzymes: More than 250 crystal structures are assigned to its EC number (EC 3.4.23.16) in 
the publicly available protein data bank (PDB).26 Successful crystallization is reported under a 
variety of different crystallization conditions and the deposited apo and complex structures 
adopt several different space groups. The most frequently observed ones are shown in Table 
1. 
cell dimensions (Å) number of protein 
structures 
space group 
a b c 
82 P21212 56-61 85-90 46-47 
66 P212121 51-53 57-61 61-63 
58 P61/ P6122 61-64 61-64 81-85 
8 P41/ P41212 45-50 45-50 100-110 
Table 1: Most frequently observed space groups in crystal structures of HIV-1 protease. 
First protein crystals obtained in absence of any ligand exhibited the space group P41212 
and the corresponding structures were determined and published in 1989 (PDB ID: 3PHV, 
2HPV).23, 24 These apo structures confirmed models postulating HIV-protease to be active 
only in its dimeric form. However, in these complexes the binding cavity was in a very open 
form and the flaps were about 7Å apart from the catalytically active aspartates. This open flap 
conformation was attributed to be a result of a kinetic trap during crystallization stabilized by 
extensive crystal contacts to symmetry-related molecules. The first crystal structures of 
protein ligand complexes (PDB ID: 4HVP (P212121),
27 5HVP (P21212)
28 and 9HVP (P61)
29) 
unveiled the flap region being in a closed conformation covering the catalytic dyad, thus 
leading to the active site in a closed, tunnel-shaped conformation. However, the solution 
structure of the HIV protease monomer resembles the open flap conformation. Additionally, 
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NMR-experiments revealed high flap flexibility and molecular dynamics suggest a similar 
energy content for the open and the closed flap conformations in the unbound state.30, 31  
Figure3: HIV protease structures, the protein is represented as cartoon in wheat and the flexible flap region is 
colored in red. (a) Apo crystal structure in space group P41212 (pdb ID: 2PC0). (b) NMR ensemble of 20 
structures (pdb ID: 1Q9P). (c-e) X-ray structures of HIV protease inhibitor complexes (c) P212121 (PDB ID: 
2NMW), (d) P21212 (PDB ID: 4PHV), and (e) P61 (PDB ID: 1HPV). 
Besides this high flexibility all studies confirmed common structural features: The protease 
is active as C2-symmetric homodimer and each monomer consists of 99 amino acids. The 
secondary structure of each monomer includes one α-h lix and two antiparallel β sheets. Even 
though each monomer contains two cysteine residues, the dimer does not contain any 
disulfide bonds but is stabilized by non-covalent ieractions. The interface of the two 
monomers is mainly formed by hydrophobic interactions and each monomer contributes one 
of the two catalytically active aspartates. The active site triad (Asp25-Thr26-Gly27) is located 
in a loop region stabilized by a network of hydrogen bonds called fireman’s grip, in which the 
Thr26 hydroxyl group is addressed by the main-chain NH of the same residue of the other 
chain and vice versa. The carboxylate groups are orientated nearly coplanar and are in close 
contact. A conserved water molecule mediates the interactions of a substrate or inhibitor to 
the β-hairpins (flap) covering the active site. 
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1.4.2   Functional aspects of HIV-1 protease 
The detailed catalytic mechanism of HIV-1 protease is up to now not fully understood.32
The similar structural features compared to non-retroviral aspartic protease, however, suggest 
a similar mechanism. The catalytic mechanism of non-viral aspartic proteases has been 
extensively studied by kinetic methods, anity labeling, and X-ray crystallography. Most 
studies are consistent with a general acid-base mechanism postulated by Suguna et al in 




























Scheme 1: Schematic representation of the catalytic mechanism of aspartic proteases.33
Activation of a water molecule facilitates the nucleophilic attack at the scissile peptide 
bond leading to a tetrahedrally coordinated gem-diol intermediate, which collapses under 
cleavage of the peptide bond thus releasing the hydrolysis products. 
1.4.3   Substrate specificity of  HIV-1 protease 
Aspartic proteases in general recognize 6-10 amino acids of their natural polypeptide 
substrates. The standard nomenclature defines the substrate residues as e.g. P3, P2, P1, P1’, 
P2’, P3’ and the corresponding recognition pockets as e.g. S3, S2, S1, S1’, S2’, S3’ as shown 
in Scheme 2.34
1. Introduction 













































Scheme 2: Nomenclature of the protease’s subsites according to Berger and Schlechter, 34 the scissile peptide 
bond is indicated by crossing lines. 
The natural substrates of HIV protease are the gag and pol polyproteines. At least nine 
different cleavage sites are recognized by the protease, which are listed in Table 1.35 Even 
though the protease is C2-symmetric, the amino acid sequences of the substrate  re 
asymmetric taking the scissile amide bond as center. In addition to the asymmetry, the 
substrates share only little sequence homology.  
Cleavage 
domains 
P4 P3 P2 P1 P1’ P2’ P3’ P4’ 
MA-CA Ser Gln Asn Tyr Pro Ile Val Gln 
CA-p2 Ala Arg Val Leu Ala Glu Ala Met
P2-NC Ala Thr Ile Met Met Gln Arg Gly 
p2-p1 Gln Ala Asn Phe Leu Gly Lys Ile 
gag
polyprotein
p1-p6 Pro Gly Asn Phe Leu Gln Ser Arg
TF-PR Ser Phe Asn Phe Pro Gln Ile Thr 
PR-RT Thr Leu Asn Phe Pro Ile Ser Pro 
RT-RH Ala Glu Thr Phe Tyr Val Asp Gly 
pol 
polyprotein
RH-IN Arg Lys Ile Leu Phe Leu Asp Gly 
Table 2:  Sequences of the cleavage sites within the HIV-1 gag and pol polyproteins that are cleaved by HIV-1 
protease. In column 2 the proteins released after cleavage of the substrates are indicated: matrix protein (MA), 
capsid (CA), nucleocapsid (NC), trans frame peptide (TF), protease (PR), reverse transcriptase (RT), RNAse H 
(RH), integrase(IN), and the structural proteins (p1/p2/p6). 
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In the P1 and P1’ position preferably hydrophobic amino acids and in P2/P2’position either 
smaller hydrophobic or polar amino acids are recognized. In more distal sites the recognition 
is non-uniform and residues with various physicochemical properties are tolerated. The mode, 
in which the different substrates interact with the HIV protease, has been elucidated on 
structural basis by the group of C.A. Schiffer. Several crystal structures of substrate analogue 
peptides in complex with an inactive Asp25Asn mutant were determined and one example, 
the complex of a synthetic decapeptide cleavage site (IRKIL-FLDGI) originating from the 
pol-polyprotein, is depicted in Figure 3.36
Figure 4: Crystal structure of a substrate analogue decapeptide, shown in green, color-coded by atom type, in 
complex with the HIV protease (pdb ID: 1KJH). The protein is represented in sticks and in wheat color-coded by 
atom type. Hydrogen bonds are indicated by dashed lin s and the flap water is illustrated as red sphere.  
The synthetic peptide is bound in an extended conformation and several hydrogen bonds to 
the peptide recognition motif comprising main-chain NHs of Asp29, Gly48, and main-chain 
carbonyl oxygen atoms of Gly27, and Gly48 of chain A and B, respectively, are formed. The 
substrate forms a parallel or antiparallel β-sheet with each of the flaps. The carbonyl oxygen 
atom of the scissile amide bond establishes a hydrogen bond to the amide nitrogen of one of 
the introduced asparagines (Asn25A). A tetrahedrally coordinated water molecule mediates 
polar contacts of the carbonyl oxygen atoms of the amide functionalities adjacent to the 
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cleavage site to the flap Ile 50 NHs. In case of the mentioned complex, about 1200Å2 of the 
peptide’s surface is buried in the protease’s binding pocket. In addition to the main-chain 
interactions, intensive hydrophobic interaction as well as additionally formed hydrogen bonds 
of the side-chains contribute to the overall affinity. 
1.5   Inhibitors of HIV-1 protease 
Currently 10 HIV protease inhibitors are approved for the treatment of the HIV infection 
and applied within the highly active antiviral therapy (HAART)(Table 1).10  
Name  Trade name Company Launched
Saquinavir Invirase Hoffmann-La Roche 1995 
Indinavir Crixivan Merck 1996 
Ritonavir Norvir  Abbott, GlaxoSmithKline 1996 
Nelfinavir Viracept  Agouron, Pfizer 1997 
Amprenavir Agenerase, Prozei Vertex 1999 
Lopinavir  
ritonavir
Kaletra, Aluvia Abbott 2000 
Atazanavir Reyataz, Zrivada Bristol–Myers Squibb, Novartis 2003 
Fosamprenavir Lexiva, Telzir Vertex, GlaxoSmithKline 2003 
Tipranavir Aptivus Boehringer Ingelheim 2005 
Darunavir Prezista Tibotec 2006 
Table 3: Licensed protease inhibitors, United States, 2007, listed by the releasing date.10
Initially, inhibitor development was mainly guided by the peptidic nature of the substrates. 
As so called substrate analogues they have a linear character and bear a non-cleavable isostere 
of the peptide bond in their central core. Several isosteres including statine, norstatine, 
phosphinate, reduced amide, dihydroxyethylene, α-keto amide, and silicon-based groups have 
been utilized. However, the continuously increasing resistance towards approved drugs 
(chapter 1.6) made the development of novel inhibitors bearing new scaffolds referred to as 
non-peptidic inhibitors necessary. Both classes of inhibitors, the substrate analogues as well 
as the non-peptidic inhibitors, will be presented in more detail in the two following chapters.  
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1.5.1   Peptidomimetic Inhibitors 
All approved inhibitors exceed the affinities of the natural substrates by several orders of 
magnitude. The peptidomimetic compounds achieve this amongst others by their structural 
similarity to the tetrahedral gem-diol intermediate. The approved peptidomimetic inhibitors 
possess either a hydroxyethylene or hydroxyethylamine moiety to interact with the catalytic 





































































































Scheme 3:Approved peptidomimetic HIV-1 protease inhibitors  
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NMR experiments suggest that in the complexed state, similar to the apo HIV protease, 
one aspartate is in the protonated whereas the second one is in the deprotonated state.37 The 
crystal structures of the inhibitors in complex with the HIV-1 protease reveal a similar 
binding situation for all representatives. In addition to the interactions with the catalytic dyad, 
water-mediated polar interactions are established to the flexible flap region. A water 
molecule, termed flap water, is similar to substrate HIV protease complexes, tetrahedrally 
coordinated by the acceptor groups flanking the transition state isoster and the NHs of the flap 
residues Ile50A and Ile50B. The binding mode of saquinavir as one representative of the class 




























Figure 5: (a) Schematic representation of the binding mode of Saquinavir. Hydrogen bonds are indicated by 
dashed lines (b) View from the top of the protease with the flap region clipped off. The ligand skeleton and 
surface are color-coded in green and the protein is represented in wheat. The occupied specificity pockets are 
indicated and labeled in red. 
The sub-pockets of the protease are addressed similarly to the natural substrates, 
successively from S3 to S3’. Like the natural substrates Saquinavir addresses the S1 and S1’ 
with hydrophobic moieties; benzyl in case of the S1 pocket and a bulky decahydroquinoline 
moiety in case of the S1’ pocket. Although the S2 and S2’ pocket exhibits a predominantly 
hydrophobic environment, most of the approved inhibitors possess hydrophilic substituents, 
an asparagin side-chain in case of saquinavir. More distal binding pockets are not as well 
defined and are reached in diverse fashion by the diff rent peptidomimetic inhibitors. 
Saquinavir reaches the S3 pocket according to the natural substrates with its quinoline ring 
system, whereas for example Atazanavir simultaneously addresses the S1 and S3 pocket with 
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its large phenyl pyridine substituent. Other inhibitors like Amprenavir omit this binding 
pocket. 
1.5.2   Non-peptidic Inhibitors 
The class of non-peptidic HIV protease inhibitors comprises mostly cyclic compounds of 














Scheme 4: Non-peptidic HIV-1 protease inhibitors  
Structural analysis of the complexes between Tipranavir or DMP 323 and the HIV-1 
protease revealed that in both cases the structural water, present in substrate as well as 
peptidomimetic inhibitor bound complexes, is repelled from the complex. Whereas in case of 
the dihydropyrones this replacement of the flap water was a happenstance, it was intended in 
the original design concept of the cyclic ureas. Based on entropic considerations, this 
displacement should be energetically favorable. Additionally, improved selectivity towards 
other mammalian aspartic proteases can be expected by this mode of binding, because the 
water-mediated flap interactions are unique for HIV protease.39 Both inhibitor developments 
are prime examples of modern drug discovery projects and will be described in detail in the 
following. 
Tipranavir was developed from a non-peptidic coumarin template that had been discovered 
by high-throughput screening.40 Upjohn (today Pfizer) screened a compound collection in a 
fluorescence-based HIV-1 protease assay and 4-hydrox coumarin (Warfarin) was identified 
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as a weak inhibitor (IC50 ~ 30µM). After the identification of this initial lead, a more focused 
screening led to the identification of phenprocoumon (Marcumar®) exhibiting a Ki of 1µM. 
The determination of the crystal structure in complex with the HIV protease enabled further 


























Scheme 5: (a) Initial screening hits used for the development of Tipranavir. (b) Schematic representation of the
binding mode of phenprocoumon observed in the crystal structure in complex with the HIV protease. 
Based on the complex structure, iterative cycles comprising synthesis, biological 
evaluation, computational methods and structural anlysis were performed to optimize the 
initial lead structure.41 Optimizations involved the benzopyran ring which was replaced by a 
5,6-dihydropyrone ring system hence facilitating the introduction of further substituents 
thought to address additional enzymatic sub-pockets. Additional favorable binding 
interactions were gained by introduction of a p-trifluoromethyl sulfonamide in meta-position 
of the phenyl ring of the core structure. The binding mode of the finally approved inhibitor 
Tipranavir is represented in Figure 6. 
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Figure 6: (a) Schematic representation of the binding mode of Tipranavir. Hydrogen bonds are indicated by 
dashed lines. (b) View from the top of the protease with the flap region clipped off. The ligand skeleton and 
surface are color-coded in light blue and the protein is represented in wheat. The occupied specificity pockets are 
indicated and labeled in red. 
The two hydrophobic substituents at the central 5,6-dihydropyrone ring system address the 
S1 and S2 pockets of the enzyme. The third substituent occupies with its ethyl group the S1’ 
pocket whereas the phenyl moiety points to the S2’ pocket. From this orientation, the S3’ 
pocket is reached by the para-trifluoromethyl substituent. Additional to the polar interactions 
formed to the catalytic dyad and the flap isoleucins, the inhibitor addresses parts of the 
peptide recognition motif with its sulfonamide functionality establishing hydrogen bonds to 
the main-chain NHs of Asp29A and Asp30A. Tipranavir possesses a binding affinity of Ki = 8 
pM. 
Whereas the staring point for the development of Tipranavir was a high-throughput 
screening, a chance-based method, the corresponding starting point for the development of the 
cyclic ureas was based on rational methods. Studies by DuPont Merck using the structural 
information obtained from extensive work on peptidic lead structures as well as the 
observation of a conserved water molecule mediating the interaction to the flap region were 
exploited to generate a vector model hypothesis facilitating the search for suitable lead 
structures in publicly available crystallographic databases.42 Consecutively, molecular 
modeling predictions suggested a simple core ring system which incorporated the hydrogen-
bonding equivalents of the flap water molecule into the inhibitor scaffold (Figure 7a). Early 
C2-symmetric lead compounds already exhibited low nanomolar affinity and finally led to the 
first clinical candidate, DMP 323.43 The design strategy was confirmed by crystal structu e 
analysis and revealed that the inhibitors are bound symmetrically in the active site of the 
protease (Figure 7). The urea oxygen atom accepts two hydrogen bonds from the flap Ile50A 
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and Ile50B and the diol of the ring system interacts with the two catalytic aspartic acids, 
Asp25A and Asp25B.  
The recognition pockets S1, S2, S1’, and S2’ of the HIV protease are addressed separately 
by the corresponding substituents branching from the rigid ring system. In case of DMP323, 
the S1 and S1’ pockets are occupied by benzyl moieties and the S2 and S2’ pockets with p-
(hydroxymethyl)-benzyl groups. The hydroxyl functionalities address the main-chain NHs of 





















Figure 7: (a) Schematic representation of the binding mode of DMP323 (pdb ID: 1QBS). Hydrogen bonds are 
indicated by dashed lines (b) View from the top of the protease with the flap region clipped off. The ligand 
skeleton and surface are color-coded in light blue and the protein is represented in wheat. The occupied 
specificity pockets are indicated and labeled in red.
DMP 323, however, failed in Phase I clinical trials due to highly variable 
pharmacokinetics. Although it was not the only clini al candidate from this series, up to now 
no cyclic urea has made it to the market, either du to a poor pharmacokinetic profile or due 
to high susceptibility to crucial active site mutations.44
1.6 Resistance development 
The emergence of drug resistant strains strongly complicates the treatment of the HIV 
infection. Like many other RNA viruses, the replicat on of HIV is highly error prone. The 
repeatedly occurring resistance is a direct consequence of the high genetic diversity of the 
virus caused by the error-prone reverse transcriptase (~ 1error per 10.000 bases) and the high 
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in vivo replication rate (108-109 replications per day) of the virus. It has been estimated that up 
to 105 point mutations occur daily within the viral population of an infected individual. This 
high mutation rate leads to dynamic distributions of related but non-identical genomes termed 
viral quasispecies.45 In this mixture of HIV strains the molecular targets of the antiviral drugs 
are present with various single-point amino acid substitutions. HAART is aimed to impede 
the viral replication, however, this is not achieved completely. Under the selection pressure of 
antiviral drugs, resistant HIV variants showing reduced susceptibility to the applied drug 
treatment regime are singled out.  
In case of the HIV protease, one has to discriminate between major and minor mutations.46
Major mutations are initially selected by drug treament and occur at residues forming direct 
interactions upon drug binding. These mutations lead to structural changes in the substrate 
cleft and reduce the binding affinity of the approved drug molecule.47, 48 Minor mutations 
consecutively improve the replicative fitness of virus variants carrying these major mutations. 
The effects of these non-active site mutations are div rse and involve effects on dimer 
stability, inhibitor binding kinetics as well as long-range structural perturbations.49 Mutations 
which are unambiguously associated with protease inhibitor therapy are listed in Table 4. 
D30 V32 V33 M46 I47 G48 I50 I54 L76 V82 I84 N88 L90
ATV   F IL V V L VALM  AF V S M 
DRV  I F  VA  V LM V F V  M 
FPV  I F IL VA  V LM V F V S M 
IDV  I  IL V   VALM V AFTS V  M 
LPV  I F IL VA  V VALM V AFTS V  M 
NFV N  F IL V V  VALM  AFTS V DS M 
SQV      V  VALM  TF V S M 
TPV  I F IL V   VA  TFSL V  M 
Table 4: Selected mutations associated with protease inhibitor resistance. 50
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The different types of point mutations can occur in nearly one half of the amino acid 
positions of the protease.51 In Figure 8, possible positions of point mutations that occur during 
treatment with the peptidomimetic inhibitor Saquinavir re illustrated as red spheres. 
Figure 8: (a) Schematic representation of  single point mutations observed under treatment with Saquinavir.  
The reason for the drop in affinity of a certain inhibitor confronted with a certain mutation 
is manifold and specific for every single case. However, increasing cross-resistance to several 
or even all the approved inhibitors has been observed thus demanding a continuous 
development of new inhibitors. These inhibitors should exhibit a different mutation profile 
compared to that of the marketed drugs to circumvent the development of cross resistance.  
1.7 Motivation and incipient studies 
Because a similar mode of action of all approved inhibitors has resulted in pronounced 
cross resistance, the need of a steadfast and continu us search for new inhibitors is evident. 
An increased structural diversity of inhibitor scaffolds could be a possible strategy to at least 
diminish the accelerated development of multidrug resistant variants. Therefore, the objective 
of this thesis was to elucidate the suitability of cyclic and acyclic amines to serve as novel 
core structures for the structure-based design of HIV-protease inhibitors utilizing molecular 
and structural biology methods. In collaboration with medicinal chemists, using SAR, X-ray 
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crystallography and modeling tools, initial lead struc ures should be developed and optimized 
with respect not only to affinity but also regarding their resistance profile towards crucial 
point mutants. 
In the late 1990s, substituted piperidines were discovered in a HTS-screening at 
Hoffmann-La Roche and further developed as inhibitors of the aspartic protease renin. 52, 53
Based on this discovery, cyclic amines have been utilized as non-peptidic core-structure for 
the development of inhibitors of β-secretase and plasmepsin, which, like renin, belong t  the 
class of pepsin-like aspartic proteases.54-56 In a previous study in our group, substituted 
pyrrolidines were successfully developed as HIV-1 protease inhibitors in cooperation with 
Bayer AG.57, 58  
The design concept of these inhibitors combined key structural elements from classical 
peptidomimetics (chapter 1.3) with a non-peptidic heterocyclic core structure comprising an 
endocyclic amino function. This functionality was intended to address the catalytic aspartates 





























Scheme 6:  General structure of  3,4-dimethyleneamino-pyrrolidine based inhibitors and the binding mode 
intended in their initial design concept. Desirable hydrogen bonds are indicated by dashed lines
Furthermore, the pyrrolidine ring was equipped with two acceptor moieties, either 
carbonyl- or sulfone groups, supposed to form hydrogen bonds to the flap water molecule 
present in substrate or peptidomimetic inhibitor complexes. To estimate the inhibitory 
potential of the developed core structure, it was decorated with side-chains already optimized 
for HIV-protease inhibitors. Docking studies suggested the S,S enantiomer to be preferred in 
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addressing the binding pocket of the protease appropriately. However, due to synthetic ease, 
an achiral synthetic route was initially chosen rendering the putative inhibitors as racemic 
mixture. The most potent derivative of the series, compound 1, exhibited a Ki of 1,5 µM 
towards HIV-1 protease. The subsequent crystal structu e analyses of 1 in complex with the 























Figure 9: (a) Schematic representation of the binding mode of the most potent 3,4-dimethyleneamino-
pyrrolidine derivative. Hydrogen bonds are indicated by dashed lines (b) View from the top of the protease with 
the flap region clipped off. The ligand skeleton and surface are color-coded in magenta and the protein is 
represented in wheat. The occupied specificity pockets are indicated and labeled in red. 
In agreement with the docking result, the central pyrrolidine moiety was found at the 
pivotal position between both catalytic aspartates (Figure 9). However, apart from this 
successful prediction, significant deviations from the proposed docking modes were observed. 
Whereas the initial design concept suggested the S,S nantiomer to be the more active one, the 
crystal structure revealed the R,R enantiomer being bound in the active site of the protease. 
Surprisingly, the flap water, which was intended to be addressed by the polar acceptor groups, 
was repelled from the complex and the inhibitor adopted an up to now unique binding mode: 
It forms a direct hydrogen bond to the backbone NH group of Ile50B with one of its sulfonyl 
oxygen atoms. The carbonyl oxygen atom of the inhibitor’s amide group does not form any 
polar contacts to the enzyme. The Ile50A NH, lacking its usual hydrogen bond partner, the 
flap water, finds a surrogate in the main-chain carbonyl oxygen atom of Ile50B. The sub-
pocket occupancy deviates strongly from the binding mode of the inhibitors presented in 
Chapter 1.4-1.5 and the binding mode intended in the design concept. Compared to 
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peptidomimetic HIV protease inhibitors (chapter 1.5. ) a rotation of about 90° of the inhibitor 
is observed. Therefore, a successive occupation of the sub-pockets S1/S2 and S1’/S2’ with 
each of the substituents at the pyrrolidine ring is impossible. Thus, the iso-butyl substituent of 
the sulfonamide part of the inhibitor addresses the S1 pocket whereas the connected phenyl 
moiety occupies the S2’ pocket. For the two remaining substituents, the N-benzyl and 2,6-
dimethylphenoxy moieties, a distinct pocket assignmet is hardly possible. Both substituents 
share an enlarged space, formally assigned to the S1’ pocket, and the N-benzyl group slightly 
streaks the S2 pocket. The hydrophobic 2,6-dimethylphenoxy group is solvent-exposed and 
may contribute to the overall high perturbations on protein side. Taking all the observed 
structural features into account, the overall affinity for the racemic mixture of 1,5 µM is 
remarkable and encouraged us to further optimize the initial scaffold.  
The thorough interpretation of the obtained complex structure was the starting point for 
this theses. However, for the further optimization of the initial scaffold, it is essential to gain 
insights whether the misplaced and bulky o,o’-dimethylphenoxy substituent is responsible for 
the perturbed binding mode or whether this is caused by the orientation of the acceptor 
moieties with respect to the cyclic amino functionality. A small series lacking either this 
sterical demanding side-chain, the benzyl moiety, or both substituents has been designed and 















3 (K i = 58µM) 4 (IC50 ~1mM)
Table 5: Chemical structure and affinity data of clipped 3,4-dimethyleneamino-pyrrolidine derivatives. Listed 
data correspond to racemic mixtures. 
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The binding affinities of derivatives lacking either one or two side-chains decrease 
indicating that the former substituents contribute positively to the overall binding affinity. 
Even though all compounds exhibited only weak affinity, it was possible to obtain a cocrystal 
structure of derivative 2 with a resolution of 1.75 Å. As expected, the flap water molecule is 
repelled from the complex and the sulfonyl group forms a direct hydrogen bond to Ile50NH. 
The flap distortion remains unchanged whereas the unmodified side-chains swap their 
positions (Figure 10). 
Figure 10 : Cα-superposition of the cocrystal structures of 1 (blue, color-coded by atom type) and 2 (green, 
color-coded by atom type). The protein surface is schematically represented in wheat and the occupied 
specificity pockets are indicated and labeled in red.
The benzene sulfonamide group occupies the S1 pocket formerly addressed by the iso-
butyl moiety which is now located at the inner part of he S2’ pocket. The benzyl ether moiety 
nearly retains the former position of the benzyl substituent. These observations suggest that 
instead of the bulky dimethylphenoxy side-chain the spacial orientation of the cyclic amino 
functionality and the connected acceptor groups are th  driving forces for protein 
deformations.  
The results obtained by these preliminary studies forced us to revise our initial design 
concept. The following chapters represent in chronological order the further development of 
HIV protease inhibitors based on a pyrrolidine scaffold. All studies have been perused in 
cooperation with Dr. Andreas Blum, who was amongst others responsible for the synthesis of 
potential inhibitors. Inhibitor molecules presented in this theses have also been synthesized by 
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Stefanie Dörr (Chapter 5) and Dipl.-Chem. Benedikt Sammet (Chapter 6 and 7). The reaction 
pathways for the synthesis of all inhibitors relevant to this thesis have been implemented for 
reader benefits. Kinetic investigations of the inhibitors towards Plasmpepsins, presented in 
Chapter 6 have been performed by Dr. Torsten Luksch. 
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2. Targeting the Open Flap Conformation of HIV-1 
Protease with Pyrrolidine-based Inhibitors * 
2.1 Introduction 
Acquired Immune Deficiency Syndrome (AIDS) is caused by infection with the human 
immunodeficiency virus (HIV). Despite the immense efforts in combating the epidemic, the 
WHO estimates that currently approximately 40 million people are infected worldwide and 
thus AIDS remains one of the most serious health problems nowadays. Potent drugs targeting 
several stages in the viral life-cycle have been developed and approved.1 The combination of 
inhibitors of the viral transcriptase and protease, termed highly active antiretroviral therapy 
(HAART), is currently the most effective treatment for HIV-infected patients.2, 3 The 
introduction of HAART has increased the quality of the patient’s life dramatically, however, 
eradication of the virus still remains an unaccomplished goal. 
HIV protease is a viral aspartic proteinase that processes the viral polyprotein gene products 
gag and pol into their functional units. The enzyme consists of 99 amino acids and is only 
active in dimeric form. It has been shown that inhibition of the protease leads to immature, 
non-infective virons, consequently making the enzyme an attractive antiretroviral drug target.4
Unprecedented efforts in drug development made HIV protease to one of the most studied and 
hence best characterized enzymes: More than 240 crystal structures are assigned to its EC 
number (EC 3.4.23.16) in the publicly available protein data bank (PDB).5 The first protein 
crystals were grown in absence of any ligand and exhibited the space group P41212. 
* Taken from original publication, Jark Böttcher, Andreas Blum, Stefanie Dörr, Andreas Heine, Wibke E.
Diederich, Gerhard Klebe. Targeting the Open Flap Conformation of HIV-1 Protease with Pyrrolidine-based 
Inhibitors. ChemMedChem2008, 3, (9),1337-44. 
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The corresponding structures were determined and published in 1989 (PDB IDs: 3PHV, 
2HVP) and revealed an expanded active site.6, 7 The flaps covering the binding pocket 
exhibited a distance of more than 7Å to the catalytically active aspartates. Because the flap 
region possesses extensive crystal contacts to symmetry-related molecules, the observed flap 
conformation was attributed to be a result of a kinetic trap during crystallization. Indeed, 
further structural analyses of HIV protease inhibitor c mplexes unveiled that the flap region 
of the enzyme covers the catalytic dyad, thus leading to the active site in a closed, tunnel-
shaped, conformation. The first crystal structures of protein ligand complexes (PDB IDs: 
4HVP, 5HVP and 9HVP)8-10 hosting peptidomimetic inhibitors revealed a conserved binding 
mode: The ligands address the catalytic dyad via a secondary hydroxyl group and the two 
flaps form a parallel and an antiparallel β-sheet with the ligand. Additionally, water-mediated 
interactions to two pivotal acceptor moieties of the ligand are formed by the Ile50 NHs being 
situated at the tip of the flaps. The crystal structure of substrate HIV protease complexed with 
an inactive Asp25Asn mutant showed a similar interaction pattern upon substrate binding 
(PDB ID: 1F7A).11 The closed flap conformation has also been observed in case of the 
tethered dimer apo-structure in space group P61 ( DB ID: 1G6L).
12
The open and the closed flap conformations were analyzed by molecular dynamics and for 
both similar energy contents were calculated in the unbound state.13 NMR experiments also 
revealed high flap flexibility, and the solution structure of the HIV protease monomer 
resembles the open flap conformation.14 Considering the multiple conformational states of the 
protease of nearly equal or close-by energy content, inhibitor design should be focused on 
addressing the protein in various states, either in the open, closed or intermediate 
conformations of the flap. Particularly in the drug development of kinase inhibitors, high 
affinity ligands have been developed against different states of the enzymes.15  
The development of HIV-protease inhibitors targeting the closed conformation was 
extremely successful and resulted in nine FDA-approved drugs.16 However, the clinical 
efficacy of these highly affinic inhibitors is strongly hampered by the increasing resistance 
development. The low fidelity of the viral reverse transcriptase and the fast replication rate 
lead to a high mutation rate thus providing HIV with a high degree of adaptability.17, 18 This 
resulted already in resistant strains exhibiting decreased susceptibility towards all approved 
inhibitors, thus impeding an effective antiviral therapy. Therefore, the development of new 
drugs preferably possessing a different mode of binding thus circumventing the occurrence of 
cross-resistance is essential. 
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Most of the inhibitors developed so far address thecatalytic dyad via a hydroxy 
functionality. Recently, cyclic amines have been developed as novel anchoring group.19, 20 In 
a previous study, the pyrrolidine derivative 1 was designed and the racemic mixture exhibited 
an affinity of 1.5 µM towards HIV-1 protease. To elucidate its binding mode, a cocrystal 
structure was determined and revealed the R,R-enantiomer to bind with a unique interaction 
profile (Scheme 1). The endocyclic nitrogen binds to the catalytic dyad. Poisson-Boltzmann
calculations suggest the amine being protonated and both aspartates being deprotonated, 
resulting in strong electrostatic interactions.21 An asymmetric flap interaction pattern is 
observed (Scheme 1), resulting in an unsatisfactory occupation of the sub-pockets and strong 



























Scheme 1:  Design of C2-symmetric inhibitors starting from the cocrystal structure of 1. 
Both observations might explain the only moderate affinity obtained by a ligand of such 
size. Based on an in-depth analysis of the crystal structure with 1, the following hypothesis 
was formulated: The pyrrolidine is a suitable anchoring group, however, the interactions to 
the flap region and the subsite occupancy should be improved. As an initial approach, 
symmetric pyrrolidine diesters with the required stereochemistry indicated in the crystal 
structure with 1 were designed, fulfilling the essential pharmacophore requirements. These 
compounds were decorated with two hydrophobic moieties to occupy the protease’s 
subpockets and equipped with acceptor groups attached loser to the central pyrrolidine ring 
compared to 1 in order to address the flap in a geometrically better suited way (Scheme 1). 
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2.2  Results and Discussion 
2.2.1   Synthesis 
3,4-Difunctionalized chiral pyrrolidines are accessible starting from tartaric acid. The 
synthesis of the 3S,4S-pyrrolidine diols 2 and 3 has already been described in previously 
(Scheme 2).22 Condensation of L-(+)-tartaric acid with benzylamine gave rise to the cyclic 
imide, which was further reduced utilizing LiAlH4 in refluxing THF. The benzyl protecting 
group was replaced by the BOC-group via catalytic hydrogenation in presence of BOC2O,
23







L-(+)-tartaric acid 2 : PG = Bn
3 : PG = BOC
c
Scheme 2: Synthesis of chiral pyrrolidine-diol 3 from tartaric acid:22 a) BnNH2, xylene, reflux, 81%; b) LiAlH4, 
THF, reflux, 65%; c) H2, Pd/C, BOC2O, EtOH, 90%. 
A series of diesters was prepared via condensation of 3 with the corresponding acid 
chlorides or the respective carboxylic acids after activation with EDC, giving rise to the 
enantiomerically pure diesters 4a-g in high yields. The BOC-group was removed by treatment 
with HCl in Et2O furnishing the inhibitors 5a-g as hydrochlorides (Scheme 3). The resulting 
inhibitor series comprises alkyl moieties of different size (5a-c), the benzoyl derivative 5d
and arylacetic acid derivatives (5e-g).  
























5g CH2-2-Naphthyl (89%)  
Scheme 3: Preparation of pyrrolidine-based inhibitors 5a-g: a) RCOCl, NEt3, CH2Cl2 or RCO2H, EDC, CH2Cl2; 
b) HCl, Et2O. 
2.2.2   Biological data 
The affinities of the pyrrolidine diesters 5a-g were determined in a fluorescence-based 
assay towards three HIV-1 protease variants: the wild type originating from the BH10 isolate 
(PRWT) and the active site point mutants Ile50Val (PRI50V) and Ile84Val (PRI84V). The 
affinities are given in Table 1. In case of PRWT and PRI50V, similar structure-activity 
relationships are observed. Whereas for the alkyl (5a-c) and phenyl (5d) substituted 
derivatives no affinity could be detected, the arylcetic acid derivatives (5e-g) exhibit a two-
digit micromolar affinity. A more pronounced structre-activity relationship can be observed 
in case of PRI84V: For all derivatives inhibition of PRI84V was observed. The benzoyl-
substituted inhibitor 5d exhibits an affinity of 170 µM. In case of the alkyl derivatives 5a-c, 
the affinity increases with the sterical demand of the substituents ranging from 280 µM for 5a
to 29 µM for 5c. The arylacetic acid derivatives 5e-g show the highest affinities in the series, 
particularly compounds 5e and 5f with a Ki of 3.0 µM and 4.5 µM, respectively. To elucidate 
the binding mode of this class of inhibitors, the most potent representatives 5e-g were selected 
for cocrystallization experiments.  
















5a n.i. n.i. 280 
5b n.i. n.i. 43 
5c n.i. n.i. 29 
5d n.i. n.i. 170 
5e 18 25 3.0 
5f 20 41 4.5 
5g 20 15 15 
Table 1. Ki-values of the inhibitors towards the wild type and mutant HIV proteases; n. i.: No inhibition 
observed. 
2.2.3   Structural Analysis 
Crystallization of HIV protease inhibitor complexes is well established in our laboratory, 
peptidomimetic and pyrrolidine-type inhibitors could be crystallized in complex with the 
protease exhibiting binding affinities ranging from low nanomolar to two-digit micromolar 
range. Surprisingly, the crystallization of the pyrrolidine diesters 5e-g in complex with PRWT
failed under the routinely applied standard crystalliz tion conditions, however, utilizing the 
same conditions for PRI84V were successful. In presence of compound 5f, large octahedral 
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crystals were obtained and data were collected directly after transferring the crystals to cryo-
protection conditions.  
Remarkably, the grown crystals exhibited tetragonal symmetry in space group P41212, 
typically adopted by apo-HIV protease for crystallizat on. In this space group, the asymmetric 
unit contains HIV-1 protease in its monomeric form. The functional protease dimer occupies a 
site coinciding with the symmetry element of a twofold axis. For clarity the amino acids of 
the protein chain A and its symmetry equivalent B are l beled as 1A to 99A and 1B to 99B, 
respectively. Due to the symmetry, all interactions within the A and the B chain are identical. 
For the description of contacts to other symmetry related monomers, the chain identifiers C 
and D are used (Figure 1). 
Figure 1: Crystal structure of 5f (color-coded by atom type, α yellow, β magenta) in complex with HIV 
protease. The protein backbone trace is schematically llustrated in wheat for monomers A and B which form the 
functional dimer. It is related via the indicated crystallographic C2-axis. Within this dimer the catalytic D25A 
and D25B are displayed with green carbon atoms. Additional selected protein monomers from crystal packing 
are shown as backbone trace in blue for C and orange for D. The Fo-Fc density for the ligands is displayed at a σ
level of 2.5 as blue mesh. Figures 1-4 were created using PyMol 0.99.24
The observed protein conformation exhibits high similarity to the apo structures found in 
this space group, e.g. a Cα-rmsd of 0.18 Å is calculated with respect to PDB-entry 2PC0.
25
The notation of the protein subpockets, usually applied to HIV protease-inhibitor complexes, 
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cannot be applied in our case, because these pockets are only regularly evolved once the flap 
is closed. Two molecules of 5 are observed in the large active site cavity, comprising an area 
encompassed by the catalytic dyad and the flaps in the open conformation. Complex 
structures of HIV protease revealing a two to one ihibitor to protein ratio have been 
previously described, however, in contrast to the complex of 5f, in these studies the second 
inhibitor molecule is found on the protein surface.26, 27
Both C2-symmetric inhibitor molecules are centered on the C2-axis (Figure 1). However, for 
both molecules two different binding modes are observed, which are not related by any 
symmetry. Consecutively, in the following both bindi g modes will be described separately: 
The ligand situated at the catalytic dyad is referrd to as α, whereas the ligand next to the flap 
region is named β. 
2.2.3.1   Binding mode of α
As intended, 5f forms with its endocyclic amino functionality, hydrogen bonds to the 
catalytic dyad Asp25A (2.9Å, 2.8Å) and Asp25B (Figure 2). 
Figure 2: Binding mode of α, shown in yellow, color-coded by atom type; the protein backbone trace is 
schematically illustrated in wheat. Ligand β is omitted for clarity. (a): Polar interactions to the catalytic dyad are 
indicated by dashed lines; (b): Protein sidechains in contact with the naphthyl moiety are shown in green, color-
coded by atom type. 
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These are the only polar interactions which can be o served; notably, the carbonyl ester 
groups thought to address the flap remain unsatisfied. The substituents at the pyrrolidine ring 
exhibit axial conformations. The naphthyl moieties tablish numerous hydrophobic 
interactions to several residues of the widely opened protease binding pocket (Gly27, Ala28, 
Val32, Ile47, Ile50, Ile54, Thr80, Pro81, Val82, Val84 of chain A and B, respectively). 
Neglecting the second inhibitor molecule β occupying part of the binding pocket, ligand α
would have to be classified as only poorly buried (62%). However, considering contacts to β, 
this value increases to 87%, leading to a pronounced burial of α. The naphthyl moieties of α
also form contacts to the symmetry-related molecules C and D via Van der Waals contacts to 
the side-chain of Gln61 (Figure 4a). However, this contact leads only to a minor increase of 
the burial (88%). 
2.2.3.2 Binding mode of β
The second inhibitor molecule β exclusively interacts with the flap region of the protease 
(Figure 3).  
Figure 3: Binding mode of β, shown in magenta, color-coded by atom type, the protein backbone trace is 
schematically illustrated in wheat. Ligand α is omitted for clarity. (a): Polar interactions ofthe pyrrolidine-
nitrogen indicated by dashed lines, waters by red spheres; (b): Amino acids in contact with the naphthyl moiety 
are shown in green, color-coded by atom type. 
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Van der Waals contacts are formed to the amino acids Ile47, Gly48, Gly49, Ile50, Gly51, 
Gly52, Phe53, and Ile54. In contrast to α, the substituents at the pyrrolidine ring now exhibit 
equatorial conformation. The amino functionality of the pyrrolidine ring forms a water-
mediated hydrogen-bond network to the backbone carbonyls of Gly51A and Gly51B. 
Furthermore, the side-chain amide functionalities of Gln61C and Gln61D, respectively, 
establish hydrogen bonds to the ester carbonyl oxygen of the ligand (3.0 Å). The 
corresponding main-chain carbonyls of Gln61C and Gln61D contribute to the above 
described water-mediated hydrogen-bond interaction network involving Gly51A and Gly51B 
(Figure 4b).  
Figure 4: Interactions of β shown in magenta, color-coded by atom type. (a): The protein backbone trace of A 
and B is schematically illustrated in wheat, ligandα is shown in yellow, color-coded by atom type. The 
monomers C (blue) and D (orange) are shown in surface representation. (b): Polar interactions are indicated by 
dashed lines, waters by red spheres. The monomers A and B are shown in wheat surface representation except 
for the backbone carbonyl oxygen of Gly51 in red. The interacting Gln61 of chains C (blue) and D (orange) are 
color-coded by atom type. Ligandα is omitted for clarity. 
Regarding only contacts formed by the inhibitor molecule β to the protease chains A and B, 
approximately half of the inhibitor’s surface is buried (53%). However, additional contacts to 
the second inhibitor molecule α increase this value to 78%. The inhibitor moleculeβ also 
experiences numerous contacts to the further two symmetry-related HIV protease molecules 
C and D in the crystal packing. Additional Van der Waals contacts are formed to amino acids 
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Pro39, Ile62, Leu63, and Ile72 of chain C and D, respectively. Taking all contacts to 
interaction partners into account, ligand β is almost completely buried (96%). 
2.3   Discussion 
The described complex, obtained by crystallization in presence of 5f, is the first HIV 
protease cocrystal structure showing the open-flap conformation of the enzyme in which the 
inhibitor addresses the catalytic dyad. In case of a previously described metallacarborane 
cocrystal structure of the HIV protease in an open flap conformation, the inhibitor molecules 
bind to the “upper” part of the active site, and no i teraction of the catalytic dyad to the 
inhibitor molecules was observed.28 A crystallization strategy starting with the crystal form of 
the apo protein and using soaking to prepare the complex likely prevents folding of the flap 
upon the accommodated ligand.29 However, in our case the open form has been obtained from 
a cocrystallization experiment where the complex forms already in solution. Under such 
conditions any constraints from the crystal packing e vironment are avoided. Regarding the 
exceptional geometry of the cocrystal structure of 5f, the question arises whether it resembles 
the binding situation in solution.  
All inhibitors of our series show improved affinity against PRI84V compared to the wild-type 
and PRI50V. In the crystal structure of 5f, the side-chain of Val84 is in Van der Waals contact 
to the methylene group adjacent to the ester carbonyl group of α (Figure 2b). The replacement 
of valine 84 by isoleucine would result in decreased urface complementarities and should 
concomitantly lead to a decrease in affinity towards PRWT which is experimentally observed. 
The rigid structure of the ligand core and the stereochemistry at both chiral centers presets the 
orientation of the introduced substituents. This hampers accommodation of the ligand at this 
position, thus explaining the low affinity of the even more rigid benzoyl derivative 5d, which 
lacks the flexible methylene linkers. Comparing theaffinity of PRWT and PRI50V, no major 
differences are observed, which is in agreement with the only small contribution of Ile50 to 
protein ligand surface contacts in case of binding α. According to the observed structure-
activity relationship, ligands with larger substituents exhibit improved affinity. This is in good 
agreement with the large binding pocket, which allows for hydrophobic interactions only. 
Summarizing all these observations, the structure-activity relationship seems to confirm the 
binding mode of α being the biologically relevant one. 
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In case of β, neither the side-chain of Val84 nor Ile50 is in contact with the inhibitor, thus 
the improved affinity towards PRI84V is most likely not attributed to β. The naphthyl moieties 
establish contacts to the main-chain atoms of the flap residues, the side-chain of Ile54 being 
the only exception, creating a comparable polar enviro ment. Taking only chains A and B 
into account, no direct polar interactions are established, and the burial of the ligand remains 
rather incomplete. Major contribution to its burial arises from interactions with chains C and 
D present in the crystal packing. However, they are not present in solution, leaving an 
unsatisfactory binding situation for β. It is likely that the presence of β might favor 
crystallization of this complex by stabilizing the flap region and by interactions to 
neighboring protein molecules. Both ligands α and β interact extensively via π-stacking of 
their naphthyl moieties with each other. In addition, both ligands as a bulk fill the large 
binding cavity. Such extensive inter-ligand interactions are only possible in case of inhibitor
5f, providing a possible explanation, why crystallization only with this particular ligand has 
been successful. 
2.4     Summary and Conclusion 
Starting from the known inhibitor 1, a novel type of pyrrolidine-based ligand skeleton was 
designed. The short and high yielding synthesis was performed via a chiral pool approach 
starting from L-(+)-tartaric acid. The resulting inh bitors 5a-g show up to low micromolar 
affinity against HIV protease variants. A cocrystal structure of 5f in complex with PRI84V
could be determined. Surprisingly, two inhibitor molecules α and β with mutually facing 
binding modes and extensive interligand contacts are accommodated in the active site. In the 
observed binding mode α, the pyrrolidine nitrogen addresses the catalytic dyad as intended by 
our structure-guided inhibitor design. The observed structure-activity relationship can be 
convincingly explained considering the binding mode of α as the relevant one under 
biological conditions as well. The second inhibitor molecule β is only used to stabilize the 
flap region and presumably supports assembly and crystal growth. The open-flap 
conformation of HIV protease has already been postulated as promising to be exploited as 
drug target.30  
The novel pyrrolidine-based ligands 5 are the first reported inhibitors that accommodate the 
protein in this conformation at least in the crystalline state. A comparable binding mode with 
a closed flap would be impossible, taking the rigidity of the ligand core and the required 
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reorganization of the protein into account. The remaining binding cavity volume would be 
insufficient to accommodate ligands of the size andshape of 5a-g. The cocrystal structure of 
5f provides a valuable novel starting point for furthe d velopment of HIV protease inhibitors 
possessing a different mode of binding compared to known drugs. 
2.5   Experimental Section 
Purification and crystallization of the HIV protease variants: HIV protease variants 
were expressed from Escherichia coli and purified as previously described.31 The HIV 
protease inhibitor complex was crystallized at 18°C by the sitting-drop vapor diffusion 
method using a 1:1 ratio. Crystals were obtained by cocrystallization of the enzyme with an 
inhibitor concentration of 1mM, final DMSO concentration of 10%. 1 µL of the well buffer 
(0.1 M BisTris, pH 6.5, 3.0 M NaCl) was mixed with 1µL protein solution (50 mM NaAc, pH 
6.5, 1 mM EDTA, 1 mM DTT) with an HIV protease conce tration of 7 mg/mL. Crystals 
were obtained within a week and had octahedral shape. For cryo-protection the crystals were 
briefly soaked in mother liquor containing 25% glycerol.  
Kinetic Assay: Enzymatic assays were performed in 172 µL assay buffer (100 mM MES, 
300 mM KCl, 5 mM EDTA, 1 mg/mL BSA, pH 5.5) by the addition of substrate dissolved in 
4 µL DMSO, distinct inhibitor concentrations dissolved in 4 µL DMSO and 20 µL HIV-1 
protease in assay buffer to a final volume of 200 µL (final DMSO concentration 4%). The 
fluorogenic anthranilyl-HIV protease substrate (Abz-Thr-Ile-Nle-(p-NO2-Phe)-Gln-Arg-NH2) 
was purchased from Bachem. The hydrolysis of the fluorogenic substrate was recorded as the 
increase in fluorescence intensity (excitation wavelength 337 nm, emission wavelength 
410 nm) over a time interval of 10 min during which the signal increased linearly with time.32
The kinetic parameters of PRWT (Km = 14.6 µM), PRI50V (Km = 139 µM) and PRI84V (Km = 70 
µM) were determined by the method of Lineweaver and Burk. IC50-values were calculated 
using nonlinear regression curves for single site competitive binding analysis using the 
program Grafit. Ki values were calculated from the following equation:    
Ki = IC50 [1 + (S/Km)]
-1 assuming a competitive binding mechanism with a one t  one ratio.33
The overall error of the measurement estimated to be ±40%. 
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Data collection, phasing and refinement: The data set was collected using a Rigaku R-
AXIS IV image plate detector using Cu Kα radiation from an in-house Rigaku RU-H3R 
rotating anode. Data were processed and scaled with Denzo and Scalepack as implemented in 
HKL2000.34 The structure was determined by the molecular replacement method with 
Phaser,35 the apo HIV protease structure (PDB ID: 2PC0) was used as the search model. The 
structure refinement was continued with SHELXL-97,36 for each refinement step at least 10 
cycles of conjugate gradient minimization were performed, with restraints on bond distances, 
angles and B-values. Intermittent cycles of model bui ding were done with the program 
COOT.37 The coordinates have been deposited in the PDB (http://www.rcsb.org/pdb/) with 
access code 3BC4.  
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5f
Resolution (Å) 25-1.82 
space group P41212 
cell dimensions (Å) a, b = 46.3 
c = 101.4 
highest resolution shell (Å) 1.85 -1.82 
no. of measured reflections 101919 
no. of independent reflections 10446 
completeness (%)a 99.3 [93.7] 
I/σa 42.2 [10.3] 
R sym (%)
a 5.3 [15.9] 
resolution in refinement (Å) 25-1.82 
Rcryst (%) F > 4 σ Fo; Fo 18,7; 19.3 
Rfree (%) F > 4 σ Fo; Fo 24.1; 25.0 
mean B-factor (Å2) (protein) 22.5 
mean B-factor (Å2) ligand α 29.1 
mean B-factor (Å2) ligand β 21.3 
mean B-factor (Å2) water 28.2 
Ramachandran plot 
most favorate geometry (%) 96.8 
additionally allowed (%) 3.2 
generously allowed (%) - 
disallowed (%) - 
RMSD bonds (Å) 0.007 
RMSD angles (°) 2.0 
Table 2. X-ray data processing and refinement for the PRI84V complex of derivative 5f. Values in brackets refer 
to the highest resolution shell. 
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3. Structure-Guided Design of C2-Symmetric HIV-1 
Protease Inhibitors Based on a Pyrrolidine Scaffold *
3.1   Introduction 
Infection with the human immunodeficiency virus (HIV) inevitably leads to the 
development of the acquired immune deficiency syndrome (AIDS). The WHO estimates that 
currently 40 million people are infected worldwide and that this number will increase 
continuously.1 In the last 20 years, chemotherapy against HIV infection has been tackled by 
modern drug discovery and development. Several stage  in the viral replication have been 
targeted to reduce the viral load thus delaying the progression to AIDS. However, an entire 
remedy of the infection or a vaccination is still unaccomplished goal.2 One of the most 
successful approaches in antiviral therapy up to dae is the highly active antiretroviral therapy
(HAART) which combines inhibitors of the viral revers  transcriptase and the viral protease. 
This viral protease, the HIV protease, belongs to the class of aspartic proteases and cleaves 
precursor polypeptides into functional viral proteins, which are essential for the infectiousness 
of the virus particles. The HIV protease is a C2-symmetric homodimer with each monomer 
consisting of 99 residues. Two glycine-rich flaps are located above the large active site, which 
binds six to seven amino acids of the nine different cleavage sites within the gag and pol
polypeptides. Because inhibition of this enzyme leads to immature virions, HIV protease has 
become a target of several marketed drugs. Up to now, ine inhibitors against the HIV 
protease have been approved by the FDA,3-6 but meanwhile the virus has shown a very high 
degree of adaptability. The high mutation rate of the virus is caused by the error-prone viral 
reverse transcriptase and its fast replication rate. This leads, especially under the additional 
selection pressure of HAART, to the development of resistant virus variants.7  
* Taken from original publication, Andreas Blum, Jark Böttcher, Andreas Heine, Gerhard Klebe, Wibke E.
Diederich. Structure-Guided Design of C2-Symmetric HIV-1 Protease Inhibitors Based on a Pyrrolidine 
Scaffold. J. Med. Chem.2008, 51, (7), 2078-2087. 
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Because a similar mode of action of all approved inhibitors has resulted in pronounced 
cross-resistance, the need of a steadfast and continu us search for new inhibitors is evident. 
An increased structural diversity of inhibitor scaffolds could be a possible strategy to at least 
diminish the accelerated development of multi-drug resistant variants. 
Most of the approved inhibitors are transition state mimetics addressing the catalytic dyad 
(D25A/D25B) via a hydroxyl group. As a different approach, cyclic amines have been 
identified as non-peptidic inhibitors for the aspartic proteases Renin,8, 9 β-Secretase,10 and 
Plasmepsins.11, 12 Recently, a pyrrolidine-based inhibitor for HIV protease has been 
developed.13, 14 The X-ray structure of the protein inhibitor complex revealed the endocyclic 
amino function binding to the catalytic dyad. Electros atic calculations suggest that the amino 
functionality should be protonated and both aspartic acid residues of the catalytic dyad 
therefore deprotonated, thus leading to strong hydrogen bonds as well as electrostatic 
interactions of the resulting cyclic ammonium function to the catalytic dyad.15 The 
sulfonamide side-chain of the inhibitor addresses the flap region by one of its oxygen atoms 
through hydrogen bonding to the backbone NH of I50A (Figure 1). A superposition of this 
structure with other crystal structures of HIV protease complexes indicated that the distance 
between the sulfonyl group and the endocyclic nitrogen is too large for appropriate flap-
interactions. The carboxamide part of inhibitor 1 showed no directed polar interactions to the 





























Figure 1: Design of C2-symmetric inhibitors starting from the cocrystal structure of 1. 
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Guided by the described polar interactions of inhibitor 1 to the enzyme, a basic 
pharmacophore model was derived: As core structure, the 3S,4S-disubstituted pyrrolidine, 
addressing the catalytic dyad via its secondary amino group, was retained. However, as 
indicated by the X-ray structure of 1, the exocyclic methylene groups were removed in order 
to improve the interaction pattern of the sulfonyl groups with the flap region of the enzyme. 
To exploit the C2-symmetry of the enzyme, exclusively symmetric inhibitors were 
synthesized. To mimic the subpocket occupation of 1, arylsulfonamides were introduced to 
occupy the S2- and S2’-subpockets. In addition, a hydrophobic moiety was attached to each of 
the sulfonamide nitrogen atoms designed to address the S1- and S1’-subsites of the enzyme 
(Figure 1).  
3.2   Chemistry 
3,4-Difunctionalized pyrrolidines are accessible in e antiopure form commencing with 
commercially available tartaric acids.16, 17 D-(-)-Tartaric acid was condensed with benzyl-
amine to furnish the corresponding cyclic imide, which was further reduced with LiAlH4 to 







D-(-)-tartaric acid 2a PG = Bn
2b PG = BOC
a, b
c
Scheme 1: (a) BnNH2, xylene, Dean-Stark (81%); (b) LAH, THF, reflux (69%); (c) H2, Pd/C, BOC2O, MeOH 
(74%). 
The synthesis of the corresponding benzyl protected pyrrolidine-3,4-diamine, accessible via 
a Mitsunobu reaction of diol 2a with HN3 and subsequent reduction of the resulting diazide,
has already been described.19 However, following this synthetic route, the removal of the 
benzyl-protecting group by catalytic hydrogenation in the last step of the synthesis to give rise 
to the final inhibitors remained unsuccessful, even after applying higher temperature and 
hydrogen pressure as well as different hydrogen sources. Furthermore, we intended to avoid 
the usage of the very toxic hydrazoic acid in the Mitsunobu reaction. Therefore, a change to 
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the easily removable BOC-protecting group was necessary. This exchange was carried out at 
the diol stage by hydrogenation of 2a in presence of BOC2O,
20 yielding the BOC-protected 
3,4-diol 2b (Scheme 1). Although an activation of the 3,4-pyrrolidine diol for the purpose of 
nucleophilic displacement reactions by conversion into its corresponding disulfonates has 
been described,21, 22 in our hands, the respective mesylate did not undergo substitution with 
NaN3 in DMSO even at 120°C. Nevertheless, utilization of the related, but significantly more 
reactive bis-triflate 2c followed by its nucleophilic substitution with NaN3 in DMPU at RT 
now yielded the 3,4-diazide 2d, which was subsequently reduced to the corresponding 







2b R = H
2c R = SO2CF3
b
a
2d R = N3
3   R = NH2
c
Scheme 2: (a) Tf2O, pyridine, CH2Cl2 -78°C→-10°C; (b) NaN3, DMPU, RT; (c) H2, Pd/C, hexane/EtOAc (86% 
over three steps). 
Diamine 3 was then condensed with suitable sulfonyl chlorides to the corresponding 
sulfonamides 4 (Scheme 3), which were further alkylated with different allyl and benzyl 
bromides in the presence of K2CO3 in acetonitrile (Scheme 4) thus yielding the BOC-
















Scheme 3: (a) ArSO2Cl, Et3N, CH2Cl2: 4a Ar: Ph (86%); 4b Ar: o-Me-Ph (87%); 4c Ar: o-Cl-Ph (94%); 4d Ar: 
p-NO2-Ph (69%); 4e Ar: p-CN-Ph (71%). 























Scheme 4: (a) RCH2Br, K2CO3, CH3CN, reflux: 4a Ar: Ph (5aa R: CH=CH2 72%; 5ab R: CH(CH3)=CH2 73%; 
5ac R: CH=C(CH3)2 68%; 5ad R: Ph 75%; 5ae R: p-Br-Ph 76%; 5af R: p-I-Ph 76%; 5ag R: p-CF3-Ph 49%); 4b
Ar: o-Me-Ph (5bd R: Ph 78%); 4c Ar: o-Cl-Ph (5cd R: Ph 65%); 4d Ar: p-NO2-Ph (5dd R: Ph 96%); 4e Ar: p-
CN-Ph (5ed R: Ph 67%; 5eg R: p-CF3-Ph 45%). 
The final deprotection was carried out under non-aqueous acidic conditions using 2 M HCl 
in Et2O furnishing the inhibitors 6 as their hydrochlorides in high yields (Scheme 5, yields are 
given in Table 1). In compounds with double lettering codes, the first letter refers to the 















Scheme 5: (a) 2 M HCl in Et2O, RT. Details are given in Table 1. 
The carboxamido-substituted compounds 5fd, and 5fg are accessible from the 
corresponding cyano-substituted derivatives 5 d, and 5eg by mild hydrolysis applying 30% 




















5fg  R: p-CF3-Ph
Scheme 6: (a) 30% aq H2O2, K2CO3, DMSO, 0°C→RT (5fd R: Ph 92%; 5fg R: p-CF3-Ph 71%). 
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The amino-substituted inhibitor 6gd was obtained from the corresponding nitro-substituted 
precursor 5dd by reduction with SnCl2 in EtOAc at elevated temperature.
24 Under these 
















Scheme 7: (a) SnCl2·2 H2O, EtOAc, 2h reflux, then 2 M HCl in Et2O 79%. 
 The synthesis of inhibitors of type 6 was achieved in 7 or 8 steps, respectively, starting 
from D(-)-tartaric acid in an overall yield ranging from 7 to 21% with an average yield of 
more than 70% for each step. 
3.3   Results and Discussion 
To gain a first insight into the structure-activity-relationship (SAR), the benzene 
sulfonamide group in 4a was alkylated with three differently alkyl-substitu ed alkenyl 
moieties and a benzyl group using allyl bromide (to5aa), 2-methyl-allyl bromide (to 5ab), 
3,3-dimethyl-allyl bromide (to 5ac), and benzyl bromide (to 5ad). After acidic deprotection of 
the BOC-group, inhibitors 6aa-6ad were obtained. All four bis-substituted sulfonamides 
showed affinity in the micromolar range against HIV protease, from which those inhibitors 
with the largest moieties (6ac and 6ad) exhibited the highest affinity (Table 1). 







6aa 12.3 76 (5aa) 
6ab 74.7 71 (5ab) 
6ac 1.57 78 (5ac) 
6ad 2.15 92 (5ad) 
6ae Br 0.46 72 (5ae) 
6af I 0.39 81 (5af) 
6ag CF3 0.80 71 (5ag) 
6bd 0.67 81 (5bd) 
6cd 
Cl
0.77 78 (5cd) 




0.26 81 (5fd) 




CF3 0.07 80 (5fg) 
Table 1: K i-values of the inhibitors 6 towards the HIV protease and yield of the terminal deprotection step. 
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The X-ray structure of 6ad in complex with the protease was determined with a resolution 
of 1.55 Å and surprisingly revealed an asymmetric binding mode (Figure 2). Similar to the 
complex structure of pyrrolidine-based inhibitor 1, the protonated cyclic amino nitrogen is 
found at its pivotal position forming a hydrogen bond network to the catalytic aspartic acid 
























Figure 2: Schematic representation of the binding mode of 6ad observed in the crystal structure in complex with 
the HIV protease; bond lengths to I50A and I50B of the flap-region are given in Å. 
Instead of a structural water molecule usually present in peptidomimetic or substrate-like 
complexes, one sulfonyl group establishes two hydrogen bonds to the backbone-NHs of I50A 
(2.9 Å) and I50B (3.3 Å), each with one sulfonyl oxygen atom. The second sulfonyl group, 
however, does not form any polar interactions (Figure 3). 
Figure 3: Crystal structure of 6ad (green, color-coded by atom type) in complex with HIV protease. The protein 
backbone trace is schematically illustrated in wheat, the catalytic D25A and D25B as well as I50A and I50B of 
the flaps are displayed in grey color-coded by atom type. The Fo-Fc density for the ligand is displayed at a σ level 
of 3.0 as blue mesh. 
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 The benzyl substituents occupy the S1/S1’-subpockets establishing Van der Waals (VdW)-
contacts with L23A, I50B, V82A, I84A (S1); R8B, L23B, I50A, P81B, V82B, I84B (S1’). The 
phenyl moieties reside in the S2/ 2’-subsites forming VdW-contacts with A28B, V32B, I50A, 
I84B (S2); A28A, D30A, V32A, I47A, I50B (S2’). Additional VdW-contacts are found to 
G27, G48, and G49 of each subunit. The deviation frm a C2-symmetrical occupation of the 
subpockets can be analyzed by superpositioning the obs rved geometry of the inhibitor with 
its geometry resulting from a rotation around the protein’s C2-axis. The average distance of 
the corresponding ring atoms is 1.7 Å in the S1- and 2.1 Å in the S2-pocket. 
This crystal structure enabled us to rationally design a second series of most likely more 
potent inhibitors. Consequently, 6ad was selected as lead structure for further optimization. 
An in-depth analysis of the crystal structure revealed three very promising symmetric 
substitution patterns for further lead optimization (Figure 4):  
Figure 4: Overview of the optimization strategies of 6ad by attachment of additional substituents; protein shown 
in wheat surface representation, D29 and D30 surface patches are shown in color-coded by atom type; (A) 
hydrophobic P1/P1’-elongation; (B) small hydrophobic P2/ 2’-ortho-substitution; (C) polar P2/P2’-para-
substitution to address D29 and D30.  
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(A) Elongation of the P1/P1’-benzyl moieties with hydrophobic substituents in para-position 
to address unoccupied space in the S1/S1’-pocket. 
(B) ortho-substitution at the P2/P2’-phenyl ring systems to improve the shape match 
between the binding pocket surface and the ligand. For this purpose small hydrophobic 
substituents were selected in order to fill remaining space flanked by V32B and I84B in 
the S2-pocket as well as V32A and I84A in the S2’-pocket. 
(C) para-substitution at the P2/P2’-phenyl moieties with substituents capable of forming 
hydrogen bonds to D29A and D30A in the S2’-pocket and D29B and D30B in the S2-
pocket. 
All three strategies were pursued, and the resulting inhibitors 6ae-6ag and 6bd-6gd were 
subsequently analyzed by kinetic measurements with respect to their affinity against the target 
enzyme. The cocrystal structures of selected represntatives, at least one of each modification 
type, in complex with HIV protease were determined. This approach allows the detailed 
analysis of additional interactions formed by the introduced substituents and provides an 
extensive understanding of the principles accounting for the SAR. Subsequently, this 
knowledge should facilitate the selection of the most promising combination of substituents 
thus leading to an even further improved inhibitor.
(A) Elongation of the P1-benzyl ring in para-position with hydrophobic residues was easily 
achieved by alkylation of benzene sulfonamide 4a with appropriately substituted benzyl 
bromides, yielding after deprotection the corresponding bromo- (6ae), iodo- (6af), and 
trifluoromethyl- (6ag) substituted inhibitors. These inhibitors indeed showed improved 
affinity by a factor of five compared to 6ad for the halide substituted ones (6ae 0.46 µM; 6af
0.39 µM). In case of the trifluoromethyl-substituted inhibitor 6ag, a factor of three (0.80 µM) 
is achieved. The crystal structure of 6af in complex with HIV protease was determined with a
resolution of 1.41 Å and revealed a binding mode resembling that of the unsubstituted 
pyrrolidine 6ad. A similar hydrogen-bond network of the core structure can be observed 
(Table 2).  
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6ad 6af 6cd 6fd 6gd 6fg
D25A Oδ1 3.0 2.9 3.0 3.0 3.0 2.9
D25A Oδ2 2.6 2.7 2.5 2.7 2.6 2.7
D25B Oδ1 3.0 2.8 2.8 2.8 2.8 2.8
D25B Oδ2 2.9 3.1 2.9 2.8 2.9 3.0
I50A N 2.9 3.0 3.1 3.0 3.1 2.9
I50B N 3.3 3.1 3.6 3.2 3.7 3.1
Table 2: Conserved hydrogen bonds of the pyrrolidine-nitrogen atom to the catalytic dyad (D25A/D25B) and 
the sulfonyl oxygen atoms to the flap (I50A/I50B) observed in the determined cocrystal structures; values given 
in Å. 
The root-mean-square deviation (rmsd) between the Cα atoms of the complexes of 6ad and 
6af constitutes 0.15 Å, resembling the overall similar binding mode. This similarity is also 
reflected by an rmsd of 0.45 Å from the respective 6ad substructure in 6af. The gain in 
affinity is presumably due to additional VdW interactions in the S1-subsite with P81A, G48B, 
and G49B and in the S1’-subsite with R8B. Obviously, the position and orientation of the 
P2/P2’-moiety is not affected by the additional substituent. 
(B) The extension of the P2/P2’-phenyl ring in ortho-position with small hydrophobic 
substituents was successfully accomplished by synthesis of the ortho-methyl and ortho-chloro 
substituted benzene sulfonamides 4b and 4c, respectively, which were subsequently alkylated 
with benzyl bromide yielding after deprotection the methyl- (6bd) and chloro- (6cd) 
substituted inhibitors. Compared to the lead structure 6ad, a threefold increase in affinity was 
observed (6bd 0.67 µM; 6cd 0.77 µM). The 2.30 Å-resolved crystal structure of the chloro-
derivative 6cd revealed a similar binding mode compared to that of 6ad. The protein structure 
remains unaffected (Cα rmsd to 6ad is 0.14 Å), however, the binding mode of 6cd slightly 
deviates from the expected conformation (rmsd to 6ad substructure is 0.67 Å). The observed 
polar interactions are in agreement with the structure of 6ad (Table 2), furthermore the ortho-
chloro-substitution is as intended in additional VdW-contacts of the chlorine atom to V32B 
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and I84B in the S2’-pocket. Moreover, the ortho-substituent induces an unanticipated change 
in the orientation of the phenyl moiety in the S2-pocket. There, the chloro-substituent points in 
the opposite direction toward the S1-pocket now interacting with G48B and G49B, hence 
retaining the orientation of 6ad.  
(C) For the decoration of the P2/ 2’-phenyl moieties in para-position with polar groups, the 
4-nitrophenyl sulfonamide 4d as well as the 4-cyanophenyl sulfonamide 4e were synthesized 
and subsequently alkylated with benzyl bromide. Thealkylated nitro compound 5dd was on 
the one hand directly deprotected to yield inhibitor 6dd. On the other hand, the nitro group in 
5dd was first reduced to the corresponding amino functio  concurrently removing the 
protecting group now giving rise to the amino-substituted inhibitor 6gd. The alkylated cyano 
compound 5ed was converted into the carboxamide 5fd and subsequently deprotected 
yielding inhibitor 6fd. Compared with the unsubstituted pyrrolidine 6ad, the nitro-substituted 
inhibitor 6dd only showed a comparable affinity (6dd 1.72 µM), whereas those inhibitors 
with hydrogen bond donor substituents revealed an eightfold increase in affinity (6fd
0.26 µM; 6gd 0.27 µM). To elucidate the hydrogen bond network established by the polar 
substituents, both inhibitors were crystallized in complex with HIV protease and the resulting 
crystal structures were determined (resolution: 6fd 1.50 Å; 6gd 1.78 Å). Both crystal 
structures show a high similarity to that of 6ad with respect to the Cα atoms of the protein (Cα
rmsd 6fd 0.25 Å; 6gd 0.12 Å) as well as the binding-mode of the ligand (rmsd of 6ad
substructure 6fd 0.54 Å; 6gd 0.36 Å). The polar interactions of the central scaffold are similar 
to those of 6ad (Table 2). Due to the asymmetric binding mode, the int raction patterns in the 
S2-and S2’-subpockets of each ligand differ from each other (Figure 5, Figure 6): The para-
amino derivative 6gd establishes two hydrogen bonds in the S2-pocket, one directly to the 
backbone carbonyl of D30B (3.2 Å) and one to the sidechain of D30B bridged by a water 
molecule (2.8 Å, 2.7 Å). In the S2’-pocket, also two hydrogen bonds are formed, however, 
now to the side-chains of D30A (2.7 Å) and D29A again mediated by an interstitial water 
molecule (3.2 Å, 2.9 Å).  




































Figure 5: Schematic representation of the hydrogen bond network observed in the crystal structure of 6gd; bond 
lengths are given in Å.  
The same number of hydrogen bonds can be observed for the para-carboxamido substituted 
inhibitor 6fd: In the S2-pocket the backbone NH of D30B is addressed via the carboxamide 
oxygen (2.8 Å), whereas the amide-nitrogen establishes a hydrogen bond to the side-chain of 
D30B (2.9 Å). In the S2’-pocket a water molecule mediates the interaction between the ligand 
amido nitrogen and the D29A side-chain (3.0 Å, 2.7 Å). The carbonyl function of the ligand 
accepts a hydrogen bond from the backbone NH of D30A ( .0 Å). The position of the P1/P1’-



































Figure 6: Schematic representation of the hydrogen bond network observed in the crystal structure of 6fd; bond 
lengths are given in Å. 
All crystal structures analyzed at this stage of the project are very similar; the rmsd 
deviation between the Cα atoms of any two complexes is less than 0.28 Å, and all inhibitors 
also show a very high degree of similarity in their binding modes (Table 3).  
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6ad 6af 6cd 6fd 6gd 6fg 6ad 6af 6cd 6fd 6gd 6fg 
 Protein Cα 6ad substructure 
6ad - 0.15 0.14 0.25 0.12 0.19 - 0.45 0.67 0.54 0.36 0.69
6af 0.15 - 0.17 0.23 0.19 0.18 0.45 - 0.56 0.66 0.57 0.61
6cd 0.14 0.17 - 0.28 0.15 0.20 0.67 0.56 - 0.85 0.72 0.81
6fd 0.25 0.23 0.28 - 0.23 0.23 0.54 0.66 0.85 - 0.28 0.32
6gd 0.12 0.19 0.15 0.23 - 0.20 0.36 0.57 0.72 0.28 - 0.48
6fg 0.19 0.18 0.20 0.23 0.20 - 0.69 0.61 0.81 0.32 0.48 - 
Table 3: Calculated rmsd after alignment of the protein Cα-atoms; for the ligands the respective 6ad substructure 
within each ligand is compared after Cα-alignment of the protein structure; values given in Å.  
The hydrogen-bond network of the lead structure 6ad is conserved in all structures (Table 
2). The rmsd between the respective substructure and 6 d is less than 0.69 Å. For the 
comparison of any two ligands, the rmsd is less than 0.85 Å. The largest differences are 
observed between the ortho-chloro-substituted ligand (6cd) and the para-amino (6gd) or the 
para-carboxamido-substituted ligand (6fd) with 0.72 Å and 0.85 Å respectively. This reflects
the different binding mode of 6cd (Table 3). This different binding mode makes an ortho-
substitution at the P2-residue less attractive for further combination with other modifications 
(Figure 7), so only the two remaining substitution strategies were combined. As substituents 
for the combined inhibitor, a trifluoromethyl group as P1/P1’- and a carboxamido moiety as 
P2/P2’-substituent were selected. 
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Figure 7: Superposition of the ligand conformations observed in the corresponding crystal structures aligned by
Cα-fit of the proteins; ligands color-coded by atom type 6af (cyan), 6cd (orange), 6fd (salmon), 6gd (grey). 
The combined inhibitor 6fg was prepared in similar manner as already described for 
carboxamide inhibitor 6fd starting from sulfonamide 4e, followed by alkylation to 5eg, and 
subsequent hydrolysis of the nitriles to the carboxamide 5fg. After acidic, non-aqueous 
deprotection, the inhibitor 6fg was tested for its affinity against HIV protease. With 74 nM the 
trifluoromethyl and carboxamido-substituted inhibitor 6fg exhibits the highest affinity within 
this series. To validate our combination strategy pursued within this project, the crystal 
structure of 6fg in complex with HIV protease was determined with a resolution of 1.48 Å 
(Figure 8).  
Figure 8: Crystal structure of 6fg (cyan, color-coded by atom type) in complex with HIV protease. The protein 
backbone trace is schematically illustrated in wheat, the catalytic D25A/D25B, D30A/D30B, and I50A/I50B of 
the flaps are displayed in grey color-coded by atom type. The Fo-Fc density for the ligand is displayed at a σ level 
of 3.0 as blue mesh. 
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No major differences could be observed comparing the protein structure to the formerly 
determined complexes (Cα rmsd to 6af 0.18 Å; to 6fd 0.23 Å). Our successful combination 
strategy is also represented in the conserved ligand co formation (rmsd of 6ad substructure to 
6af 0.61 Å; 6fd 0.32 Å). The polar interaction pattern of the carboxamido-substituted 
inhibitor 6fd is retained. Compared to 6af, additional VdW-contacts of the trifluoromethyl 
group to R8A in the S1-subsite are observed. In the structure of 6fg, both CF3 groups show 
disorder of a rigid rotor. They were refined as double conformations.  
3.4   Summary and Conclusion 
C2-symmetric 3,4-disubstituted pyrrolidines have been d veloped as a new class of HIV 
protease inhibitors. Starting from the initial lead6ad, which showed affinity in the low 
micromolar range, the activity of this new class of HIV protease inhibitors could be 
significantly optimized by means of rational structure-based design up to the two digit 
nanomolar range for the final inhibitor 6fg. Based on our developed synthetic strategy, the 
synthesis of the enantiopure key intermediate 3 commencing with D-(-)-tartaric acid is 
straightforward and high-yielding. Condensation of 3 with appropriately chosen sulfonyl 
chlorides renders the corresponding sulfonamides. Alkylation of which, followed by further 
functional group transformations and deprotection gave rise to the desired inhibitors. These 
are obtained via a 7 or 8 step synthesis with an overall yield ranging from 7 to 21%. 
Following the outlined synthetic route, the synthesis of a plethora of putative protease 
inhibitors is readily feasible.  
Initial SAR-studies as well as the crystal structure determination resulted in selection of 6ad
as lead compound for further structural optimization. The analysis of the cocrystal structure of 
6ad revealed three possible strategies for optimization via symmetric introduction of 
substituents to the original P1/ 1’- and P2/P2’-phenyl moieties. From each class of possible 
modifications, at least one representative was synthesized and thoroughly analyzed by crystal 
structure determination of the protein-ligand complex. The observed interactions of the core 
structure are highly conserved throughout this serie  of inhibitors. These structures provided 
deeper insights into the protein-ligand interactions a d the underlying principles of the SAR. 
Taking this information into account, the most promising combination of P1/P1’- and P2/P2’-
moieties was selected and the resulting inhibitor 6fg indeed showed the expected 
improvement in affinity with a Ki = 74 nM. The cocrystal structure of this inhibitor c nfirmed 
the successful application of our optimization strategy. The complete structural 
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characterization of crucial intermediates prevents mi direction by only taking the affinity of 
the compounds into account. This project clearly shows that the rational design of inhibitors 
based on the successful cooperation between synthetic m dicinal chemistry and structural 
biology can lead to a highly efficient optimization f lead structures. 
3.5   Experimental Section 
Kinetic Assay: Inhibition data for HIV protease were determined as follows: IC50 values 
were taken from plots of vi/v0 versus inhibitor concentration, in which vi is the velocity in 
presence, and v0 the velocity in the absence of an inhibitor. The fluorogenic substrate Abz-
Thr-Ile-Nle-(p-NO2-Phe)-Gln-Arg-NH2 was purchased from Bachem. Recombinant HIV 
protease was expressed from Escherichia coli and purified as previously described.25
Enzymatic assays were performed in 172 µL assay buffer (100 mM MES, 300 mM KCl, 
5 mM EDTA, 1 mg/mL BSA, pH 5.5) by the addition of sub trate dissolved in 4 µL DMSO, 
distinct inhibitor concentrations dissolved in 4 µLDMSO and 20 µL HIV-1 protease in assay 
buffer to a final volume of 200 µL (final DMSO concentration 4%). The hydrolysis of the 
substrate was recorded as the increase in fluorescence intensity (excitation wavelength 
337 nm, emission wavelength 410 nm) over a time period of 10 min during which the signal 
increased linearly with time.26 The kinetic constants for HIV protease (Km = 14.6 µM) were 
determined by the method of Lineweaver and Burk with a HIV protease concentration of 
2.8 nM with varied substrate concentrations. The active-site concentration was quantified by 
titrating three different HIV protease concentrations with the strong binding inhibitor 
Saquinavir (Ki = 0.3 nM). Ki values were calculated from the following equation: Ki = [IC50 –
 (Et/2)][1 + (S/Km)]
-1
Crystallization of HIV protease inhibitor complexes: HIV protease inhibitor complexes 
were crystallized at 18°C in 0.1 M BisTris, pH 6.5, 2.0-3.5 M NaCl and a protein 
concentration of 7 mg/mL in the space group P21212 (crystal data, Table 4 and 5). The 
crystals were obtained by cocrystallization of the enzyme with inhibitor concentrations 
ranging from 20 to 100 fold the Ki value. Crystals were further optimized using streak-seeding 
techniques. For cryoprotection the crystals were bri fly soaked in mother liquor containing 
25% glycerol.  
Data collection, phasing and refinement: The data sets were collected at the synchrotron 
BESSY II in Berlin/Germany on PSF beamline 14.2 (PDB I : 2PQZ 6ad, 2QNP 6af, 2PWC 
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6gd, 2QNN 6fg), the EMBL/DESY in Hamburg/Germany on beamline X13, (pdb ID: 2PWR 
6fd) both equipped with a MAR-CCD detector and (pdb ID: 2QNQ 6cd) on a Rigaku R-
AXIS IV image plate detector using Cu Kα radiation from an in-house Rigaku rotating anode. 
Data were processed and scaled with Denzo and Scalepa k as implemented in HKL2000.27
The structures were determined by the molecular replac ment method with Phaser,28 one 
monomer of the 1.5 Å structure of the HIV-1 protease in complex with a pyrrolidine based 
inhibitor (PDB ID: 1XL2) and consecutively a monomer of the determined structure (PDB 
ID: 2PQZ 6ad) was used as the search model. The structure (PDB ID: 2QNP 6af) was 
determined by single isomorphous replacement with anomalous scattering method (SIRAS) 
using the HKL2MAP graphics user interface,29 the dataset of the unsubstituted pyrrolidine 
was used as native data. The positions of the iodine atoms were identified using SHELXD30
and the phase problem was solved with SHELXE.31 The resulting phases were applied and 
after density modification with DM,32 ARPwARP33 as implemented in CCP434 was used for 
automated model building. 
Refinement was continued with CNS35 and SHELXL-97,36 for each refinement step at least 
10 cycles of conjugate minimization were performed, with restraints on bond distances, 
angles and B-values. Intermittent cycles of model bui ding were done with the program 
COOT.37 The coordinates have been deposited in the PDB (http://www.rcsb.org/pdb/) with 
access codes: 6ad 2PQZ; 6af 2QNP; 6cd 2QNQ; 6fd 2PWR; 6gd 2PWC; 6fg 2QNN. 
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6ad 2PQZ 6af 2QNP 6cd 2QNQ
Resolution (Å) 25-1.55 25-1.41 30-2.30 
space group P21 12 P21212 P21212 
cell dimensions (Å) a = 57.53 
b = 86.00 
c = 46.72 
a = 57.36 
b = 85.90 
c = 46.65 
a = 57.57 
b = 85.90 
c = 46.54 
highest resolution shell (Å) 1.58-1.55 1.43-1.41 2.35-2.30 
no. of measured reflections 153817 168404 57399 
no. of independent reflections 32912 44939 10478 
completeness (%)a 96.3 [87.3] 99.5 [94.1] 97.1 [93.9]
I/σa 13.4 [3.0] 21.9 [2.83] 16.1 [5.27]
R sym (%)
a 8.6 [33.5] 5.0 [33.4] 11.0 [25.2]
refined residues 198 198 198 
refined ligand atoms 39 41 41 












resolution in refinement (Å) 10-1.55 10-1.41 25-2.30 
Rcryst (%) F > 4 σ Fo; Fo 16.4 17.6 20.5 
Rfree (%) F > 4 σ Fo; Fo 20.4 21.3 23.9 
mean B-factor (Å2) 
(peptide chain A; B) 15.7; 14.2 14.9; 13.5 23.3;20.5 
main-chain (Å2) 12.8; 11.5 12.5; 10.9 22.6; 20.1 
side-chains (Å2) 18.8; 17.2 17.7; 15.4 24.2; 21.2 
ligand (Å2) 24.0 12.7b 38.0 
water (Å2) 28.1 24.8 23.4 
Cl ions (Å2) 17.1 16.9 22.1 
Glycerol (Å2) - - - 
Ramachandran plot    
most favorate geometry (%) 96.8 95.6 97.5 
additionally allowed (%) 3.2 4.4 2.5 
generously allowed (%) - - - 
disallowed (%) - - - 
Table 4:  X-ray data processing and refinement for the HIV protease complexes of derivatives 6ad, 6af and 6cd. 
(a) Values in brackets refer to the highest resolution shell. (b) In case of 6af the ligand occupancy was refined to 
63% with respect to the protein.  
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6fd 2PWR 6gd 2PWC 6fg 2QNN
Resolution (Å) 25-1.50 25-1.78 25-1.48 
space group P21 12 P21212 P21212 
cell dimensions (Å) a = 56.77 
b = 84.80 
c = 46.06 
a = 57.28 
b = 85.78 
c = 46.45 
a = 57.38 
b = 86.18 
c = 46.29 
highest resolution shell (Å) 1.53-1.5 1.81-1.78 1.51-1.48 
no. of measured reflections 141076 87548 137979 
no. of independent reflections 33531 22211 38945 
completeness (%)a 92.1 [93.7] 98.2 [99.5] 99.5 [96.4] 
I/σa 34.2 [6.6] 13.5 [2.9] 23.5 [3.71] 
R sym (%)
a 3.9 [23.0] 9.7 [46.3] 4.8 [28.7] 
refined residues 198 198 198 
refined ligand atoms 45 41 53 












resolution in refinement (Å) 10-1.50 10-1.78 10-1.48 
Rcryst (%) F > 4 σ Fo; Fo 16.8 16.3 17.0 
Rfree (%) F > 4 σ Fo; Fo 20.2 21.1 19.3 
mean B-factor (Å2) 
(peptide chain A; B) 14.4; 13.0 17.1; 15.5 16.3; 14.4 
main-chain (Å2) 12.3; 13.0 14.7; 13.2 13.8; 12.2 
side-chains (Å2) 16.9; 15.4 19.8; 17.9 19.1; 16.9 
ligand (Å2) 13.5 21.2 14.1 
water (Å2) 24.7 26.7 26.2 
Cl ions (Å2) 16.7 17.1 18.4 
Glycerol (Å2) 22.9 40.3 30.5 
Ramachandran plot    
most favorate geometry (%) 96.2 96.8 96.8 
additionally allowed (%) 3.8 3.2 3.2 
generously allowed (%) - - - 
disallowed (%) - - - 
Table 5: X-ray data processing and refinement for the HIV protease complexes of derivatives 6fd 6gd and 6fg. 
(a) Values in brackets refer to the highest resolution shell.
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4. Structural and Kinetic Analysis of Pyrrolidine-
based Inhibitors of the Drug Resistant Ile84Val 
Mutant of HIV-1 Protease *  
4.1   Introduction 
Human immunodeficiency virus (HIV) protease is a well established target for the 
development of antiviral therapeutics.1 The protease processes the gag and pol encoded 
polyproteins into functional enzymes which are essential for the viral replication.2 Inhibition 
of the viral protease leads to immature non-infectious virions.3 Currently, nine HIV protease 
inhibitors (PIs) are approved by the FDA.4 The highly active antiretroviral therapy
(HAART), which combines protease and reverse transcriptase inhibitors, not only 
significantly prolongs but also improves the quality of the patient’s life.5, 6 However, an entire 
remedy of the infection still remains an unaccomplished goal. Moreover, although most of the 
inhibitors initially exhibit a strong inhibitory effect, this efficacy decreases over time due to 
the continuously new formation of drug resistant virus variants. 
The relatively low fidelity of the viral reverse transcriptase and the fast replication rate are 
the main driving factors for the high mutation rate of the HIV. It has been estimated that up to 
105 point mutations occur daily within the viral population of an infected individual.7 Due to 
high mutation rates, there are several non-identical genomes termed viral quasispecies, hence 
making it difficult to define one wild-type protease as reference point.8 The following studies 
were performed using a clone of the BH10 isolate.  
* Taken from original publication, Jark Böttcher, Andreas Blum, Andreas Heine, Wibke E. Diederich, Gerhard 
Klebe. Structural and Kinetic Analysis of Pyrrolidine-based Inhibitors of the Drug Resistant Ile84Val Mutant of 
HIV-1 Protease. J. Mol. Biol 2008, (383),2, 347-57 
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Mutations in the binding pocket as well as in distal ites of the HIV protease affect inhibitor 
and substrate binding by altering the number and streng h of subsite interactions. Since the 
applied inhibitors effectively inhibit wild-type proteases and limit wild-type duplication, they 
also provide a selective advantage to those HIV variants with reduced susceptibility. The 
occurrence of multi-drug resistant HIV variants diminishing the efficacy of all protease 
inhibitors in clinical use hampers an effective antiviral treatment of patients infected by these 
variants. Under selective drug pressure, mutations have been proven to occur nearly in one-
half of the HIV-1 protease amino acid positions.9 The mutations can generally be classified 
into major and minor ones.10 Major mutations are initially selected by drug treatment and 
mainly occur at residues forming interactions upon drug binding. Minor mutations 
consecutively improve the replicative fitness of virus variants carrying major mutations. 
The high adaptability of the virus demands a continuous and persistent search for new 
inhibitors. Novel inhibitors should exhibit a different mutation profile compared to that of the 
marketed drugs to circumvent the development of cross- esistance. Most of the currently 
approved inhibitors are transition state mimics targeting the catalytic aspartates 25A and 25B 
via a secondary hydroxyl group. As an alternative skeleton, cyclic amines have been proposed 
as novel anchoring groups.11 Very recently, we have described the design and synthesis of C2-
symmetric 3,4-disubstituted pyrrolidines as a new class of HIV-1 protease inhibitors. The 
cocrystal structures of six derivatives were determined in complex with wild-type HIV-1 
protease (compound (PDB ID): 1 (2PQZ); 3 (2QNP); 6 (2QNQ); 8 (2PWC); 9 (2PWR); 10
(2QNN) Table 2) and further utilized within a struct re-guided optimization process.12 These 
crystal structures revealed a conserved binding mode for all investigated derivatives, 
schematically represented in Figure 1: The endocyclic amino function addresses the catalytic 
dyad and a unique flap interaction pattern is observed. Only one sulfonyl group of the C2-
symmetric inhibitor is involved in two hydrogen bonds to the backbone NHs of Ile50A and 
Ile50B each formed by one of the sulfonyl oxygen atoms. The second sulfonyl group remains 
uncoordinated and establishes no polar contacts. Thi  leads to an overall slightly asymmetric 
binding mode of the C2-symmetric inhibitors.  

























Figure 1: Schematic representation of the conserved binding mode of the pyrrolidine-3,4-bis-N benzyl-
sulfonamides. Hydrogen bonds are indicted by broken lines and main-chain bonds are denotated by bold lines. 
However, each symmetry-related subpocket is occupied by the corresponding symmetry- 
related substituent of the inhibitor. The cocrystal structure of the most potent derivative 
(compound 10)12 is shown together with the cocrystal structures of all currently approved HIV 
protease inhibitors in Figure 2 (inhibitor (PDB ID): Ritonavir (1HXW),13 Atazanavir 
(2AQU),14 Darunavir (1T3R),15 Amprenavir (1HPV),16 Indinavir (1HSG),17 Nelfinavir 
(1OHR),18 Saquinavir (1HXB),19 Lopinavir (2O4S)20 and Tipranavir (2O4P)20).  
Figure 2: Superposition of the final lead structure (compound 10) with the cocrystal structures of all approved 
HIV protease inhibitors (PIs). Compound 10 in green, color-coded by atom type, whereas the ligand geometries 
of the approved PIs are displayed in wheat.  
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This comparison reveals a completely different mode in targeting the protease’s subsites by 
this new class of inhibitors: Whereas the approved inhibitors bind to the subsites successively 
from S3 to S3’, the pyrrolidine-based inhibitors occupy the S1-S3/S2’ and the S1’-S3’/S2 
pockets via the two substituents at the pyrrolidine ri g, respectively. This leads to a unique 
binding mode in the active site, particularly at the borders of the S1/S2’ and the S1’/S2 
pockets, composed by the amino acids Ile50 and Ile84 of chain A and B. Both residues are 
referred to as major mutations. Whereas the Ile84Val mutation in HIV-1 protease is 
associated with resistance to all approved inhibitors, the Ile50Val mutation is mainly linked to 
the resistance against Amprenavir.21 Due to their importance and the remarkable differences 
in binding of the pyrrolidine-based inhibitors, particularly in the contact area next to Ile50 and 
Ile84, we selected these two mutations for further investigations. Both mutations have already 
been studied extensively by kinetic measurements,22, 23 structural biology,24, 25 isothermal 
titration calorimetry,26, 27 and computational methods.28 These studies attribute the reduced 
affinity with respect to the Ile84Val mutant primarily to the loss of Van der Waals contacts 
with the P1/P1’ moieties of the inhibitors. The senitivity of Amprenavir towards the Ile50Val 
mutation is attributed to strong interactions of the Cδ of Ile50A with the P2’-residue of the 
inhibitor.26
Encouraged by the deviating and up to now unique mode in which the C2-symmetric 
pyrrolidine-based inhibitors bind to the protease’s subsites, we investigated their potential 
against these drug-resistant mutations. The two active site mutants Ile50Val and Ile84Val 
were generated by site directed mutagenesis. Followed by kinetic studies two representatives 
8 and 9 were crystallized in complex with the wild-type and the two corresponding mutant 
proteases. Throughout the paper the wild-type protease (BH10 isolate) is referred to as PRWT
and the mutant proteases PRI50V and PRI84V, respectively.  
4.2    Results 
4.2.1   Kinetic characterization 
In order to estimate the consequences of the point mutations to putative natural substrates, 
the kinetic parameters of PRWT, PRI50V and PRI84V were determined in a fluorescence-based 
assay (Table 1) using four different commercially available substrates. The four fluorescence 
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substrates were purchased from Bachem (substrates A and B) and Sigma Aldrich (substrates 
C and D). PRI50V and PRI84V exhibited a significantly reduced Km to all studied substrates 
compared to PRWT. For PRI50V, the affinity towards the substrates is reduced tenfold whereas 
for PRI84V, an affinity reduction by a factor of five was determined. The reduced catalytic 
efficiency (kcat/Km) is driven by this loss in affinity of the mutant proteases towards these 
substrates. 
WT PRI50V (/WT) PRI84V (/WT) Anthranilyl-
HIV protease 
substrate 
Km [µM] kcat/Km 
[µM-1s-1] 
Km [µM] kcat/Km 
[µM-1s-1] 
Km [µM] kcat/Km 
[µM-1s-1] 
A 



























5.2 ±0.4 1.66 ±0.36 54.9 ±1.9 
(11) 






Table 1: Kinetic characterization of PRWT, PRI50V and PRI84V with fluorogenic substrates. Values in parentheses
refer to the relative change compared to the wild-type protease. 
 The affinities of the pyrrolidine-based inhibitors were determined towards the protease 
variants using substrate A, and the results are summarized in Table 2. In case of the Ile50Val 
mutation, on average, a decrease in affinity of the pyrrolidine-based inhibitors by a factor of 
five is observed. This overall decrease in affinity seems therefore to occur as a general 
phenomenon of this class of compounds and not a result of a special substitution pattern. In 
contrast, the pyrrolidine-based inhibitors exhibit an equal or even improved affinity towards 
the Ile84Val mutant: Pyrrolidine 1 exhibits a twofold increase in affinity. Compounds with 
only one additional hydrophobic substituent at the P1/P1’-aromatic rings (2, 3 and 4) at least 
retain their affinity, whereas all other derivatives carrying additional polar or hydrophobic 
substituents at the P2/P2’ moieties exhibit significantly improved potency. Particularly for the 
amide-substituted derivatives (9 and 10), an up to sevenfold increase in affinity towards thi  
drug-resistant point mutant is observed.  

























1 2.2 10.9 1.1 5 0.5 
2 Br 0.46 2.6 0.55 6 1.2 
3 I 0.39 1.4 0.33 4 0.8 
4 CF3 0.80 3.0 0.50 4 0.6 
5 0.67 2.1 0.46 3 0.7 
6 
Cl
0.77 2.6 0.48 3 0.6 
7 NO2 1.7 8.0 0.92 5 0.5 








CF3 0.07 0.26 0.012 4 0.2 
Table 2: Ki-values of the inhibitors towards the wild-type and mutant HIV proteases. 
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To investigate the contrasting behaviour of the inhibitors towards the single point mutants 
PRI50V and PRI84V, we determined the cocrystal structures of two derivatives in complex with 
the mutant proteases. Due to the largest relative diff rence in affinity towards the mutants, 
along with good potency, compounds 8 and 9 were selected, exhibiting deviating P2/P2’ 
substituents. 
4.2.2  Structural analysis
The amino (8) and carboxamido (9) derivatives were crystallized in complex with the
PRI50V and PRI84V variants. The crystallographic data and refinement sta istics of the four 
structures are listed in Table 3. All cocrystal struc ures, discussed within this study, 
crystallized with identical packing, in the space group P21212 with very similar lattice 
constants. Therefore, an influence of crystal packing on the observed differences can be 
neglected. In the space group P2121 , the asymmetric unit contains the HIV-1 protease with 
two symmetry-independent chains labelled as 1A to 99A and 1B to 99B, respectively. The 
collected datasets have comparable quality with resolutions between 1.58 Å and 1.92 Å. In all 
cases, the ligand geometries were clearly visible in the Fo-Fc omit-map at a sigma level of 3.0 
(Figure 3) and could be refined as one single conformer. All structures were determined by 
molecular replacement and consecutively refined following the same protocol. 
Figure 3: Ligand geometries of 8 and 9 color-coded by 
atom type in the cocrystal structures with PRWT: (a) 
green; PRI50V: (b) yellow; PRI84V: (c) magenta; The Fo-Fc
omit map for the ligand and the water in case of (c) is 
displayed at a σ level of 3.0 as blue mesh. 










resolution (Å) 25-1.58 25-1.92 30-1.80 30-1.81 
space group P21 12 P21212 P21212 P21212 
cell dimensions (Å) a = 57.9 
b = 86.0 
c = 46.3 
a = 57.3 
b = 85.7 
c = 46.6 
a = 57.2 
b = 85.5 
c = 46.7  
a = 57.4 
b = 85.7 
c = 46.6  
highest resolution shell (Å) 1.61-1.58 1.95 -1.92 1.83 -1.80 1.84 -1.81 
no. of measured reflections 141102 76478 89944 75858 
no. of independent 
reflections 
31985 17926 20882 21217 
completeness (%)a 99.1 [90.6] 98.6 [97.0] 95.5 [100] 97.8 [100] 
I/σa 13.5 [2.5] 15.8 [3.2] 18.8 [3.1] 16.2 [2.6] 
R sym (%)
a 9.0 [37.5] 9.1 [46.3] 7.3 [49.1] 7.0 [42.2] 
resolution in refinement (Å) 10-1.58 10-1.92 10-1.80 10-1.81 
Rcryst  (F > 4 σ Fo; Fo) (%) 17.0 ; 19.8 17.8 ; 20.1 17.7 ; 19.3 18.1 ; 20.4 
Rfree (F > 4 σ Fo; Fo) (%) 20.7 ; 24.5 23.0 ; 26.4 23.3 ; 25.3 23.8 ; 26.0 
mean B-factor (Å2) 
(peptide chain A; B) 
15.2 ; 13.5 27.3 ; 24.9 31.9 ; 28.4 23.3 ; 21.1 
main-chain (Å2) 12.3 ; 11.2 24.8 ; 22.5 28.3 ; 25.8 20.7 ; 19.0 
side-chains (Å2) 18.2 ; 15.9 30.2 ; 27.5 35.9 ; 31.2 26.4 ; 23.5 
ligand (Å2) 20.3 27.1 25.3 20.7 
water molecules (Å2) 24.8 31.0 35.4 27.9 
Ramachandran plot     
most favorate geometry (%) 96.8 95.6 97.5 94.9 
additionally allowed (%) 3.2 4.4 2.5 5.1 
rmsd bonds  (Å) 0.007 0.005 0.006 0.006 
rmsd angles (°) 2.0 1.9 2.0 1.9 
Table 3: Crystallographic data for the complexes of the amino derivative 8 and the carboxamido derivative 9 
Values in brackets refer to the highest resolution shell.  
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4.2.2.1   Crystal structures of 8 
The crystal structures of the amino derivative 8 in complex with the HIV protease variants 
were determined with a resolution of 1.58 Å (PRI50V) and 1.92 Å (PRI84V), respectively. Both 
complexes exhibit a high level of similarity to the corresponding wild-type complex 
(determined at a resolution of 1.78 Å), studied previously.12 This similarity is reflected by the 
root-mean-square deviation (rmsd) between the Cα atoms of 0.12 Å for PRI50V and 0.18 Å for 
PRI84V compared to the PRWT complex. Using the Cα-based alignment, the ligand geometries 
also show a high level of similarity with an rmsd of 0.19 Å for the PRI50V and 0.28 Å for the 
PRI84V in comparison to the PRWT ligand coordinates (Figure 4).  
Figure 4: Ligand geometries of the Cα superposition of the cocrystal structures of 8 in complex with PRWT
(green), PRI50V (yellow), PRI84V (magenta), color-coded by atom type. 
The overall binding mode is conserved and schematically represented in Figure 5, the 
distances of polar contacts are given in Table 4.  























































Figure 5: (a) Schematic representation of the binding modes of 8 observed in the crystal structures in complex 
with PRWT, PRI50V and PRI84V. (b) Additional hydrogen bond network of water O308  in complex with PRI84V. 
Hydrogen bonds are indicted by dashed and main-chain bonds using bold lines. 
PRWT PRI50V PRI84V
D25 Oδ 2.6-3.0 2.7-3.0 2.7-3.0 
I/V50A N 3.1 3.0 3.2 
I/V50B N 3.7 3.8 3.7 
D29A Oδ/H2O 3.2/2.9 3.3/2.8 - 
D30A Oδ 2.7 2.7 2.7 
D30B Oδ/H2O 2.8/2.7 2.9/2.7 2.8/2.8 
D30B O 3.2 3.1 3.1 
Table 4: Polar contacts of the ligand 8 observed in the cocrystal structures with the different HIV-protease 
variants. Values are given in Å. 
 The pivotal nitrogen of the pyrrolidine core structure interacts with the catalytic dyad. In 
case of the wild-type complex, the nitrogen atom is in close contact with the carboxylic 
4. Pyrrolidine-based Inhibitors of the Drug Resistant Ile84Val HIV-1 Protease Mutant
83
oxygen atoms of Asp25A and Asp25B. This important interaction is conserved for the mutant 
proteases. The flap interactions formed via hydrogen bonds of the sulfonyl oxygens to the 
main-chain NH of Ile50A and Ile50B or Val50A and Val50B are comparable in all 
complexes. The inhibitor’s benzyl moieties occupy the S1 and S1’ pockets whereas the p-
amino-phenyl sulfonamide groups bind in the S2 and S2’ pockets. The amino substituents 
form a hydrogen-bond network, which, due to the asymmetric binding mode, differs in S2 and 
S2’. The observed polar interactions in S2 are highly conserved: The amino group hydrogen 
bonds to the main-chain carbonyl oxygen of Asp30B and, mediated via a water molecule, to 
the corresponding side-chain carboxyl oxygen atom. In the S2’ pocket, differences are 
noticed: The water-mediated interaction to the carboxyl function of Asp29A is only observed 
in PRWT and PRI50V, whereas the H-bond to the side-chain of Asp30A is conserved in all 
complexes. In PRWT and PRI50V, the Cδ atoms of Ile84A and Ile84B are in close Van der 
Waals contact to the benzylic methylene groups of the ligand (3.5/3.3 Å PRWT and 3.6/3.4 Å 
PRI50V), compared to Cγ of the corresponding Val84A and Val84B in PRI84V (3.8/4.0 Å). The 
burial of the ligand surface varies slightly between 95% and 96%, exhibiting the highest value 
in the PRWT complex. 
The most pronounced differences are observed in the PRI84V complex: The Ile84Val 
exchange at the border of the S1/S2’ pockets enlarges the binding site, and the newly created 
additional space is filled by a water molecule (O308 , Figure 5b). This water mediates polar 
interactions between one oxygen atom of the sulfony group of 8 and to the main-chain 
carbonyl of Val82A and the side-chain of Thr80A. The binding pockets of the three structures 
were consecutively analyzed with a water probe using the program GRID to evaluate whether 
the position of the additional water is energetically favourable. In Figure 6c, the GRID 
interaction fields for the PRI84V binding pocket are displayed.  
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Figure 6: The calculated GRID interaction fields for the binding pockets of PRWT (a) PRI50V (b) and (PRI84V (c) 
in complex with 8 are displayed as blue mesh at a contour level of 8 kcal/mol. The protein surface is 
schematically represented in wheat, the corresponding ligand is color-coded by atom type in green, yellow and 
magenta for PRWT, PRI50V and PRI84V, respectively. Experimental observed water molecules are shown as red 
spheres.  
A contour is observed at the position of the additionally enclosed water molecule, together 
with an area next to the catalytic Asp25A and Asp25B and at the far end of S2 and S2’ and 
near Gly27A and Gly27B, which are part of the peptide recognition motif. The positions of 
the experimentally observed water molecules are in good agreement with the calculated fields. 
In case of the PRWT (Figure 6a) and the PRI50V (Figure 6b) complexes, similar observations are 
made except for the GRID interaction field near Thr80A and Val82A. 
4.2.2.2   Crystal structures of 9 
The crystal structures of the carboxamido derivative 9 were determined with a resolution of 
1.80 Å (PRI50V) and 1.81 Å (PRI84V) (Table 3). As for 8, the overall binding of 9 is conserved 
compared to the wild-type counterpart (1.50 Å), described previously.12 Compared to the 
PRWT structure, the Cα rmsd of PRI50V is 0.23 Å and of PRI84V is 0.24 Å. The corresponding 
rmsd for the ligand atoms using this alignment is 0.19 Å for PRI50V and 0.28 Å for PRI84V
(Figure 7).  
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Figure 7: Ligand geometries of the Cα superposition of the cocrystal structures of 9 in complex with PRWT
(green), PRI50V (yellow), PRI84V (magenta), color-coded by atom type. 
The same subsite occupancy is observed in all complexes and is schematically represented 






















































Figure 8: (a) Schematic representation of the binding modes of 9 observed in the crystal structures in complex 
with PRWT, PRI50V and PRI84V. (b) Additional hydrogen bond network of water O3074 in complex with PRI84V. 
Hydrogen bonds are indicted by dashed and main-chain bonds using bold lines. 
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The hydrogen bond network established by the inhibitor is conserved, and the polar contact 
distances are given in Table 5.  
PRWT PRI50V PRI84V
D25 Oδ 2.7-3.0 2.7-3.0 2.7-2.9 
I/V50A N 3.0 3.0 3.2 
I/V50B N 3.2 3.5 3.6 
D29A Oδ/H2O 3.0/2.7 3.4/2.5 3.1/2.4 
D30A N 3.0 3.0 3.0 
D30B Oδ 2.9 2.9 3.1 
D30B N 2.8 3.0 2.9 
Table 5: Polar contacts of the ligand 9 observed in the cocrystal structures with the different HIV-protease 
variants. Values are given in Å. 
The pivotal nitrogen is in close polar contact to the carboxylate oxygens of Asp25A and 
Asp25B, while the flap only interacts with the oxygen atoms of one sulfonyl group forming 
hydrogen bonds to the main-chain NHs of amino acid residues 50A and 50B. In S2, direct 
interactions of the carboxamido oxygen to the main-chain NH of Asp30B and of the 
carboxamido nitrogen to the corresponding Asp30B side-chain are observed in all complexes. 
The water-mediated interaction to the side-chain of Asp29A and the direct interaction to the 
backbone NH of Asp30A in S2’ exhibit a high level of similarity. The Cδ of Ile84A and 
Ile84B are in close contact to the benzylic methylene groups of the ligand (3.3/3.3 Å PRWT
and 3.5/3.6 Å PRI50V). In PRI84V, the Cγ of Val84A and Val84B only show Van der Waals 
contacts of 3.8 and 4.1 Å. The burial of the ligand surface within the binding pocket sums up 
to 95% in case of PRI50V and to 96% in case of PRWT and PRI84V.
An intercalation of a water molecule (O3074), is observed in PRI84V and results in 
additional polar protein-ligand interactions. The water molecule establishes hydrogen bonds 
to backbone carbonyl of Val82A, to side-chain of Thr80A, and to one ligand sulfonyl oxygen 
atom (Figure 8b). The binding pockets were analyzed with the program GRID. The resulting 
interaction fields of a water probe for PRI84V are displayed in Figure 9c.  
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Figure 9: The calculated GRID interaction fields for the binding pockets of PRWT (a) PRI50V (b) and (PRI84V (c) 
in complex with 9 are displayed as blue mesh at a contour level of 8 kcal/mol. The protein surface is 
schematically represented in wheat, the corresponding ligand is color-coded by atom type in green, yellow and 
magenta for PRWT, PRI50V and PRI84V, respectively. Experimental observed water molecules are shown as red 
spheres.  
Energetically favourable water contacts are predict in the region surrounding the catalytic 
Asp25A and Asp25B, at the far end of the S2 and S2’ pockets and next to Gly27A and 
Gly27B. The position of the additionally enclosed water molecule is identified as preferred 
position for a water molecule only in case of PRI84V (Figure 9a-c). The positions of the 
experimentally observed waters are in good agreement with the calculated interaction fields. 
4.3     Discussion
The intention of this study was to elucidate the potential of a new class of HIV protease 
inhibitors against crucial point mutations. The unique mode in addressing the enzyme’s 
subpockets observed for the C2-symmetric pyrrolidines suggests deviating susceptibility 
towards amino acid exchanges at the S1/S2’ and S1’/S2 pocket interfaces. The studied 
variants Ile50Val and Ile84Val are major mutations, both expanding the protease’s binding 
pocket. Kinetic characterization reveals significant ffinity decrease towards all four applied 
fluorogenic substrates with respect to the mutants. Similar observations are made for the 
inhibitors in case of the Ile50Val mutation, however, they were less pronounced as compared 
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to the substrates. In contrast, the inhibitors retain or even increase affinity towards the 
Ile84Val mutant. Obviously, removal of the methylene groups drew a different response in 
terms of binding affinity. 
Both inhibitors 8 and 9 are almost completely buried in all complexes due to the tunnel-
shaped binding cavity of the protease. The mutations at the pivotal positions do not influence 
the burial of the ligands. With respect to the Ile50Val complexes high similarity with the 
wild-type counterparts is observed. The side-chains of Ile50B form presumably unfavourable 
close contacts to the sulfonyl oxygen atoms in PRWT and PRI50V. In the wild-type protease, Cδ
of Ile50A is in Van der Waals contact to carbon atoms of the phenyl moiety of 8 and 9. In 
contrast, in PRI50V, the isoleucine exchange results in a loss of these favourable interactions, 
thus explaining the drop in inhibitor affinity. In case of Amprenavir, which bears a similar P2’ 
moiety, the susceptibility towards the Ile50Val mutation, is also attributed to these 
interactions.26
Larger differences are observed in case of the PRI84V complexes. Ligand and protein 
conformation, along with the formed polar interactions, is highly conserved. In PRI84V, Cδ of 
Ile50B forms Van der Waals contacts to the phenyl moiety of the inhibitors. This contact is 
not observed in the wild-type. Regarding the PRWT complexes, the Cδ atoms of Ile84A and 
Ile84B have unfavourable short Van der Waals contacts with ligand atoms. Through exchange 
of these residues to valine, these unfavourable conta ts are relaxed. The overall hydrophobic 
surface present in PRWT and PRI50V changes significantly, leading to a stronger exposure of 
the polar surfaces of Thr80 and Val82. In the wild-type complexes, the hydroxyl group of 
Thr80 is generally involved in a hydrogen bond to the main-chain carbonyl of Val82. As a 
result of the created additional space in PRI84V, a water molecule is picked up and participates 
in polar interactions, forming a hydrogen-bond network connecting Thr80A and Val82A with 
one sulfonyl oxygen atom of the ligand. In PRWT complexes, this oxygen atom is not involved 
in any polar interactions. At the symmetry-related B-domain, intercalation of a water 
molecule is not observed in the mutant, likely due to the shorter distance of the sulfonyl 
oxygen atom to the polar groups. Considering the results of a GRID analysis, the intercalation 
of a water molecule seems to be highly favourable in the A-domain. The additional hydrogen 
bonds to Thr80A and Val82A and the loss of short Van der Waals contacts to the residue in 
position 84A induce a slightly different loop conformation of the A-chain residues 79-84 of 
PRI84V. This is reflected by an increased rmsd of this region to PRWT: 0.56 Å in case of 8 and 
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0.54 Å in case of 9. This reorganization leads to a better mutual surface match of the ligand in 
the S1 pocket. 
 In summary these contributions add up to an improved affinity of this class of ligands 
towards the Ile84Val mutant. The amount of each indiv dual contribution is difficult to assign 
and will depend on slight differences in the shape nd accordingly accommodated binding 
mode. Clearly, the individual contributions are notadditive as can be seen when compounds 
8, 9 and 10 are compared. Inhibitors 8 versus 9 and 10 are equipped with different polar 
substituents (NH2 versus CONH2). They induce slightly different arrangements in the 
corresponding S2/S2’-pockets. Via the rigid central scaffold, this discrepancy is translated 
into small orientational differences of the ligands in the S1/S1’-pockets. They result in shorter 
Van der Waals contacts to Ile84 for 9 compared to 8. Mutating this residue to the smaller 
valine results in a relief of steric strain and provokes the observed increase in affinity 
discrimination between PRI84V and PRWT.  
4.4     Summary and Conclusion
The investigated pyrrolidine-based inhibitors provide a novel strategy to target the 
subpockets of HIV protease. This leads to a different occupation of the binding pocket, 
especially next to the border between the S1/S2’ and S1’/S2-pockets. The properties of the 
new inhibitor class have been examined towards the active-site mutations Ile50Val and 
Ile84Val. Kinetic data indicate a contrary behaviour: Reduced affinity towards PRI50V and 
improved potency towards PRI84V. The determination of cocrystal structures of two 
representative inhibitors (8 and 9) with the wild-type and the two variants provides the 
structural basis to explain this observation. The reduced affinity towards PRI50V could be 
rationalized in terms of reduced Van der Waals contacts, an observation already described in 
literature for Amprenavir. In case of PRI84V, multiple contributions are responsible: Amplified
Van der Waals contacts, enhanced polar interactions mediated by an intercalating water 
molecule that fills the gap created by the mutational exchange, and relief of steric strain likely 
given in the wild-type complexes. The Ile84Val mutation is discussed in literature mainly as 
an expansion of the active-site volume, lowering beneficial Van der Waals contacts to a 
bound ligand. Here, we can trace the exchange in more detail and make changes in the 
4. Pyrrolidine-based Inhibitors of the Drug Resistant Ile84Val HIV-1 Protease Mutant
90
exposed physicochemical properties responsible for the modified interaction profile. The 
investigated pyrrolidines are very rigid ligands. They cannot optimally adapt their shape to the 
PRWT binding pocket. Surface complementarity of the PRI84V binding pocket is more 
appropriate to accommodate an inhibitor compared to the wild-type, exhibiting in best case, a 
Ki = 12 nM for inhibitor 10. 
The message to be learned from this study concerns the change in physicochemical 
properties of the binding pocket upon Ile84Val mutation that can be exploited for inhibitor 
design. Taking advantage of these features might avoid the susceptibility towards this 
mutation, which has proven to be problematic for all presently approved inhibitors. 
Furthermore, this study unambiguously shows that large ffinity changes, e.g. a factor of 40 in 
case of 9, might result from very small deviations in the protein-ligand complexes. It also 
points to the limitations in modeling such differenc s. Only the detailed analysis of multiple 
complexes in terms of structure-activity relationship  provides deeper insights into the various 
contributions responsible for protein-ligand interactions. 
4.5  Experimental Section 
Inhibitor preparation: The Inhibitors were synthesized enantioselectively from D-(-)-
tartaric acid as recently reported.12 Stock solutions of inhibitors for kinetic measurements and 
cocrystallization were obtained by dissolving them in DMSO.  
Mutant preparation, purification and crystallizatio n: Mutants were prepared using the 
polymerase chain reaction with the Quick Change Site-directed Mutagenesis Kit 
(Stratagene).29 The pET11a plasmid containing the HIV-1 protease gene was kindly provided 
by Professor Helena Danielson, University of Uppsala. Synthetic oligonucleotides containing 
the desired mutation were used as mutagenic primers, 5'- CCAAAAATGATA-
GGGGGAGTTGGAGGTTTTATCAAAGTAAG-3' and 5'- CTTACTTTGATAAAACCTC-
CAACTCCCCCTATCATTTTTGG-3' for I50V; 5'- GGACCTACACCTGTCAACGTAAT-
TGGAAGAAATCTGTTG-3' and 5'- CAACAGATTTCTTCCAATTACGTGACAGGTGT-
AGGTCC-3' for I84V. All constructs were verified by DNA sequencing. The PRWT, PRI50V, 
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PRI84V  HIV protease variants were consecutively expressed from Escherichia coli and 
purified as previously described.30  
The HIV protease inhibitor complexes were crystallized at 18°C by the sitting drop vapour 
diffusion method using a 1:1 ratio. Crystals were obtained by cocrystallization of the enzyme 
with inhibitor concentrations ranging from 50- to 100-fold the Ki value and a final DMSO 
concentration of 5%. 1 µL of the well buffer (0.1 M BisTris, 2.5-3.0 M NaCl, pH 6.5) was 
mixed with 1 µL protein solution (50 mM NaAc, 1 mM EDTA, 1 mM DTT, pH 6.5) with a 
HIV protease concentration of 7-10 mg/mL. Crystals were obtained within 1-2 days and 
exhibited a rectangular shape. Crystals were further optimized using streak-seeding 
techniques. For cryoprotection the crystals were bri fly soaked in mother liquor containing 
25% glycerol. 
Kinetic Assay: Enzymatic assays were performed in 172 µL assay buffer (100mM MES, 
300 mM KCl, 5 mM EDTA, 1 mg/mL BSA, pH 5.5) by the addition of substrate dissolved in 
4 µL DMSO, distinct inhibitor concentrations dissolved in 4 µL DMSO and 20 µL HIV-1 
protease in assay buffer to a final volume of 200 µL (final DMSO concentration 4%). The 
fluorogenic anthranilyl-HIV protease substrates A (Abz-Thr-Ile-Nle-(p-NO2-Phe)-Gln-Arg-
NH2) and B (Abz-Lys-Ala-Arg-Val-Nle-(p-NO2-Phe)-Phe-Glu-Ala-Nle-NH2) were purchased 
from Bachem and C (Abz-Ala-Arg-Val-Nle-(p-NO2-Phe)-Phe-Glu-Ala-Nle-NH2) and D
(Abz-Arg-Val-Nle-(p-NO2-Phe)-Phe-Glu-Ala-Nle-NH2) from Sigma Aldrich. The kinetic 
constants for PRWT, PRI50V and PRI84V were determined by the method of Lineweaver and 
Burk. The total enzyme concentration was quantified by titrating with the strong binding 
inhibitor Saquinavir at a 200-fold higher enzyme con entration. Inhibition data for PRWT, 
PRI50V and PRI84V were determined as follows: IC50 values were taken from plots of vi/v0
versus inhibitor concentration, in which vi is the velocity in presence, and v0 the velocity in 
the absence of an inhibitor. The hydrolysis of the substrate A was recorded as the increase in 
fluorescence intensity (excitation wavelength 337 nm, e ission wavelength 410 nm) over a 
time period of 10 min during which the signal increas d linearly with time.31 Ki values were 
calculated from the following equation: Ki = [IC50 – (Et/2)][1 + (S/Km)]
-1
Data collection, phasing and refinement: The data sets were collected at the synchrotron 
BESSY II in Berlin/Germany on PSF beamline 14.2 (8 PRI50V, PDB ID: 3R43), equipped with 
a MAR-CCD detector and on a Rigaku R-AXIS IV image plate detector using Cu Kα
radiation from an in-house Rigaku rotating anode (8 PRI84V, 9 PRI50V, 9 PRI84V, PDB ID: 
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2R3W, 2R3T, 2R38). Data were processed and scaled with Denzo and Scalepack as 
implemented in HKL2000.32 The structures were determined by the molecular replac ment 
method with Phaser,33 one monomer of the 1.50 Å HIV-1 protease in complex with a 
pyrrolidine based inhibitor (PDB ID: 2PQZ) was used as the search model. The structure 
refinement was continued with SHELXL-97,34 for each refinement step at least 10 cycles of 
conjugate minimization were performed, with restraints on bond distances, angles and B-
values. Intermittent cycles of model building were done with the program COOT.35 The 
coordinates have been deposited in the PDB (http://www.rcsb.org/pdb/) with access codes: (8
PRI50V 2R43, 8 PRI84V 2R3W, 9 PRI50V 2R3T, 9 PRI84V 2R38). 
GRID Analysis and surface calculations: The calculations of the molecular interaction 
fields were performed with GREATER, a graphical user interface for the program GRID, 
version 22.36 The interaction box was defined to enclose the entire active sites. The grid 
spacing was = 0.33 Å (NPLA = 3) and the maximum positive cut-off energy was set to 8 
kcal/mol and visualized with Pymol. The buried surface area was calculated with the program 
MS developed by Connolly.37 The program calculates the molecular surface from atom 
coordinates; the probe radius was set to 1.4 Å.  
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5. Two Solutions for the same Problem: Multiple 
Binding Modes of Pyrrolidine-based HIV-1 Protease 
Inhibitors *  
5.1   Introduction 
The first successful application of structure-based drug design (SBDD) was reported in 
1976 by Beddell et al. who utilized the three dimensional structure of hemoglobin for ligand 
development.1 Since then the number of protein structures publicly available in the protein 
data bank (PDB) has increased exponentially resulting in more than 50000 entries nowadays.2
Due to the steadily growing amount of available protein structures and methodological 
advances in structural analysis, SBDD has meanwhile become an integral part of drug 
discovery projects.3  
The analysis of a protein-ligand complex gives detailed information about the protein-
ligand interactions. Once an initial lead has been id tified and the target protein is accessible 
for structural analysis it can further be optimized using iterative cycles comprising synthesis, 
biological evaluation, computational methods and structural analysis.4 The structural analysis 
using X-ray crystallography usually suggests the exist nce of one single well-defined state, 
anticipated as a unique binding mode, which is then utilized to propose the most promising 
modifications of the initial scaffold to further optimize a given lead. Numerous successful 
projects of SBDD have been published which led at best to the development of an approved 
drug, as for example in case of Tipranavir.5
* Taken from a manuscript in preparation, Andreas Blum, Jark Böttcher, Stefanie Dörr, Andreas Heine, Grhard 
Klebe, Wibke E. Diederich. Two solutions for the same problem: multiple binding modes of Pyrrolidine-based 
HIV-1 Protease Inhibitors. 
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However, the iterative process can face a lot of obstacles as well as surprises and numerous 
examples of a non-unique behavior within a series of imilar ligands have been described of 
which only the three following should be mentioned as representative examples: A reversed 
binding mode was detected by X-ray crystallography in due course SBDD process of non-
peptidic HIV protease inhibitors. In the reported case an alkylation of the inhibitor’s amide 
functionaleties resulted in a completely different occupation of the individual specificity sub-
pockets.6 The small energy deviations of such opposing binding modes have been investigated 
in detail, e.g. by the pH-dependency of the binding mode observed in case of trypsin inhibitor 
complexes.7 An extraordinary observation was made in case of Pr tein Kinase C: the inhibitor 
binds in different orientations to the two monomers present in the asymmetric unit.8
Observations like these mentioned above suggest that the occurrence of several binding 
orientations within a series of similar compounds or even for one certain ligand is not a rare 
case. Such phenomena can be indicated e.g. from a co plex SAR, which cannot be explained 
using the broadly accepted hypothesis that similar lig nds bind in a similar fashion.9  
Recently we reported our design and synthesis of C2-symmetric 3,4-disubstituted 
pyrrolidines as a new class of HIV-1 protease inhibitors.10 Our structure guided optimization 
was based on the initially observed cocrystal structure of the N-benzyl substituted inhibitor 1
























Figure 1: Schematic representation of the conserved binding mode of the pyrrolidine-3,4-bis-N benzyl-
sulfonamides. Hydrogen bonds are indicted by dashed and main-chain bonds using bold lines. 
In due course of the project additional cocrystal structures of the further developed 
inhibitors were determined to elucidate their interactions explaining a fully consistent SAR. 
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The conserved binding mode observed in the five crystal structures is depicted in Figure 1. 
All complexes between the topologically C2-symmetric inhibitors and the sequentially C2-
symmetric protein adopt an unsymmetrical binding mode with respect to the ligand. However, 
each sub-pocket related by an imposed C2-symmetry is occupied by substituents at the core 
skeleton of the inhibitor that mutually correspond by topological symmetry. The benzyl 
moieties occupy the S1- and S1’- subpockets whereas the sulfonamide side-chains of the 
inhibitor address the S2- and S2’-subpockets. The N-benzyl substituted derivatives were 
additionally analyzed with respect to their susceptibility towards the active site mutants 
Ile50Val (PRI50V) and Ile84Val (PRI84V), and revealed promising properties towards the 
Ile84Val mutation located at the borders of the S1/S2’- and S2/S1’-subpockets, respectively. 
Particularly, compounds bearing polar substituents in he S2/S2’-pockets showed significantly 
improved affinity towards the mutation of isoleucine by valine (e.g. compound 2).11 This 
observation was further analyzed by X-ray crystallography of the corresponding complexes of 
two derivatives together with the protease variants and could finally be explained by 
amplified Van der Waals (VdW) contacts, enhanced polar interactions mediated by an 
interstitial water molecule, and relief of steric strain likely given in the wild-type complexes.  
Interestingly enough, the determination of the binding affinities towards the PRI84V and 
PRI50V mutants of inhibitors bearing smaller N-alkyl substituents (3-5) revealed a different 
selectivity profile (Table 1). In order to further lucidate this peculiar difference in the SAR, a 
new small series of inhibitors was designed. Inhibitor 5, comprising the N-dimethylallyl 
substituents, which showed the best potency of the series, was picked as a reference. Its 
properties were further varied by decorating the sulfonamide benzyl group with para-
substituents of different physicochemical properties, such as polar carboxylate and amide 
groups and non-polar bromine and cyano groups. Based on the previously observed binding-
modes, this moiety was thought to occupy the S2- and S2’-pockets.  
5.2   Results and Discussion 
5.2.1   Chemistry 
The inhibitor scaffold is easily accessible in enantiomerically pure form from D-(-)-tartaric 
acid and inhibitors 1-5 have been synthesized as previously described.10 3,4-Diamino-
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pyrrolidine 10 reacts with para-bromo-phenylsulfonyl chloride. It renders the corresponding 
sulfonamide which is then alkylated using 3,3-dimethylallyl bromide thus leading to the key 
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Figure 2: Preparation of the inhibitors, the BOC-protected 3,4-diamino-pyrrolidine was prepared from D-(-)-
tartaric acid as previously described.10 a) p-Br-PhSO2Cl, NEt3, CH2Cl2: b) 3,3-dimethylallyl bromide, K2CO3, 
CH3CN, 0° to RT.: 92%; c) CH2Cl2:TFA 1:1: 74%; d) Zn(CN)2, Pd(PPh3)4, DMF, µW: 51%; e) 30% H2O2, 
K2CO3, DMSO: 38%; f) NaOH, H2O, µW: 46%. 
Deprotection of 11 under acidic non-aqueous conditions renders 7. Substitution of the para-
bromo substituent using Zn(CN)2 as cyanide source using Pd-catalysis under microwave 
irradiation required prolonged reaction times and high temperatures, which resulted in a 
concomitant cleavage of the BOC-protecting group and thus directly furnished inhibitor 8.12
Intermediate 8 was further utilized for the preparation of the inhibitors 6 and 9. Saponification 
of the nitrile functionality in 8 under basic conditions and microwave yielded the 
corresponding acid 9. Mild hydrolysis with 30% hydrogen peroxide in DMSO under catalysis 
of K2CO3 gave rise to 6.
13 Via the microwave-assisted approach the differently substituted 
pyrrolidines 6-9 are easily accessible in only 1-2 steps utilizing 11 as key intermediate in 
moderate overall yields. After purification with RP-MPLC, the inhibitors were obtained as 
triflouroacetate salts and tested for their affinity against the different HIV proteases.  
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5.2.2   Biological evaluation 
Determination of the affinities towards the protease variants gave rise to a structure-activity 
relationship (SAR) which surprisingly showed no clear preference for one type of substituents 
(Table 1).  
. P2/P2’ P1/P1’ 
PRWT




K i [µM] 
1 




0.26 1.4 0.036 
3 12 n.i.* 84 
4 75 340 53 




0.48 13 1.9 
7 Br 0.69 2.0 0.91 




3.3 11 2.9 
Table 1: Ki-values of the inhibitors towards the HIV protease. * n i. = Ki > 500µM 
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Whereas 6 bearing a polar amide functionality and 7 bearing a hydrophobic bromide 
substituent gain similarly in affinity towards PRWT and PRI84V, substitution with a carboxylate 
functionality 9 or the corresponding nitrile moiety 8 did not lead to an improvement in any of 
the cases. In comparison to PRWT and PRI84V binding, all compounds within this series reveal 
a reduced affinity towards PRI50V, similar to the previously studied series of N-benzyl 
substituted derivatives. In contrast to the N-benzyl substituted inhibitors no significant 
improvement in affinity towards PRI84V is observed for all the inhibitors comprising 3,3-
dimethylallyl substituents. The substitution with polar substituents in para-position of the 
sulfonyl-aryl moieties improves the binding affinites towards this mutation in case of the N-
benzyl derivatives. However, in case of the dimethylallyl substituted inhibitors, particularly 
for the most potent derivative 6, no change in the relative affinity difference can be observed, 
when compared to the unsubstuitueted counterpart 5. Compared with the corresponding 
benzyl derivative 2 which showed a seven-fold improvement with respect to PRI84V, the now 
four fold decrease can hardly be explained regarding only the steric demand of the different 
N-alkyl moieties. To rationalize these observations in tructural terms and in order to compare 
with the known binding mode of 2, we crystallized compound 6 in complex with the wildtype 
HIV-protease and consecutively determined its crystal structure. 
5.2.3   Structural Analysis 
Crystals of the PRWT in complex with 6 were obtained by cocrystallization of the enzyme 
with an inhibitor concentration of 100 µM and final DMSO concentration of 10% following 
our standard protocol. Crystals grew within a week and showed deviating appearance, cubic 
shaped at a precipitant concentration of 3.5 M NaCl and needle-like shaped at a concentration 
of 3 M NaCl. Whereas the cubic crystals exhibited the space group P212121 the needle-shaped 
crystal form corresponded to the space group P6122. Both structures could be determined with 
a resolution of 1.65 Å and ligand geometries were clearly visible in the Fo-Fc omit-map at a 
sigma level of 2 (Figure 3a and 3b). However, two completely different binding modes were 
observed and will be described separately: The geometry in space group P21 121 is referred to 
as orthorhombic binding mode, whereas the binding mode in P6122 is named hexagonal 
binding mode. 
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Figure 3: The Fo-Fc densities for the ligands is displayed at a σ level of 2.0 as blue mesh. (a) space group 
P212121, (green, color-coded by atom type ) (b) space group P6122 (blue, color-coded by atom type). 
P212121 P6122 
resolution (Å) 25-1.65 25-1.65 
space group P21 121 P6122 
cell dimensions (Å) a = 52.0 
b = 57.6 
c = 61.4 
a = 62.5 
b = 62.5 
c = 82.3 
highest resolution shell (Å) 1.68-1.65 1.68-1.65 
no. of measured reflections 99069 80672 
no. of independent reflections 22526 11774 
completeness (%)a 98.8 [89.4] 97.8 [96.2] 
I/σa 26.1 [2.7] 23.2 [4.3] 
R sym (%)
a 5.2 [35.0] 8.0 [36.8] 
resolution in refinement (Å) 10-1.65 10-1.65 
Rcryst (F > 4 σ Fo; Fo) 18.3; 20.2 22.4; 23.4 
Rfree(F > 4 σ Fo; Fo) 23.9; 26.2 27.4; 29.7 
mean B-factor (Å2) 
(peptide chain A; B) 
18.3; 17.3 30.5 
main-chain (Å2) 15.6; 15.5 27.5 
side-chains (Å2) 21.2; 19.4 33.9 
ligand (Å2) 32.4 38.2 
Cl (Å2) 19.2 - 
Water (Å2) 26.1 33.5 
Ramachandran plot   
most favored geometry (%) 96.2 94.9 
additionally allowed (%) 3.8 5.1 
Table 4: Crystallographic data. (a) Values in brackets refer to the highest resolution shell. 
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5.2.3.1   Binding mode in the orthorhombic form  
In the orthorhombic space group inhibitor 6 exhibits a binding mode closely related to the 
one previously observed for all our pyrrolidine-3,4-bis-N-benzyl-sulfonamides. The 
endocyclic amino functionality addresses the catalytic dyad and forms a hydrogen bond 
network with the aspartic acid residues 25A (2.8 Å / 2.8 Å)  and 25B (2.8 Å / 2.9 Å). Flap 
interactions are established via hydrogen bonding of only one of the inhibitor’s sulfonyl 
oxygen atoms to the main-chain NH of Ile50A (2.6 Å). The second sulfonyl oxygen atom of 
this sulfonamide group remains uninvolved in any polar interaction (Figure 4).  
Figure 4: Crystal structure of 6 (green, color-coded by atom type) in complex with HIV protease (P212121). The 
protein backbone trace is schematically illustrated in wheat, the catalytic Asp25A and Asp25B, Ile50A, Ile50B, 
Asp30A and Asp30B are displayed in grey color-coded by atom type. Hydrogen bonds are indicated by dashed 
lines. 
The opposing sulfonyl group of 6 does not form any polar interactions. Also the subsite 
occupancy is comparable to the previously determined complexes. Whereas the dimethylallyl 
substituents occupy the S1/ 1’-subpockets establishing contacts to Gly27A, Gly48A, Gly49A, 
Leu23B, Pro81B, Val82B, Ile84B (S1) and Leu23A, Gly27B, Ile84A (S1’), the S2/S2’-
pockets are addressed by the phenyl moieties of 6 forming numerous vdW contacts with 
Ala28A, Val32A, Ile47A, Gly48A (S2); Ile50A, Ala28B, Gly48B, Ile84B (S2’). The amide 
functionalities form hydrogen bonds to the main-chain NH of Asp30A (2.6 Å) and Asp30B 
(2.7 Å), and additionally in the S2’ pocket to the corresponding Asp30B side-chain (2.8 Å).  
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The Cα superposition of this structure with the crystal structure of the corresponding N-
benzyl substituted inhibitor (PDB ID: 2PWR) reveals that the overall binding mode is only 
slightly affected by the exchange of the N-benzyl to N-dimethylallyl moiety, which is 
reflected by a root mean square deviation (rmsd) between the Cα atoms of the complexes of 
0.53 and an rmsd of 0.60 Å for the identical ligand atoms of 2 and 6, using this alignment. 
The ligand is deeply buried in the binding pocket (90%).  
5.2.3.2   Binding mode in the hexagonal form 
The binding mode observed in the hexagonal space group deviates dramatically from the 
previously discribed binding mode which is in agreem nt to all examples yet observed for our 
pyrrolidine-based HIV protease inhibitors. In the hxagonal case, the complex of the C2-
symmetric protease and the C2-symmetric inhibitor 6 fully agrees to C2-symmetry (Figure 5).  
Figure 5: Crystal structure of 6 (light blue, color-coded by atom type) in complex with HIV protease (P6122). 
The protein backbone trace is schematically illustrated in wheat, the catalytic Asp25A and Asp25B, Ile50A, 
Ile50B, Arg8A and Arg8B are displayed in grey color-c ded by atom type. Hydrogen bonds are indicated by 
dashed lines. 
In this space group, the asymmetric unit comprises one monomer of HIV-1 protease. The 
functional dimer is generated via a twofold crystallographic symmetry. For purpose of 
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comparison amino acids of the protein chain A and their symmetry equivalents will be 
referred to as 1A to 99A and 1B to 99B, respectively. According to the imposed symmetry 
any ligand interactions to the A and B chain are identical. Similar to the orthorhombic case
the catalytic aspartates Asp25A and Asp25B are addressed by the endocyclic pyrrolidine 
nitrogen of 6 (2.8 Å / 2.9 Å). However, this is the only conserved f ature shared by the two 
binding modes. In contrast to the orthorhombic mode each sulfonyl group of 6 forms a direct 
hydrogen bond to Ile50A and Ile50B, respectively, with one sulfonyl oxygen atom of each 
sulfonamide group (3.0 Å). The para-carboxamido-benzenesulfonamide moieties occupy the
S1 and S1’-pockets forming vdW interactions to Leu23, Gly27, Gly49, Pro81, Val82, Ile84 
and polar interactions to Arg8 with the amide substituent (3.0 Å / 3.2 Å), of chain A and B, 
respectively. The S2 and S2’-pockets are now occupied by the dimethylallyl moieties 
establishing vdW contacts to Ala28, Val32, Ile47, and Ile50 of chain A and B. Comparison of 
the complex with the corresponding complex of the N-benzyl substituted inhibitor using a Cα
superposition reveals high similarity of the protein structures reflected by a root mean square 
deviation of 0.60 Å, but high dissimilarity for the identical ligand atoms (rmsd = 5.4 Å) using 
this alignment. Similarly to the orthorhombic case, the ligand is deeply buried in the binding 
pocket (86%). 
5.3    Discussion 
Investigation of the inhibitory potency of a series of pyrrolidine-based inhibitors against 
mutant-HIV protease variants resulted in a remarkably different selectivity profile of the N-
allyl substituted derivatives compared to the N-benzyl substituted initial lead structure. To 
elucidate the reasons for this opposing behavior especially against the Ile84Val mutant, a 
small series of inhibitors was synthesized based on the most potent derivative 5 of the initial 
series.  
However, the non-uniform SAR obtained within this series, comprising substituents with 
different physicochemical properties in para-position of the inhibitor’s sulfonamide aryl 
groups, did not match the activity pattern being expected from the binding mode of the N-
benzyl derivatives. For a detailed analysis of thisphenomenon and for comparison with the 
corresponding N-benzyl derivative 2, 6 was selected for crystal structure determination in 
complex with HIV protease. To our surprise protein crystals were obtained in two crystal 
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forms at very similar crystallization conditions. Both exhibited a space group deviating from 
the former series, in which 10 complexes of N-benzyl substituted inhibitors revealed identical 
crystal packing in P21 121.  
The analysis of the complex in space group P212121 revealed a binding mode closely 
resembling the one observed for all examples of theN-b nzyl series. Due to the similarity of 
the surface complementarities observed for this orthorhombic binding mode with those 
previously determined for 2, particular in the contact area to Ile84 (Figure 6a and 6c) a 
convincing explanation for the deviating selectivity profile is difficult to provide.  
Figure 5: Crystallographically observed binding modes in HIV protease in equal orientation and size (a – d) 
Surface representation of the ligand (color-coded by atom type) and the corresponding protein structure (wheat), 
view from the top with the flap region clipped off. Ile84 is highlighted in hot pink (a) orthorhombic binding 
mode of 6 (b) hexagonal binding mode of 6 (c) binding mode of 2 (PDB ID: 2PWR) (d) binding mode of 
Amprenavir (pdb ID: 1HPV) (e) Superposition of the ligand orientations observed in the corresponding 
orthorhombic (green) and hexagonal (blue) crystal structures of 5 aligned by a Cα-fit of the protein coordinates. 
However, the structural evidence found in the second hexagonal crystal form suggests that a 
different binding mode can be adopted. This binding mode reveals an inhibitor orientation 
much closer to that found for all approved peptidomimetic inhibitors, which are all known to 
exhibit susceptibility towards the I84V substitution (Figure 6b and 6d). The commonly 
accepted assumption that similar ligands bind in a similar fashion can definitely be ruled out 
in this case at least considering the crystalline state. Regarding the two different binding 
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modes, it is not evident which orientation will be preferred under biological conditions. The 
nature of the substituent and the different binding-pocket shape of the mutant enzymes might 
induce different preferences, resulting in an overall non-uniform SAR. Whether the adopted 
space groups impose special symmetry constrains onto the deviating binding modes or 
whether the preferred binding mode reinforces the crystal packing cannot be resolved at this 
point. A comparison of protein-protein contacts due to crystal packing as well as the 
additional observation of two chloride ions present in he P212121 complex, which exhibit at 
least a distance of 10Å to the closest ligand atom, however, do not satisfactorily explain why 
the binding mode observed in the orthorhombic case should not be possible in the hexagonal 
P6122 space group and vice versa. Both binding modes se m to possess a very close by 
energy content, however, they obviously resolve spontaneously by crystallization.  
5.4    Summary and Conclusion 
Recently, we developed N-benzyl substituted HIV protease inhibitors and investigated in 
detail their behavior toward the active site mutants PRI50V and PRI84V. The observation of an 
overall affinity increase towards PRI84V was, amongst others, attributed to relief of steric 
strain present in the wildtype complexes. The serie 3-9 presented in this contribution was 
intended to elucidate whether smaller hydrophobic residues might be better suited to address 
the S1 and S1’ pockets appropriately. However, an inconsistent SAR demanded the 
determination of a cocrystal structure of at least one derivative bearing such modifications. 
Crystal structures of the most potent derivative 6 were determined based on two different 
crystal forms, found serendipitely. Remarkably they could be grown under very similar 
crystallization conditions exhibiting only a concentration difference in the precipitating NaCl 
concentration. Both crystal forms exhibited comparable diffraction quality and in each case a 
well defined however, distinct inhibitor orientation could be identified. To our surprise, the 
complexes of identical overall composition exhibit d fferent protein-inhibitor interactions. 
Only the interactions to the catalytic dyad are similar along with a comparable burial of the 
ligands. The observation of two different binding modes for 6, suggests that also other 
members of this series could occur with more than one binding mode thus explaining the non-
consistent SAR within the series. Are the results obtained by this study a peculiar rarely 
occuring phenomenon or of fundamental importance also for other structure-based drug 
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discovery projects? There might be some statistical evidence for the widely accepted oppinion 
that similar ligands bind in similar fashion, however, this is by no means a “truism”! The 
question remains how often a similar behavior as found in this study remains unnoticed in a 
congeneric ligand series. Thoroughly and exhaustively p rformed structural biology has to be 
integral part of drug discovery projects and has to escort the entire optimization process. The 
same holds for the biological evaluation, which hasto be interpreted in very careful manner to 
identify possible changes of binding orientations during lead optimization. In fact, the 
observation of a different binding mode for members of a series might even provide 
unexpected opportunities to optimize ligands towards a particular binding profile. 
Furthermore, such ligands might exhibit remarkable advantage to escape resistance 
development. Likely both binding modes are close in nergy. Mutational changes can affect 
and influence either of the two modes and change the energetic balance. However, an 
inhibitor capable to bind in two close-by alternative modes might swap from one to the other 
in order to escape resistance development. A similar concept has been followed during the 
development of TMC125-R165335 (etravirine) and TMC120-R147681 (dapivirine), two 
novel allosteric site inhibitors of the reverse transcriptase with remarkable resistance profile.14
The authors describe such an advantage to overcome resistance development by the ability to 
bind the target enzyme in multiple conformations. 
5.5   Experimental Section 
Kinetic Assay: Enzymatic assays were performed in 172 µL assay buffer (100 mM MES, 
300 mM KCl, 5 mM EDTA, 1 mg/mL BSA, pH 5.5) by the addition of substrate dissolved in 
4 µL DMSO, distinct inhibitor concentrations dissolved in 4 µL DMSO and 20 µL HIV-1 
protease in assay buffer to a final volume of 200 µL (final DMSO concentration 4%). The 
fluorogenic anthranilyl-HIV protease substrate (Abz-Thr-Ile-Nle-(p-NO2-Phe)-Gln-Arg-NH2) 
was purchased from Bachem. The hydrolysis of the fluorogenic was recorded as the increase 
in fluorescence intensity (excitation wavelength 337 nm, emission wavelength 410 nm).15 The 
kinetic parameters of PRWT (Km = 14.6 µM), PRI50V (Km = 139 µM) and PRI84V (Km = 70 µM) 
were determined by the method of Lineweaver and Burk. IC50 values were generated by 
nonlinear regression analysis from plots of vi/v0 versus inhibitor concentration, in which vi is 
the velocity in presence, and v0 the velocity in the absence of an inhibitor. Ki values were 
calculated from the following equation: Ki = IC50/[1 + (S/Km)] 
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Crystallization of HIV-1 protease: Crystals of HIV-1 protease in complex with 6 were 
obtained by cocrystallization using the sitting drop vapor diffusion method. The well buffer 
(0.1 M BisTris, pH 6.5, 3-3.5 M NaCl) was mixed with 1µl protein solution (50 mM NaAc, 
pH 6.5, 1 mM EDTA, 1 mM DTT) with a HIV protease concentration of 7mg/mL. Crystals 
exhibited space group P212121 at a precipitant concentration of 3.5 M NaCl and P6122 at 3 M 
NaCl. For cryo-protection both crystal forms were biefly soaked in mother liquor containing 
25% glycerol. 
Data collection, phasing and refinement: The data sets were collected at the synchrotron 
BESSY II in Berlin/Germany on PSF beamline 14.2. Data were processed and scaled with 
Denzo and Scalepack as implemented in HKL2000.16 The structures were determined by the 
molecular replacement method with Phaser,17 one monomer of the 1.5 Å structure of the HIV-
1 protease in complex with a pyrrolidine-based inhibitor (PDB ID: 2PQZ) was used as the 
search model. Refinement was continued with SHELXL-97,18 for each refinement step at 
least 10 cycles of conjugate gradient minimization were performed, with restraints on bond 
distances, angles and B-values. Intermittent cycles of model building were done with the 
program COOT.19 The coordinates have been deposited in the PDB 
(http://www.rcsb.org/pdb/) with access codes: 3CKT (orthorhombic), 2ZGA (hexagonal).
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6. Achiral Oligoamines as Versatile Tool for the 
Development of Aspartic Protease Inhibitors * 
6.1    Introduction 
Aspartic proteases belong to the class of endopeptidases and have shown to play an 
important role in many physiological but also patho-physiological processes. The active site 
comprises two aspartic acid residues which activate a water molecule hence facilitating the 
nucleophilic attack at the scissile amide bond. Thecleavage of the substrate follows a general 
catalytic acid-base mechanism in which one of the two aspartates is protonated, the other 




























Scheme 1: Schematic representation of the catalytic mechanism of aspartic proteases. 
The nucleophilic attack of the activated water molecu  leads to a tetrahedral gem-diol 
intermediate which collapses under cleavage of the peptide bond. In general, 6-10 amino acids 
of the natural polypeptide substrates are recognized by aspartic proteases, thus demanding an 
extended active site. The standard nomenclature defines the substrate residues as e.g. P3, P2, 
P1, P1’, P2’, P3’ and the corresponding recognition p ckets as e.g. S3, S2, S1, S1’, S2’, S3’ 
as depicted in Scheme 2.3
* Taken from original publication, Andreas Blum, Jark Böttcher, Benedikt Sammet, Torsten Luksch, Andreas 
Heine, Gerhard Klebe, Wibke E. Diederich. Achiral Oligoamines as Versatile Tool for the Development of
Aspartic Protease Inhibitors.  Bioorg. Med. Chem.2008, 16, (18), 8574-86 























Scheme 2: Nomenclature of the protease’s subsites according to Berger and Schechter,3 the scissile peptide bond 
is indicated by crossing lines. 
Two classes of aspartic proteases have received pronounced attention as potential drug 
targets; the pepsin-like4 (family A1) and the retroviral proteases (family A2).5-7 The family of 
the pepsin-like proteases includes e.g. renin (cardiovascular diseases),8, 9 BACE-1 
(Alzheimer’s disease),10, 11 and the plasmepsins (malaria)12, 13 which all share a common 
folding motif: The N-terminal and the C-terminal domain, each contributing one catalytic 
aspartic acid residue, are connected via a β-sheet domain. The active site is formed by the 
closure of a flexible loop region termed “flap” whic  covers the active site and forms two 
hydrogen bonds to the substrate carbonyl groups adjacent to the cleavage site (Figure 1, PDB 
code: 1PSO).14  
Figure 1: Crystal structures of the peptidomimetic inhibitor Pepstatin A, shown in light blue color-coded by 
atom type, in complex with pepsin (PDB code 1PSO). The protein is represented as cartoon and flap region 
establishing interactions to the inhibitor is highlted in magenta. Hydrogen bonds are indicated by dashed 
lines. The catalytic aspartates are color-coded by atom type in grey and selected flap amino acid residues are 
color-coded by atom type in magenta.  
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In the S1 and S1’ pocket, preferably hydrophobic amino acids are recognized, whereas in 
the S2, S3, S2’, and S3’ pockets the recognition is on-uniform (Table 1). The retroviral 
aspartic proteases belong to the A2 family, among which the HIV-1 protease was shown to be 
a valuable drug target for treatment of HIV-infection.15-18 The HIV-1 protease is a C2-
symmetric protein consisting of two identical subunits each contributing one catalytic 
aspartate. In contrast to family A1, the binding pocket is formed by the closure of two flaps. A 
conserved water molecule mediates the interactions of the peptide carbonyls adjacent to the 
cleavage site and the flap residues Ile50A and Ile50B (Figure 2, PDB code: 5HVP).19  
Figure 2: Crystal structure of the peptidomimetic inhibitor Pepstatin A, shown in light blue color-coded by atom
type, in complex with the HIV-1 protease (PDB code 5HVP). The proteins are represented as cartoons and fl p 
regions establishing interactions to the inhibitor are highlighted in magenta. Hydrogen bonds are indicated by 
dashed lines. The catalytic aspartates are color-coded by atom type in grey, selected flap amino acid residues are 
color-coded by atom type in magenta and the flap water molecule is shown as red sphere. 
The HIV protease recognizes a variety of natural substrates with a strong preference for 
those bearing hydrophobic amino acids in P1 and P1’ and variable amino acids in farther 
positions (Table 1).20
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protease substrate P3 P2 P1 P1’ P2’ P3’ 
pepsin A - - - F/L F - - 
Plm II hemoglobin α-chain R M F L S F 
Plm IV hemoglobin α-chain R M F L S F 
renin angiotensinogen F H L L/V V/I H 
BACE-1 amyloid-precursor-protein V K M D A Q 
HIV-1 protease gag polyprotein Q N Y P I V 
  R V L A E A 
  T I M M Q R 
  A N F L H K 
  G N F L Q S 
 pol polyprotein F N F P Q I 
  L N F P I S 
  E T F Y V D 
  K I L F L D 
Table 1: Cleavage sites in natural substrates of the selected aspartic proteases as annotated in the MEROPS 
database.6
Despite immense efforts in the development of clinially effective drugs targeting aspartic 
proteases, up to now, only for HIV protease21 and renin inhibitors have been approved for 
disease therapy.22-24 The rational design of inhibitors has mostly been guided by the structure 
of the natural peptide substrates thus resulting in very potent inhibitors. However, the 
pharmacokinetic properties of these peptidic compounds bearing secondary hydroxyl groups 
as transition state isosters are often not optimal, thus hampering their clinical efficacy.25 The 
synthesis of these complex and chiral inhibitors often turns out to be very challenging and the 
optimization of the sub-pocket-addressing moieties is very resource-intensive and time-
consuming. Replacement of the secondary hydroxyl group in transition state mimetics by the 
nearly isosteric amino functionality as well as by cyclic amidines has also been successfully 
pursued.26-29 Additionally, reduced amide transition state isoters have been exploited recently 
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as BACE-1 inhibitors.30, 31 However, for a more efficient development of novel aspartic 
protease inhibitors, an easily accessible and achirl core structure would be preferable. 
Utilizing such scaffolds would facilitate the development of promising moieties addressing 
the protease’s sub-pockets. As suitable core structure for this approach we selected secondary 
amines, which have already been successfully utilized as anchoring groups for the 
development of aspartic protease inhibitors. 
 In the late 1990s, researchers at Roche discovered th  piperidine moiety as a novel 
privileged skeleton addressing the catalytic dyad of aspartic proteases with its secondary 
nitrogen as revealed by X-ray crystallography.32-34 Based on this discovery, several projects 
for the development of non-peptidic amine-based aspartic protease inhibitors have been 
pursued, which led to the development of potent inhib tors for the aspartic proteases 
plasmepsin (Plm) II and IV,35-38 BACE-1,39 and very recently for HIV-1 protease.40 All 
inhibitors share in common a cyclic amino functionality addressing the enzyme’s catalytic 
dyad directly or mediated by a water molecule. However, numerous scaffolds have been 
utilized. Depending on the nature of the scaffold an the target enzyme studied, the specificity 
pockets are addressed differently. In case of a pyrrolidine-based HIV-1 protease inhibitor, the 
interaction of the endocyclic, secondary amino functio ality to the catalytic aspartic acid 
residues was studied by X-ray crystallography and Poisson-Boltzmann calculations. The latter 
study suggests the amine being in the protonated and the catalytic dyad in the fully 
deprotonated state resulting in strong electrostatic in eractions.41
6.2   Results 
 To further exploit this promising anchoring group for the design of novel, easily accessible 
inhibitors, linear oligoamines were selected as novel core structure. This scaffold bears a 
central secondary amino function aimed to address the catalytic dyad. Via the distal amino 
functionalities, the introduction of appropriate acceptor groups addressing the flap regions of 
the respective target enzyme is easily amenable. Concomitantly hydrophobic moieties 
intended to address the S2 and S2’ specificity pockets are introduced. Via further alkylation 
of the distal nitrogen atoms, additional hydrophobic substituents can be implemented to 
address the S1/S1’-pockets, thereby avoiding the gen ration of any chiral center. This strategy 
allows the quick and straightforward generation of achiral inhibitors following a highly 
flexible and short synthetic route. To optimize theamine-acceptor distances with respect to a 
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certain target enzyme, oligoamines with varying chain length between the central and each of 
the distal amino functionalities can be employed. 
 For the design of an initial library, linkers with wo and three methylene groups separating 
the amino groups were selected. As hydrophobic moieties intended to address the S1/S1’ sub-
pockets, iso-butyl and benzyl groups resembling the side chains of leucine and phenylalanine 
of substrate peptides were introduced. For appropriate flap interactions, two types of acceptor 
functionalities were investigated: on the one hand carboxamides present in the natural 
substrate and on the other hand sulfonamides, which allow additional rotational degrees of 
freedom. The introduction of residues addressing the S2/S2’ pockets is easily achieved via 
further substitution at the lateral nitrogen atoms. In case of the sulfonamides, the hydrophobic 
phenyl and the more polar p-amino phenyl group were chosen. For carboxamides, phenyl 
acetic acid derivatives were utilized offering additional flexibility between the rigid amide 
functionality and the phenyl ring. 
6.2.1      Chemistry 
Oligoamines 3a-c, BOC-protected at the pivotal, secondary amino functio , are accessible 
from commercially available precursors 1a-c by transient protection of the terminal amino 
groups as their trifluoroacetamides 2a-c (Scheme 3).42 Condensation with sulfonyl chlorides 
furnished the sulfonamides 4a-f which were further alkylated with benzyl bromide giving rise 
to the protected inhibitors 5a-f. The phenyl-substituted sulfonamides 6a-c were obtained via 
deprotection of 5a-c with HCl in Et2O. The p-amino phenyl-substituted sulfonamides 6d-f
were synthesized by reduction of the corresponding n tro-compounds 5d-f with SnCl2*2H2O 
in refluxing 32% HCl under concomitant cleavage of the BOC-protecting group. The iso-
butyl-substituted inhibitors 9a,b are accessible via reductive amination of 3a with iso-
butyraldehyde and NaBH4 as reducing agent yielding 7, followed by condensation with 
sulfonyl chlorides rendering 8a,b. The final inhibitors 9a,b were obtained by reduction of the 
nitro functionality or by acidic cleavage of the BOC-protecting group as described above. 
Carboxamide inhibitors 12 were synthesized following a similar synthetic sequence: The 
benzyl-substituted oligoamines 10a-c were obtained by reductive amination of the amines3a-
c and benzaldehyde utilizing Pd/BaSO4 as catalyst. Subsequent condensation with 
phenylacetic acid chloride gave rise to the protected inhibitors 11a-c, which were deprotected 
under acidic anhydrous conditions yielding 12a-c.  







































































(n,m): a (1,1), b (1,2), c (2,2)
( )n ( )m ( )n ( )m
( )n ( )m
2a-c
(n,m): a (1,1), b (1,2), c (2,2)
3a-c
(n,m): a (1,1), b (1,2), c (2,2)
3a-c
( )n ( )m
4a-f
R = Ph: a (1,1), b (1,2), c (2,2)
R = p-NO2Ph: d (1,1), e (1,2), f (2,2)
( )n ( )m
5a-f
R = Ph: a (1,1), b (1,2), c (2,2)
R = p-NO2Ph: d (1,1), e (1,2), f (2,2)
( )n ( )m
6a-f
R = Ph: a (1,1), b (1,2), c (2,2)
R = p-NH2Ph: d (1,1), e (1,2), f (2,2)
3a
7
8a R = Ph
8b R = p-NO2Ph
9a R = Ph
9b R = p-NH2Ph
3a-c
( )n ( )m
10a-c
a (1,1), b (1,2), c (2,2)
( )n ( )m
11a-c
a (1,1), b (1,2), c (2,2)
( )n ( )m
12a-c
a (1,1), b (1,2), c (2,2)
Scheme 3: Synthetic sequence for the preparation of the oligoamines. 
6.2.2     Kinetic characterization 
To elucidate the potential of this new class of inhibitors, the affinity toward selected 
aspartic proteases was determined in fluorescence-bas d assays using commercially available 
substrates. The results are listed in Table 2. The anthranyl-HIV protease substrate was utilized 
in case of the HIV-1 protease (Km = 14.6 µM), pepsin (Km = 13.3 µM), and the plasmepsins II 
(Km = 63 µM ) and IV (Km = 28 µM). For renin and BACE-1, suitably labeled olig peptides 
derived from their natural substrates with comparable ffinity were used (renin substrate Km = 
3.3 µM, BACE-1 substrate Km = 7.9 µM).  
























( )n ( )m
12a-c 
n m P2 P1 HIV-1 pr. Plm II Plm IV renin BACE-1 pepsin 
6a 1 1 3.8 7.0 36 n.i. n.i. 5.7 
6b 1 2 14 18 17 n.i. n.i. 15 
6c 2 2 n.i. 21 42 n.i. 150 n.i. 
6d 1 1 NH2 9.6 4.2 7.5 n.i. n.i. 3.9 
6e 1 2 NH2 n.i. 22 7.5 n.i. n.i. n.i. 
6f 2 2 NH2 n.i. 2.8 20 n.i. 64 4.0 
9a 1 1 10 23 87 n.i. n.i. 4.5 
9b 1 1 NH2 0.9 6.8 56 n.i. n.i. 4.8 
12a 1 1 n.i. 91 98 5,7 n.i. n.i. 
12b 1 2 n.i. 63 56 n.i. n.i. n.i. 
12c 2 2 n.i. 120 170 16 n.i. n.i. 
Table 2: Ki-values of the inhibitors towards selected aspartic proteases in µM ( n.i. (IC50 > 250 µM)). 
 Except for BACE-1, for each of the investigated target enzymes an inhibitor with an 
affinity in the single-digit micromolar range could be identified (Table 2). In case of the HIV-
1 protease, a strong preference for inhibitors bearing ethylene linkers and a sulfonyl moiety 
was observed, with affinities ranging from 10 µM for 9a up to 0.9 µM for 9b. Considering the 
pepsin-like proteases, the tolerance of extended linkers is noteworthy. Particularly the 
plasmepsins II and IV reveal a remarkable tolerance toward the linker length: inhibitor 6f
exhibits the highest affinity towards Plm II (2.8 µM) and the corresponding analogues 6d and 
6e toward Plm IV (7.5 µM). An inhibition of renin could only be observed in case of 
derivatives equipped with carbonyl groups as acceptor functionalities. With compound 12a
bearing the shortest linkers, the highest affinity (5.7 µM) could be achieved. An inhibition of 
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pepsin is only accomplished with sulfonamide derivatives, 6d being the most active 
compound (3.9 µM) in the series. However, no preference toward a certain chain length could 
be observed. In case of BACE-1, the sulfonamides equipped with the longest linkers show 
moderate inhibition with an affinity of 64 µM for compound 6f.  
6.2.3   Structural analysis 
 To elucidate whether the oligoamine derivatives indeed exhibit the expected binding mode 
thus being in agreement with our initial design concept, the crystal structure in complex with 
one of the target enzymes was determined. Since the crystallization of HIV-1 protease is well 
established in our lab, this enzyme was selected for crystallization. The inhibitors 6a, 6d, and 
9b exhibiting the highest potency were selected for cocrystallization experiments. However, 
crystals could only be obtained in case of the better soluble compounds 6d and 9b. The X-ray 
structures of these compounds in complex with HIV-1 protease were determined with a 
resolution of 1.90 and 1.80 Å, respectively. The crystallographic data and refinement statistics 
are listed in Table 3. Both complexes adopt space group P21212 and the inhibitors are clearly 
visible in the Fo-Fc density at a sigma level of 3. They could be refined as one single 
conformer (Figure 3). 
Figure 3: Ligand geometries of 6d (a, color-coded by atom type in green) and 9b (b, color-coded by atom type 
in yellow) in the cocrystal structures with the HIV-1 protease. The Fo-Fc omit maps for the ligands are displayed 
at a σ level of 3.0 as blue mesh. The protein surface is schematically represented in grey and the catalytic
aspartates Asp25A and Asp25B are highlighted in red.
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6d 9b 
resolution (Å) 50-1.80 30-1.90 
space group P21 12 P21212 
cell dimensions (Å) 
a = 57.4 
b = 85.7 
c = 46.5 
a = 56.0 
b = 85.9 
c = 46.5 
highest resolution shell (Å) 1.83 -1.80 1.93 -1.90 
no. of measured reflections 49890 65713 
no. of independent reflections 21367 18795 
completeness (%)a 97.4 [97.6] 99.0 [100] 
I/σa 16.0 [2.0] 15.6 [2.6] 
R sym (%)a 7.8 [44.4] 8.0 [49.0] 
Rcryst (F > 4 σ Fo; Fo) 18.4; 20.8 18.2; 20.9 
Rfree(F > 4 σ Fo; Fo) 23.0; 26.0 23.9; 27.1 
mean B-factor (Å2)  
protein (chain A; B) 
25.9; 22.4 29.5; 27.1 
mean B-factor (Å2) ligand 35.1 33.1 
mean B-factor (Å2) water 31.0 34.0 
Ramachandran plot   
most favored geometry (%) 96.8 95.6 
additionally allowed (%) 3.2 4.4 
RMSD bonds (Å) 0.006 0.005 
RMSD angles (°) 2.0 2.0 
Table 3: X-ray data processing and refinement for the HIV-1 Protease complexes of derivative 6d and 9b. 
(a)Values in brackets refer to the highest resolution shell.
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6.2.3.1 Binding mode of 6d 
 The binding mode is schematically represented in Scheme 4. The pivotal secondary 
nitrogen of the inhibitor points toward Asp25A forming polar contacts to the terminal oxygen 















































Scheme 4: Schematic representation of the binding mode of 6d. Hydrogen bonds are indicated by dashed lines 
and distances are given in Å. 
  The N-benzyl moieties of the inhibitor address the S1 and S1’ pockets, whereas the p-
amino-phenyl sulfonamide groups occupy the S2 and S2’ pockets. The p-amino substituents 
form a similar hydrogen bond network in both pockets: hydrogen bonds are observed to the 
main chain carbonyl oxygen atoms of Asp30A and Asp30B and to the corresponding side 
chain carboxyl oxygen atoms in each case mediated by a water molecule. One sulfonyl 
oxygen atom of each sulfonamide functionality establishes hydrogen bonds to a tetrahedrally 
coordinated water molecule mediating polar contacts to the main chain NHs of Ile50A and 
Ile50B, which are located at the tips of the flaps. One of the sulfonyl oxygen atoms remains 
unsatisfied showing no direct polar contacts to the protein. The ligand is deeply embedded in 
the binding pocket with a surface burial of 94%.  
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6.2.3.2 Binding mode of 9b 
The crystal structure of 9b in complex with HIV-1 protease exhibits a high similarity to the 
previously described complex. Comparable polar interactions of the secondary amino group 













































Scheme 5: Schematic representation of the binding mode of 9b. Hydrogen bonds are indicated by dashed lines 
and distances are given in Å. 
The sub-pocket occupancy resembles the binding situation of 6d: The iso-butyl moieties 
occupy the S1 and S1’ pockets, and the p-amino-phenyl sulfonamide groups are located in the
S2 and S2’ pockets. The amino substituents form a similar hydrogen bond network as already 
described for 6d: hydrogen bonds to the main chain carbonyl oxygen of Asp30A, Asp30B as 
well as water-mediated to the corresponding side chain carboxyl oxygens are formed. The 
most pronounced difference between both complexes is the deviating polar interaction of the 
sulfonyl groups of the inhibitor to the flap. Although a water molecule is involved in the 
mediation of polar contacts of the sulfonyl oxygen atoms in both cases, a different 
coordination is observed. In contrast to 6d, the water in the enzyme-inhibitor complex of 9b is 
not tetrahedrally coordinated. It only forms hydrogen bonds to two sulfonyl oxygen atoms and 
the main chain NH of Ile50A. One of the sulfonyl oxygen atoms establishes an intramolecular 
hydrogen bond to the pivotal oligoamine nitrogen atom, as observed in case of 6d. In contrast 
to the previous structure, the second sulfonyl oxygen atom directly addresses Ile50 NH of the 
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B chain, whereas in case of 6d, this oxygen atom remains without any polar contacts. The 
overall burial of the inhibitor sums up to 93%.  
6.3 Discussion 
The biological data as well as the crystal structures of 6d and 9b in complex with HIV-1 
protease clearly reveal that our initial design concept has been successful. For all of the 
investigated aspartic proteases inhibitors binding in the micromolar range could be identified. 
Noteworthy, for most of these enzymes a preference toward ethylene linkers is observed. The 
sulfonamide acceptor groups allowing additional rotati nal degrees of freedom are favored 
compared to the carbonyl groups for all targets except for renin. In the latter case the more 
rigid structure of N-alkylated carboxamides is obviously preferred for inhibition.   
The binding modes of 6d and 9b in HIV-1 protease reveal how these compounds fulfill the 
initial pharmacophore hypothesis. As intended, the secondary amino group addresses the 
catalytic dyad, and two of the sulfonamide oxygen atoms mimic the substrate’s amide 
carbonyl groups. This is illustrated by the Cα-superposition of the complex structures of 6d
and 9b, respectively, with the crystal structure of a substrate analogue oligopeptide in 
complex with an inactive HIV-1 protease mutant (PDB code: 1KJH) (Figure 4a and 4b).20  
Figure 4: (a, b) Cα-superposition of the cocrystal structures of 6d (green, color-coded by atom type) and 9b
(yellow, color-coded by atom type) with the structure of a substrate analogue polypeptide (magenta, color- ded 
by atom type) in complex with an inactive Asp25Asn HIV protease mutant (PDB-code: 1KJH) The protein 
surface is schematically represented in grey and the catalytic aspartates Asp25A and Asp25B are highlighted in 
red. 
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In addition, the specificity pockets of the enzyme ar occupied analogously, however, the 
direction in which the S1/S1’ pocket is addressed dviates from the substrate’s one. The ten-
fold lower binding affinity of the inhibitor 6d compared to 9b can most likely be attributed to 
this difference: the benzyl moieties of 6d are in our case now slightly too large to occupy the 
S1/S1’ pockets appropriately. 
The Cα-superposition of the crystal structures in complex with the HIV-1 protease of the 
approved peptidomimetic inhibitor Amprenavir (PDB code: 1HPV) and 9b, which bears the 
same P1 and P2 substituents, is shown in Figure 5.43   
Figure 5: Cα-superposition of the cocrystal structures of 9b (yellow, color-coded by atom type) with the 
cocrystal structure of the approved inhibitor Amprenavir (blue, color-coded by atom type, PDB-code: 1HPV). 
The protein surface is schematically represented in grey and the catalytic aspartates Asp25A and Asp25B are 
highlighted in red. 
 Comparing the positions of the N-iso-butyl-N-p-amino-phenyl sulfonamide moieties of the 
inhibitors which address the S1 and S2 pocket, only slight differences can be observed. 
Although the inhibitors comprise different moieties, the occupation of the S1’ and S2’ pockets 
appears similar. However, due to their polymethylene li kers, the oligoamine derivatives are 
very flexible molecules and a high degree of pre-organization prior to binding to the protein is 
required, resulting in an entropic penalty thus lowering the overall affinity. Additionally, the 
position of the flap-water molecule present in the complexes of 6d and 9b is different in the 
oligoamine structures when compared to the substrate-like oligopeptide and Amprenavir 
complexes. In case of 6d, a similar tetrahedral coordination of the water molecule is observed, 
but it is shifted about 1 Å away from the catalytic dyad. A deviation from the usually 
6. Achiral Oligoamines as Versatile Tool for the Development of Aspartic Protease Inhibitors 
127
observed coordination is detected in case of the 9b complex leading to a direct interaction of 
one sulfonyl oxygen atom with the flap. These observations indicate that the flap interactions 
of the oligoamines 6d and 9b in case of HIV-1 might require some further improvement. 
Taking all these facts into account, the lower affinity by three orders of magnitude of the 
oligoamines compared to Amprenavir (Ki = 0.6 nM) could find an explanation. 
 The observed peptide-like binding mode in case of the ethylene-bearing inhibitors 6d and 
9b in complex with HIV-1 protease suggests a similar binding situation in case of the other 
pepsin-like proteases. In this case, the acceptor functionalities of the inhibitors mimic the 
carbonyl groups of the substrate adjacent to the cleavage site, resulting in the same subsite 
occupation as observed for 6d and 9b. However, in contrast to HIV protease, there is no clear 
preference for the ethylene linkers. In pepsin-like proteases, amino acids bearing flexible 
polar side chains are located in the flap region: Thr77 in case of pepsin (Figure 1b), Ser76 and 
Thr77 in case of renin, Thr72 and Gln73 in case of BACE-1, and Ser79 in case of Plm II and 
Plm IV. In addition to the peptide recognition motifs, these residues might also be addressed 
by the acceptor groups of the inhibitors resulting i  the preference for longer linkers. The 
binding of inhibitors with propylene linkers results in a larger distance between the sub-
pocket-addressing hydrophobic moieties and could omit ccupancy of the S1 or S1’ pockets. 
This might explain the inhibition of BACE-1 only by the inhibitors 6c and 6f, because the 
S1’-pocket of BACE-1 is featured to recognize an aspartic acid side chain. Most likely, the 
studied oligoamine inhibitors are not suitable to address this site. 
6.4   Summary and Conclusion 
 In this study, we present a novel rational strategy for the development of aspartic protease 
inhibitors. This method is based on achiral linear oligoamines, which are easily accessible via 
a short and flexible synthetic route starting from commercially available precursors. Within 
the initial compound series comprising eleven inhibitors, several hits for the target enzymes 
could be identified. Some of them reveal remarkable selectivity, others show broad 
promiscuity. Noteworthy, for five out of six target enzymes, at least one single-digit 
micromolar inhibitor could be identified. The crystal structures of two representatives in 
complex with the HIV-1 protease proved the concept initially used for their design. The 
central amino group addresses the catalytic dyad, the acceptor groups establish polar 
6. Achiral Oligoamines as Versatile Tool for the Development of Aspartic Protease Inhibitors 
128
interactions to the flap, and the hydrophobic moieties occupy the sub-pockets of the enzyme. 
The binding mode exhibits high similarity to the binding orientation of substrates as well as to 
that of other peptidomimetic inhibitors. Taking this into account, the generalization of the 
observed binding situation to other aspartic proteases appears reasonable thus providing a first 
insight into the observed structure-activity relationships. 
The straightforward synthesis allows the combinatori l introduction of numerous different 
substituents, thus facilitating the preparation of a plethora of putative aspartic protease 
inhibitors. The derived SAR data from such libraries can easily be utilized for the selection of 
promising moieties for selectively addressing the sp cificity pockets of a target enzyme in 
order to optimize inhibitors bearing other scaffolds. Hits from these oligoamine libraries can 
also be utilized as suitable starting point for furthe  optimization. Structural variation of the 
oligoamine chain based on a certain inhibitor, at best guided by a crystal structure, can lead to 
novel derived amine-based scaffolds. Increasing the rigidity of the linker chain is the most 
promising approach, leading to a better preorganization of the inhibitor and a reduction of the 
entropic penalty costs upon binding hence most likely resulting in a gain of affinity. 
6.5   Experimental Section 
6.5.1   Enzyme Assays 
 Enzyme Assays: All enzyme assays were performed at room temperature on a microplate 
reader (Safire²™) using black 96-well microtiter plates purchased from Nunc. The assay 
volume was 200 µl, and inhibitors and substrates were previously dissolved in dimethyl 
sulfoxide (final concentration 4%). The hydrolysis of the substrates was recorded as increase 
in fluorescence intensity. IC50 values were generated by nonlinear regression analysis from 
plots of vi/v0 versus inhibitor concentration, in which vi is the velocity in presence, and v0 the 
velocity in the absence of an inhibitor. The kinetic constants were determined by the method 
of Lineweaver and Burk and Ki values were consecutively calculated from the following 
equation: Ki = IC50 / [1 + (S/Km)]. The overall error of the assays is estimated to be ±40%.
HIV-1 Protease: Recombinant HIV-1 protease was expressed from Escherichia coli and 
purified as previously described.44 The fluorogenic substrate Abz-Thr-Ile-Nle-(p-NO2-Phe)-
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Gln-Arg-NH2 was purchased from Bachem and exhibited a Km of 14.6 µM. The assays were 
performed in 100 mM MES, 300 mM KCl, 5 mM EDTA, 1 mg/ L BSA, pH 5.5, and a 
substrate concentration of 20 µM, (excitation wavelength 337 nm, emission wavelength 
410 nm).45
  Plasmepsin II and Plasmepsin IV: Recombinant plasmepsin II and plasmepsin IV were 
expressed from Escherichia coli and purified following the protocol described by Hill et al.46
The fluorogenic substrate Abz-Thr-Ile-Nle-(p NO2-Phe)-Gln-Arg-NH2 was purchased from 
Bachem (Km (Plm II) = 63 µM and Km (Plm IV) = 28 µM). The assays were performed in 100
mM NaAc, pH 4.5, 1 mg/mL BSA and a substrate concentration of 18 µM (excitation 
wavelength 337 nm, emission wavelength 410 nm). 
 Renin: The fluorogenic substrate Arg-Glu(EDANS)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-
Thr-Lys(DABCYL)-Arg and recombinant renin were purchased from Sigma-Aldrich 
(Km = 3.3µM). Assays were performed in 50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 
pH 8.0 and a substrate concentration of 5 µM (excitation wavelength 340 nm, emission 
wavelength 500 nm).47
 β-Secretase: The fluorogenic substrate MOCAc-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-
Arg-(2,4-dinitrophenyl)-Lys-Arg-Arg-NH2 and recombinant β-secretase were purchased from 
Sigma (Km = 7.9 µM). Assays were performed in 100 mM NaAc, pH 4.5, and a substrate 
concentration of 5 µM (excitation wavelength 320 nm, e ission wavelength 405 nm).
 Pepsin: Pepsin from porcine gastric mucosa was purchased from Sigma-Aldrich and the 
HIV protease substrate Abz-Thr-Ile-Nle-(p NO2-Phe)-Gln-Arg-NH2 was used for kinetic 
measurements (Km = 13.3 µM). Assays were performed in 10 mM NaHCOO, pH 3.5 and a 
substrate concentration of 20 µM (excitation wavelength 337 nm, emission wavelength 
410 nm). 
6.5.2   Structural analysis 
 Crystallization of the HIV-1 protease inhibitor complexes: The HIV-1 protease inhibitor 
complexes were crystallized at 18°C in 0.1 M BisTri, pH 6.5, 2.5-3.0 M NaCl and a protein 
concentration of 7 mg/mL in the space group P21212 (crystal data, Table 4). The crystals were 
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obtained by cocrystallization of the enzyme with inibitor concentrations ranging from 20 to 
100 fold the Ki value. Crystals were further optimized using streak-seeding techniques. For 
cryoprotection the crystals were briefly soaked in mother liquor containing 25% glycerol.  
 Data collection, phasing and refinement: The data sets were collected on a Rigaku R-
AXIS IV image plate detector using Cu Kα radiation from an in-house RU-H3R Rigaku 
rotating anode. Data were processed and scaled with Denzo and Scalepack as implemented in 
HKL2000.48 The structures were determined by the molecular replac ment method using 
Phaser,49 one monomer of the 1.50 Å HIV-1 protease in complex with a pyrrolidine based 
inhibitor (PDB code 2PQZ) was used as the search model. The structure refinement was 
continued with SHELXL-97,50 for each refinement step at least 10 cycles of conjugate 
gradient minimization were performed, with restraints on bond distances, angles and B-
values. Intermittent cycles of model building were done with the program COOT.51 The 
coordinates have been deposited in the PDB (http://www.rcsb.org/pdb/) with access codes: 
3BGC and 3BGB. 
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7. Chasing Binding Modes in HIV Protease: From 
Seemingly Perturbed to Seemingly Relaxed Pose 
Without Altering Affinity * 
7.1  Introduction 
Inhibition of HIV protease has been successfully established as a therapeutic strategy to 
combat AIDS.1, 2  Hardly any other drug target has been studied with similar intense by 
structural biology and medicinal chemistry over the last 20 years. Nowadays, rational 
approaches to drug discovery heavily exploit crystal tructure analyses to learn about binding 
modes and the effectiveness of protein-ligand binding in order to draw conclusions for further 
drug optimization.3 Innumerable reports discuss binding modes in terms of protein-ligand 
complementarity and frequently the argument is used that a ligand “sits perfectly in the 
binding pocket” or the structure “suggests optimal utual complementarity”. This observation 
is translated into arguments to explain effectiveness of binding. However, is this intuitively 
very welcome concept of a perfect-fit-to-high-affinity correlation really justified?  
In the present report we want to discuss the binding of five related HIV protease inhibitors. 
Instinctively, one would argue that for the first in the series all goes wrong that could go 
wrong. Both, protein and ligand should feel quite “unhappy” with the achieved binding mode. 
For the last example in the series, a nice and relaxed binding mode is suggested and both 
interaction partners should feel “comfortable”. However, with respect to affinity, hardly any 
difference could be detected. 
* Taken from a manuscript in preparation, Andreas Blum, Jark Böttcher, Stefanie Dörr, Andreas Heine, Grhard 
Klebe, Wibke E. Diederich. Chasing binding modes in HIV Protease: From seemingly perturbed to seemingly 
relaxed pose without altering affinity. 
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7.2  Results and Discussion 
Recently, we introduced a novel privileged skeleton  successfully address the catalytic 
dyad of HIV protease, a C2-symmetric viral protease.
4, 5 In its core, the novel compound class 
features a pyrrolidine moiety (1, Scheme 1). Confirmed by crystal structure analysis, the basic 
nitrogen binds most likely in double protonated and positively charged state at the pivotal 
position between both aspartates.6 Next to the central building block but spaced by two 
methylene amino linkers, the inhibitor skeleton has been decorated with two acceptor 
functionalities planned to interact via the unique structural water in HIV protease with the 
backbone NH groups of Ile50 and Ile50’ in the flap region. Further hydrophobic substituents 
connected to the linking amide nitrogens and terminal to the carboxy or sulfone ends were 
thought to address the four specificity pockets S2, S1, S1’, and S2’ of the protease. Although 
the inhibitor skeleton of 1 had been thoroughly designed, the crystal structure in complex with 


























Scheme 1: Molecular structure and schematic representation of the observed binding modes of  1  in complex 
with the HIV-1 protease. 
The inhibitor repells the structural water molecule from the binding site and uses its sulfone 
group to directly form a hydrogen bond to the NH of Ile50 in the flap. The carbonyl oxygen at 
the opposite side remains uncoordinated without forming any H-bond to the protein. The 
unbalanced H-bonding inventory concerning the Ile50’NH leads to a perturbance of the flap 
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loop thus resulting in a direct contact with the neighbouring flap. Considering the well-
planned and accurately balanced occupancy of the four specificity pockets, the inhibitor only 
addresses S1 and S2’ properly whereas S2 remains virtually unoccupied and S1’ appears 
overcrowded by the sterically demanding o,o’-dimethylphenoxy group. The structure even 
suggests that the latter bulky substituent remains partly solvent-exposed. It sterically 
interferes with the flap loop likely causing some of its perturbed spatial orientation. In 
summary, the crystal structure of 1 implies that the designed inhibitor should feel rather 
“unhappy” in the protein binding pocket. The more the binding affinity of Ki = 1.5 µM, 
measured for the racemate, is surprising.  
In order to probe the hypothesis whether the bulky and obviously misplaced o,o’-
dimethylphenoxy substituent is responsible for the p rturbed binding mode, a model 
compound lacking this sterically demanding side chain has been synthesized. This goal of 
preparing an inhibitor with only three sidechains could be accomplished by replacing the 
amide nitrogen by an ether oxygen. The obtained compound 2 shows a Ki = 52 µM (again 
determined for the racemate) against the protease. Interestingly, its crystal structure provides 






















Scheme 2: Molecular structure and schematic representation of the observed binding modes of  2  in complex 
with the HIV-1 protease. 
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Still, the structural water is repelled from the binding site and the sulfonyl group forms a 
direct hydrogen bond to Ile50NH. The other flap loop remains in its perturbed geometry 
establishing a direct contact to the facing C2-symmetrical counterpart. Occupancy of the S1 
site appears to be similar to the complex with 1, even though 2 places its benzene sulfonamide 
group instead of the iso-butyl substituent into this pocket. The unsatisfactory occupancy of the 
S2 pocket remains quite similar compared to the previous complex. Finally, the iso-butyl 
substituent of 2 is hosted in a cavity between S2’ and S1’ leaving both pockets only partially 
filled. In conclusion, the bulky o,o’-dimethylphenoxy substituent is not causing the perturbed 
binding mode. More likely the stereochemical arrangement of the five-membered ring and the 
attached SO2 group are the determinant elements inducing the obs rved binding mode. 
As a consequence of this observation, we anticipated to move the two branching substituents 
on either sides of the heterocycle closer together. At the pyrrolidine skeleton the methylene 
amino groups were replaced by amino groups to furnish the core structure of 3. Furthermore, 
we decided to move to a C2-symmetrical inhibitor skeleton to better match with the imposed 
constraints of the protein binding pocket.7 Decorated with a benzyl moiety at nitrogen and a 
benzene sulfone group at both terminal ends, the produced inhibitor experiences a binding 
affinity of Ki = 2.2 µM (enantiomerically pure). Even though the inhibitor was endowed with 
C2 symmetry, the crystal structure shows deviations from a proper C2-symmetrical binding 























Scheme 3: Molecular structure and schematic representation of the observed binding modes of  3  in complex 
with the HIV-1 protease. 
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Besides this unexpected observation it provides some further surprises: The structural water 
is still repelled from the binding site. One of the sulfone oxygens of one sulfonamide group 
interacts with Ile50NH and Ile50’NH. The second oxygen of the same group forms an H-bond 
to Ile50’NH. In contrast, the facing SO2 group remains uninvolved in any polar interactions. 
The orientation of the flap loops appears rather unperturbed. The phenyl substituents on both 
ends of the inhibitor are nicely hosted in the four recognition pockets. The N-benzyl groups 
are found nearly C2-symmetrically in S1 and S1’ whereas the benzene sulfone moieties are 
placed into the S2 and S2’ sites. 
Finally, we decided to cut the C3 to C4 bond of thefiv -membered pyrrolidine moiety 
resulting in symmetrical open chain compounds.8 The central basic nitrogen and both 
sulfonamide nitrogens are bridged by an ethylene liker on either side. Two derivatives 4 and 
5 were prepared both featuring p-amino benzene sulfone groups. At the amide nitrogens either 
a benzyl (4) or an iso-butyl group (5) were examined. Both open chain derivatives inhibit the 
protease with low micromolar affinity (4: Ki = 9.6 µM, 5: Ki = 0.9 µM). With both ligands a 
crystal structure could be determined.  Interestingly, they exhibit a binding mode with bound 



















































Scheme 4: Molecular structures and schematic representation of the observed binding modes of the inhibitors 
4 and 5 in complex with the HIV-1 protease. 
 Both SO2 groups involve one of their oxygens in a direct hydrogen bond to this water. The 
basic nitrogen is placed between the two aspartates. However, it does not occupy the pivotal 
position between both residues. The structures suggest that they preferentially interact with 
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one of the two aspartates. Interestingly, a second tact, likely performed by the other polar 
hydrogen at the basic central nitrogen, is formed via an intramolecular H-bond to one of the 
sulfone oxygens. In the complex with 4, the corresponding oxygen at the other SO2 group 
remains unsatisfied. In the iso-butyl derivative 5, the second sulfone oxygen is involved in a 
hydrogen bond to Ile50’NH. As a consequence, the tetrah dral arrangement around the 
structural water is slightly perturbed. Apart from these differences both inhibitors occupy, 
similar to 3, all four recognition pockets. As in 3, the benzyl (or iso-butyl) substituents are 
placed into the S1/S1’ pockets and the p-amino benzene sulfone moieties are hosted in 
S2/S2’. There they form hydrogen bonds to Asp30 and Asp30’, located at the far end of these 
pockets. 
7.3  Summary and Conclusion 
What conclusions can be drawn from this study? On first sight, 1 with a unsymmetrically 
decorated 3,4-dimethyleneamino pyrrolidine core shows an “ugly” and rather perturbed 
binding mode. The protein appears perturbed next to the bound inhibitor and the occupancy of 
the four binding pockets appears quite unsatisfactory (Figure 1G). Nevertheless, 1 achieves 
single digit micromolar inhibition. To trace possible reasons for this at first glance 
“perturbed” binding mode, the inhibitor 2 with only three substituents was synthesized. It 
looses in affinity by a factor of ~30. Despite these changes, 2 adopts a binding mode which 
even suggests a more unpleasant binding. In consequence, the size of the core fragment and 
the mutual distance between the branching side chains attached to address S2, S1, S1’ and S2’ 
were made responsible for the ”ugly” binding modes of 1 and 2. Moving the side chains 
closer together and producing a C2-symmetrical inhibitor results in a more “convincing” 
binding mode. The four specificity pockets are nicely filled, however, the structural water is 
still repelled from the binding pocket and deviations from a C2-symmetrical binding are 
detected. Even though the binding mode appears intuitively more “relaxed” and the ligand 
exhibits better shape complementarity with the protein, the binding affinity remains in the one 
digit micromolar range (Figure 1H). Possibly, as one f the SO2 groups remains uninvolved in 
any polar contacts, a rather high prize has to be paid for this unbalanced solvation/desolvation 
inventory. Finally, we opened the central pyrrolidine core to endow the inhibitor with a 
possibly required adaptivity to address properly the binding pocket.  
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Figure 1: Crystallographically observed binding modes of 1-5 in HIV protease.9 In A – E a side-on view is given 
showing the hydrogen-bonding pattern of 1 – 5 with the protein. F shows a view from the top with the flap region 
clipped off; all five inhibitors are superimposed and the four specificity pockets are indicated. In G – I  the same 
top view is used on 1, 3 and 4 as in F, showing the space filling and the achieved occupancy in the four 
subpockets. The ligand’s surface color corresponds to the color used for the ligand skeleton in A, C and D, surface 
portions next to sulphur, oxygen and nitrogen are color-coded by atom-type. (A, G): 1 (orange) binds to the 
enzyme repelling the flap water. The bulky o,o’-dimethylphenoxy substituent penetrates only partly into S1’ and 
seems to perturb the flap region. S2 seems to remain nearly entirely unoccupied. (B): 2 (green) fills the S2’ and 
S1’ site quite inefficiently, also here the flap water is discarded from the complex. (C, H): 3 (cyan) binds nearly 
C2 symmetrically and places the benzene sulfone groups in S2 and S2’ whereas the N-benzyl moieties are found in 
S1, S1’. The flap water is also repelled from the complex. (D, I): 4 (yellow) places its aminobenzene sulfone 
moieties in S2, S2’ and the N-benzyl substituents occupy the S1, S1’ pocket. Both SO2 groups form a hydrogen 
bond to the flap water present in the complex. (E): 5 (magenta) binds very similarly to the protease, th N-iso-
butyl substituents are placed into the S1, S1’ pockets. (F): Superposition of 1-5 (1 orange, 2 green, 3 cyan, 4
yellow, 5 magenta) shows the deviating distances between the acceptor groups thought in the design to address the 
flap water. However, in the observed binding mode they are placed in rather different positions in the catalytic 
site.  
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Interestingly enough, the structural water returns back into the binding pocket. Both acceptor 
functionalities, represented by the two SO2 groups, are properly involved in mediating 
contacts to both flaps. The distance between the two sulfonamide nitrogens at the branching 
positions is the longest in these complexes (5.2 Å). In the pyrrolidine derivatives 1 and 2
bearing the methylene linkers, this distance shrinks to 4.3 Å (1) and 5.0 Å (2) respectively, 
whereas 3 brings the branching positions with 3.7 Å closest together. Hence, the SO2 groups 
(in 3 – 5 or SO2/C=O in 1) are spatially placed differently. Obviously, this leads to the 
deviating addressing of the flap region (Figure. 1F). In 4 and 5, the achieved occupancy of the 
four recognition pockets S2, S1, S1’ and S2’ appears very satisfactory (Figure 1I). It is 
tempting to describe the binding modes of the open-chain inhibitors 4 and 5 as “almost 
perfect” and hardly perturbed. Nevertheless, their binding affinity still remains in the one digit 
micromolar range, even though they are decorated at the benzene sulfone termini with amino 
groups that get involved in further hydrogen bonds to the protein. This fact has to be faced 
with the corresponding amino-substituted ligand from the series of 3 which shows a ten-fold 
improved affinity. Most likely, the open-chain derivatives pay to some extent an entropic 
prize as they have to freeze an increased number of rotational degrees of freedom. The 
pronounced pre-organization of the structural arrangement of the side chains required to fill 
the subpockets of the protein is not satisfactorily g ven in these ligands. In summary, this 
comparative study shows that tracing the “ugly” and “beauty” of binding modes is not a 
question of energy and symmetry. Also obvious arguments concerning the perturbance of 
parts of the protein structure or rough estimates in terms of degrees of binding pocket filling 
are not convincing. Apparently, the picture is much more complex and results as a detailed 
composition of multiple contributions that finally determine affinity and binding geometry of 
a protein-ligand complex. 
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8.  Summary/Zusammenfassung  
8.1   Summary 
Infections with the HI virus, which inevitably lead to the development of AIDS, are still 
among the most serious global health problems causing more than 2.5 million deaths per year. 
In the patho-physiological processes of this pandemic, HIV protease has proven to be an 
invaluable drug target due to its essential role in the virus’ replication process. Currently, nine 
HIV protease inhibitors are approved by the FDA and re being applied within the highly 
active antiretroviral therapy (HAART). However, the occurrence of multi-drug resistant HIV 
variants diminishes the efficacy of all approved protease inhibitors. In addition to that, the 
pharmacokinetic properties of the mostly peptidomimet c compounds are often not optimal 
and the chemical access to these complex and chiral inhibitors is challenging and resource-
intensive. This demands a continuous and persistent earch for new inhibitors of the protease. 
Novel inhibitors should preferably exhibit a different mutation profile compared to that of the 
marketed drugs to circumvent the development of cross resistance. As novel promising 
scaffold for HIV protease inhibition, pyrrolidine-derived inhibitors have recently been 
reported. However, the reported compounds exhibited only a moderate affinity and the 
thorough investigation of the X-ray structure of the protease in complex with the most potent 
derivative revealed an unsatisfactory occupation of the sub-pockets and an asymmetric flap 
interaction, resulting in strong deformations of the protein structure. In this thesis, the 
stepwise improvement of this compound class to potent inhibitors of wildtype as well as 
selected mutant proteases utilizing rational drug discovery methods is reported. 
   
The in-depth analysis of the crystal structure of a (rac)-3,4-dimethyleneamino-pyrrolidine 
in complex with HIV-1 protease provided a promising starting point for further inhibitor 
design: As initial approach symmetric pyrrolidine-di sters possessing the same 
stereochemistry as indicated in the cocrystal structu e of the initial 3,4-dimethyleneamino-
pyrrolidines were synthesized following a chiral-pool approach. The structure-guided design 
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of these inhibitors is described in Chapter 2. The compounds were designed taking the 
essential pharmacophore requirements for a HIV protease inhibitor into account: In addition 
to the cyclic amino functionality addressing the catalytic dyad, the compounds were equipped 
with hydrophobic moieties intended to occupy the protease’s subpockets. Furthermore, two 
acceptor groups allowing appropriate flap-interactions were introduced. Compared to the 3,4-
dimethyleneamino-pyrrolidine derivatives, the acceptor groups are attached closer to the 
central pyrrolidine ring to address the flap in a geometrically better-suited way. The most 
potent compounds of the series achieve one-digit micro olar inhibition towards wild type as 
well as two mutant proteases (Ile50Val and Ile84Val). The cocrystal structure of one 
derivative in complex with the Ile84Val HIV protease could be determined with a resolution 
of 1,82 Å. To our surprise, this complex structure revealed that two inhibitor molecules are 
bound in the large active site cavity comprising an area encompassed by the catalytic dyad 
and the flaps in the open conformation. This crystal ructure is the first HIV protease 
cocrystal structure in which the open-flap conformation of the enzyme is stabilized by an 
inhibitor that concomitantly addresses the catalytic dyad. Thus, this cocrystal structure 
provides a valuable novel starting point for the further development of HIV protease 
inhibitors possessing a different mode of binding compared to known drugs.  
In Chapter 3, as an alternative approach towards HIV protease inhibitors, the development 
of symmetric 3,4-bis N-alkyl sulfonamide-pyrrolidines is described. Similar to the diesters, 
these inhibitors also possess a 3S,4S-disubstituted pyrrolidine, which addresses the catalytic 
dyad via its secondary amino functionality. Utilizing the analogous 3,4-diaminopyrrolidine as 
core structure, arylsulfonyl moieties were introduced not only intended to occupy the S2- and 
S2’-subpockets but also to address the flap region of the enzyme. Via alkylation of the 
secondary sulfonamides, two additional hydrophobic moieties were introduced designed to 
address the S1- and S1’-subsites of the enzyme. The compounds are accessible following the 
same chiral pool approach, however, utilizing D-(-)-tartaric acid thus rendering the putative 
inhibitors in a 7- or 8-step synthesis in high overall yield. The initial lead structure possessing 
benzene sulfonamide groups and benzyl substituents exhibited a Ki of 2.2 µM and the X-ray 
structure in complex with the protease was determined with a resolution of 1.55 Å. 
Surprisingly, the C2-symmetric inhibitor adopts an asymmetric binding mode in the complex 
with the C2-symmetric protein. This crystal structure enabled the rational design of a second 
series of inhibitors and revealed three promising symmetric substitution patterns for further 
lead optimization: (A) Elongation of the P1/P1’-benzyl moieties with hydrophobic 
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substituents in para-position, (B) ortho-substitution at the P2/P2’-phenyl ring systems, and
(C) para-substitution at the P2/P2’-phenyl moieties. All three strategies were pursued and 
resulted in inhibitors with improved affinities up to 260 nM. To elucidate the underlying 
factors accounting for the SAR, consecutively the crystal structures of four representatives, at 
least one of each modification type, in complex with HIV protease were determined (1.5-2.3Å 
resolution). These structures provided deeper insight  into the protein–ligand interactions and 
the underlying principles of the SAR thus enabling us to choose the most promising 
combination of substituents in the next design cycle. As ortho-substitution at the P2/P2’-
phenyl led to a slightly different binding mode, ortho-substitution at the P2-residue seemed to 
be less attractive for the further inhibitor design. As substituents for the combined inhibitor, a 
trifluoromethyl group as P1/P1’(strategy A) and a carboxamido moiety as P2/P2’-substituent 
(strategy B) were selected. The combination rendered a final inhibitor showing a significantly 
improved affinity of Ki = 74 nM. The cocrystal structure of this inhibitor in complex with the 
HIV protease (1.55Å resolution) confirmed the successful application of the pursued 
optimization strategy. 
The extremely successful development of the symmetric pyrrolidine-3,4-bis-N-benzyl-
sulfonamides as inhibitors of the wildtype protease suggested also an investigation of their 
potential towards active site mutants. In Chapter 4 the influence of the active site mutations 
Ile50Val and Ile84Val on these inhibitors is investiga ed by structural and kinetic analysis. 
Both single-point mutants were selected due to their importance and the remarkable 
differences in binding of the pyrrolidine-based inhibitors, particularly in the contact area next 
to Ile50 and Ile84. Whereas the Ile50Val mutation leads to a significant decrease in affinity 
for all compounds in this series, they retain or even show increased affinity towards the 
crucial Ile84Val mutation. By detailed analysis of the crystal structures of two representatives 
in complex with wild-type and mutant proteases (1.58-1.92Å), we were able to elucidate the 
structural basis of this phenomenon. In case of the Ile50Val mutant the reduced affinity 
towards PRI50V could be rationalized in terms of reduced Van der Waals contacts, an 
observation already described in literature for the approved inhibitor Amprenavir. In case of 
the Ile84Val mutation multiple contributions could be identified for the improved affinities. In 
addition to amplified Van der Waals contacts and relief of steric strain likely given in the 
wild-type complexes, enhanced polar interactions mediat d by an interstitial water molecule 
that fills the gap created by the mutational exchange could be observed. The observation of 
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the change in physicochemical properties of the binding pocket upon Ile84Val mutation can 
be exploited for further inhibitor design. 
In Chapter 5 a remarkably observation, which was made during the further development of 
the symmetrically disubstituted 3,4-amino-pyrrolidines as HIV-1 protease inhibitors, is 
investigated in depth. The determination of the binding affinities towards the Ile50Val and 
Ile84Val mutants of inhibitors bearing smaller N-alkyl substituents revealed a selectivity 
profile not being explicable with the initial SAR: In contrast to the N-benzyl-substituted 
derivatives, a reduced affinity is observed towards both active site mutants. By 
cocrystallization of the most potent derivative of a small series with HIV-1 protease, 
astonishingly two different crystal forms, P212121 and P6122, were obtained. Structural 
analysis revealed two completely different binding modes, the interaction of the pyrrolidine 
nitrogen atom to the catalytic aspartates being the only similarity. The binding mode observed 
in the complex in space group P212121 closely resembles the one observed for all examples of 
the N-benzyl series (Chapter 3). However, due to the similar surface complementarities of 
these complexes, particularly in the contact area to Ile84Val, this binding mode does not 
provide a convincing explanation for the deviating selectivity profile. The binding mode 
observed in P6122 resembles more that one adopted by all approved peptidomimetic 
inhibitors, which are known to show high susceptibili y towards the Ile84Val substitution. It 
can not be predicted which of the two binding orientations is be preferred under biological 
conditions. The nature of the substituent and the diff rent binding-pocket shape of the mutant 
enzymes might induce different preferences thus explaining the overall non-uniform SAR 
observed for derivatives bearing smaller N-alkyl substituents. 
Encouraged by the successful utilization of cyclic se ondary amines as anchoring group in 
the development of HIV protease inhibitors, this strategy was expanded into a general 
approach for lead structure identification for aspartic proteases in Chapter 6. Due to the 
important role that aspartic proteases play in many patho-physiological processes, they have 
already been targeted intensively by modern drug development. However, up to now, only for 
two family members, renin and HIV protease, inhibitors have been approved for disease 
therapy. The inhibitor development, so far mostly guided by mimicking the natural peptide 
substrates, resulted in very potent inhibitors for several targets, but the pharmacokinetic 
properties of these compounds were often not optimal. For a more efficient development of 
novel aspartic protease inhibitors, an easily accessible and achiral core structure would be 
preferable. Therefore, an initial library comprising eleven inhibitors based on easily accessible 
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achiral linear oligoamines was developed and screened against six selected aspartic proteases 
(HIV-1 protease, plasmepsin II, plasmepsin IV, renin, BACE-1, and pepsin). The compounds 
bear a central secondary amino function aimed to address the catalytic dyad, acceptor groups 
to address the flap regions of the respective targe enzyme, and hydrophobic moieties to 
address the specificity pockets. Several hits could be identified, among them selective as well 
as rather promiscuous inhibitors. The design concept was consecutively confirmed by 
determination of the crystal structure of two derivati es in complex with HIV-1 protease 
(1.80/1.90Å). The binding mode exhibits high similarity to the binding orientation of 
substrates as well as to that of peptidomimetic inhib tors. Using this information, a 
generalization of this binding situation to other asp rtic proteases appears reasonable thus 
providing a first insight into the observed structure-activity relationships. Hits from this 
oligoamine library can be easily exploited as suitable starting point for the further 
development of aspartic protease inhibitors. 
In Chapter 7 the binding modes of the structurally related secondary amine-based HIV 
protease inhibitors presented in Chapters 1-6 are discussed with respect to their affinity. It is 
commonly assumed that a perfect protein-ligand comple entarity is one of the main driving 
forces for a high binding affinity. The asymmetrically decorated 3,4-dimethyleneamino-
pyrrolidine (Chapter 1.5) achieves one-digit micromolar inhibition, even though the protein 
structure appears to be perturbed next to the bound inhibitor and the occupancy of the 
specificity pockets appears to be quite unsatisfactory. In contrast, the initial lead structure of 
the 3,4-bis-N-alkylsulfonamides (Chapter 3) show approximately the same inhibitory activity, 
however, without protein deformations and a virtually good occupation of the selectivity 
pockets as revealed by X-ray crystallography. The oligoamine derivatives presented in 
Chapter 6 show a high degree of adaptivity and possess a binding mode with a nearly ideal 
protein-ligand complementarity. However, their binding affinity still remains in the one-digit 
micromolar range. In case of the 3,4-bis-N-alkylsulfonamides one of the sulfonyl groups 
remains uninvolved in any polar contacts and the resultant negative solvation/desolvation 
inventory could be the reason for the comparably low affinity with respect to the better 
surface complementarity. In case of the oligoamines, an entropic price has to be paid for the 
freezing of an increased number of rotational degres of freedom. This points out that the 
obvious arguments concerning the perturbance of parts of the protein structure or rough 
estimates in terms of degrees of binding pocket filling are not sufficient to explain a certain 
affinity. The picture is much more complex and the final affinity is a result of a detailed 
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composition of multiple contributions certainly invol ing the binding geometry of a protein-
ligand complex. 
In summary, this thesis clearly points out that structural biology has to be integral part of 
drug discovery projects and, if applied, has to escort the entire optimization process. It can 
provide novel strategies for ligand development, e.g. by the discovery of unexpected protein-
ligand interaction patterns. The discovery of a completely new class of inhibitors targeting an 
alternative protein conformation of HIV protease would have been undiscovered without the 
structural investigation of the protein-ligand complex. It has been shown that the cooperation 
between synthetic medicinal chemistry and structural biology on equal footing and in short 
time intervals can lead to a highly efficient optimization of lead structures. The detailed 
structural analysis of related protein-ligand complexes revealed that large affinity changes 
might result from very small deviations in the protein-ligand complexes. The limitation of 
structural biology has been shown by the identification of two complexes of identical 
composition exhibiting two completely different protein-inhibitor interaction patterns. 
However, in combination with the biological evaluation, hints for such multiple binding 
orientations can be gained and even provide novel opportunities to optimize ligands towards a 
particular binding profile. Using the knowledge gained within the development of pyrrolidine-
based HIV protease inhibitors, a general approach for lead structure identification for aspartic 
proteases has successfully been established. The structural and kinetic information gained 
within the different projects display the difficulty o estimate the potency of a certain lead 
compound in terms of degrees of binding pocket filling and observed binding geometry.  
8.2   Zusammenfassung 
Im Rahmen dieser Arbeit wurden neuartige Leitstrukturen für die Inhibition von 
Aspartylproteasen, insbesondere der HIV-1-Protease, unt r Verwendung strukturbiologischer 
Methoden entwickelt. Als Startpunkt diente die Kristallstruktur eines Komplexes der HIV-1-
Protease mit einem 3,4-Dimethylenamino-pyrrolidin-Derivat, welches mit der zyklischen 
Aminofunktion die katalytische Dyade der Protease adressiert. Ausgehend von der 
Beobachtung starker Proteinverzerrung und einer unbefriedigenden Taschenbesetzung in 
dieser Struktur wurden Verbindungen entwickelt, die nur die essentiellen Pharmacophor-
Erfordernisse für einen HIV-Protease-Inhibitor in sich vereinen. Die symmetrischen 
Pyrrolidindiester-Derivate, ausgestattet mit einer zyklischen sekundären Aminofunktion zur 
Adressierung der katalytischen Aspartate, zwei hydrophoben Resten für die Besetzung der 
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Erkennungstaschen und zwei Akzeptorfunktionen zur Adressierung der flexiblen Flapregion, 
zeigten einstellig mikromolare Inhibitionswerte. Die Kristallstrukturanalyse eines Derivates 
im Komplex mit der Protease offenbarte eine einzigarti e Bindungssituation, in der zwei 
Inhibitormoleküle an ein Protease-Dimer in der geöffneten Konformation binden. Diese 
Beobachtung ermöglichte nun das rationale Design voInhibitoren, die gezielt diese 
Konformation der Protease adressieren. Parallel zu diesem Ansatz wurden Verbindungen auf 
Basis eines 3S,4S-Diamino-pyrrolidin-Gerüstes entwickelt, die über vier Reste zur 
Adressierung der Subtaschen verfügen. Auch hier zeigten die ersten Verbindungen einstellig 
mikromolare Inhibition. Aus dem mittels Röntgenkristallographie aufgeklärten 
Bindungsmodus wurden drei Strategien zur Affinitätssteigerung postuliert und umgesetzt. 
Alle drei Strategien führten zu Inhibitoren mit einm deutlichen Affinitätsgewinn. Mindestens 
ein Vertreter jeder Strategie wurde anschließend im Komplex mit der HIV-Protease 
kristallisiert und analysiert. Aus den beobachteten Bi dungsmodi wurden die beiden 
vielversprechendsten Strategien zur Kombination ausgewählt und in dem finalen Inhibitor 
vereint. Dieser wies mit 74 nM eine weitere deutliche Affinitätssteigerung auf, und die 
Analyse der Kokristallstruktur bestätigte den methodischen Ansatz. Mit den deutlich affineren 
Substanzen wurden kinetische Untersuchungen an zwei ausgewählten, klinisch relevanten 
Punktmutanten der HIV-Protease durchgeführt. Während i  Affinitätsverlust im Falle der 
Ile50Val-Mutation zu beobachten ist, zeigen die Verbindungen eine erhebliche 
Affinitätssteigerung im Falle der Ile84Val-Mutation. Zwei Verbindungen, bei denen dieses 
Phänomen besonders zu Tage tritt, wurden anschließend im Komplex mit den Protease-
Varianten strukturell untersucht. Aus der Analyse ergab sich, dass im Falle der Ile84Val 
Mutation eine Kombination aus mehreren Faktoren zur beobachteten Affinitätssteigerung 
beiträgt. Besonders die Beobachtung veränderter physikochemischer Eigenschaften in der 
Kontaktregion zur Aminosäure 84 ist hierbei von erheblicher Relevanz für die Entwicklung 
zukünftiger Generationen von HIV-Protease-Inhibitoren, mit einer wahrscheinlich deutlich 
geringeren Empfindlichkeit gegen diese Mutation. Aus den kinetischen Studien ergab sich 
zudem, dass Verbindungen mit kleineren Alkylresten ein deutlich verändertes Aktivitätsprofil 
gegenüber den Mutanten aufweisen. Bei dem Versuch, diese Beobachtung strukturell zu 
untersuchen, wurden Kokristalle eines in der Zusammensetzung identischen Protein-Ligand 
Komplexes in zwei verschieden Raumgruppen erhalten. In der orthorhombischen Kristallform 
ist ein Bindungsmodus vergleichbar zu den vorher untersuchten Verbindungen zu beobachten, 
wohingegen in der hexagonalen Kristallform ein Bindu gsmodus zu beobachten ist, der sich 
fundamental von diesem unterscheidet. Eine uneinheitliche Struktur-Aktivitäts-Beziehung in 
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Bezug auf die Protease-Varianten legt ein paralleles Vorliegen dieser beiden Bindungsmodi 
nahe. Anhand der in den Projekten gesammelten Erfahrungen wurde ein genereller Ansatz für 
die Leitstrukturfindung für Aspartylprotease-Inhibitoren auf der Basis eines Oligoamin-
Grundgerüstes entwickelt und umgesetzt. In einer 11 Verbindungen umfassenden Bibliothek 
konnten mikromolare Inhibitoren für 6 der 7 untersuchten Proteasen identifiziert werden. Mit 
der Hilfe der  Kokristallstrukturen zweier Derivate im Komplex mit der HIV-Protease konnte 
eine generelle Bindungssituation für die untersuchten Aspartylproteasen postuliert und mit 
Affinitätsdaten bestärkt werden. In dieser Arbeit wurden vielfältige Ansätze für die 
Entwicklung sekundärer Amine als Aspartylprotease-Inhibitoren erarbeitet. Besonders 
hervorzuheben ist die Entwicklung von Verbindungen, die an die geöffnete Konformation der 
HIV-Protease binden und somit die Entwicklung einer neuen Klasse von Inhibitoren 
ermöglichen. Zudem ist es gelungen, eine neue, potente Klasse von Inhibitoren zu etablieren, 
die im Vergleich zu den literaturbekannten Inhibitoren über einzigartige Eigenschaften 
gegenüber der Ile84Val Punktmutation verfügt. Diese Arbeit untermauert die Bedeutung, die 
der Strukturbiologie in der Entwicklung von biologisch aktiven Verbindungen zukommt. 
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